

SHAARE ZEDEK UK

England & Wales · Charity number 1143272

Details

Status Registered

Legal form Charitable company

Company number [07469168](#)

Registered 2011-08-08

Register [View on the Charity Commission register](#)

Contact

Address 4 Theobald Court
Theobald Street
Borehamwood
Hertfordshire
WD6 4RN

Phone 02082018933

Email office@shaarezedek.org.uk

Website <http://www.shaarezedek.org.uk>

Activities

Objects: TO ASSIST IN THE RELIEF OF SICKNESS AND POOR HEALTH AND THE PRESERVATION OF LIFE OF THE PATIENTS OF THE SHAARE ZEDEK MEDICAL CENTRE IN JERUSALEM BY THE PROVISION OF RESOURCES FOR EQUIPMENT, FACILITIES AND SERVICES FOR ALL PERSONS AND PATIENTS IRRESPECTIVE OF THEIR ABILITY TO PAY, NATIONALITY, RACE OR RELIGION.

Activities: Our mission is to assist Shaare Zedek Medical Centre to provide world class care for all patients irrespective of their ability to pay, age, race or religion. We provide financial support to fund services, capital projects, research and the purchase of equipment for the hospital. Funds are raised through donations and legacies, solicited mailings, events, direct approaches and special appeals.

Classification

- **How:** Makes Grants To Organisations
- **What:** The Advancement Of Health Or Saving Of Lives, Disability, Overseas Aid/famine Relief, Religious Activities, Human Rights/religious Or Racial Harmony/equality Or Diversity
- **Who:** Children/young People, Elderly/old People, People With Disabilities, The General Public/mankind

Geography

- Israel
- Scotland

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£1,716,356	£1,747,478	£1,075,168	5
2023-12-31	£2,251,821	£2,129,718	£1,106,290	5
2022-12-31	£1,643,255	£1,625,872	£984,187	5
2021-12-31	£2,149,747	£2,032,339	£966,903	5
2020-12-31	£4,509,957	£4,549,373	£849,484	5

Trustees

Name	Role	Appointed
Jonathan Maurice Paull	Chair	2022-09-11
ALAIN LEON STECHLER		2011-08-08
Benjamin Berrick		2025-07-28
MICHAEL SANDLER		2013-10-24
Margaret Gioia Rothem		2024-10-01
Nigel Spencer Sloam		2020-08-06
Oliver Julian Richard Sloam		2024-10-01

SHAARE ZEDEK UK

England & Wales - Charity number 1143272

Accounts

Charity registration number 1143272 (England and Wales)

Company registration number 07469168

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Mr Alain Stechler	
Mr Martin Paisner	
Mr Michael Sandler	
Mr Nigel Sloam	
Mr Jonathan Paull	
Mr Oliver Julian Sloam	(Appointed 1 October 2024)
Ms Margaret Rothem	(Appointed 1 October 2024)
Dr Claire Lemer	(Appointed 1 October 2024)

Charity number 1143272

Company number 07469168

Registered office

4 Theobald Court
Theobald Street
Borehamwood
Hertfordshire
United Kingdom
WD6 4RN

Auditor

RDP Newmans LLP
Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW

Bankers

HSBC Bank Plc
8 Canada Square
London
E14 5HQ

National Westminster Plc
135 Bishopgate
London
EC2M 3UR

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) CONTENTS

	Page
Trustees' report	1 - 5
Statement of Trustees' responsibilities	6
Independent auditor's report	7 - 10
Statement of financial activities	11
Balance sheet	12
Statement of cash flows	13
Notes to the financial statements	14 - 30

SHAARE ZEDEK UK

(A COMPANY LIMITED BY GUARANTEE)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees present their annual report and financial statements for the year ended 31 December 2024.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Memorandum & Articles of Association, the Companies Act 2006 and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

In this context the Trustees have complied with the duty in section 17 (5) of the 2011 Charities Act in giving due consideration to the Charity Commission's guidance on Public Benefit. The report is prepared in accordance with the small companies' regime (Section 419(2) of the Companies Act 2006).

Principal aims and objectives

"To save a life is to save the world. Nowhere is this clearer than at Shaare Zedek. A hospital not just with a heart but with a soul that makes the world a better place." - Quote from a relative of a Shaare Zedek patient.

Shaare Zedek UK exists to support the vital, life-saving work of Shaare Zedek Medical Center in Jerusalem. Our objective is to raise funds to enable the hospital to provide world-class medical care, invest in ground-breaking innovation, and remain at the forefront of healthcare in Israel.

We aim to engage the UK Jewish community and wider society through education, philanthropy, and advocacy to promote and sustain the hospital's essential services. Our work ensures that the hospital has the resources it needs to serve all members of Jerusalem's diverse population with compassion, dignity, and excellence.

History

Shaare Zedek Medical Center was founded in 1902 and has been serving the people of Jerusalem and beyond, for over 120 years. Originally established to provide modern medical care to all residents of the city, it has grown into one of Israel's largest and most advanced hospitals. Today, it operates across multiple campuses, treating over 1 million patients each year and is recognised as a centre of excellence in trauma, maternity, emergency care, oncology and medical innovation.

Achievements and Performance in 2024

2024 has been one of the most challenging years in Israel's recent history. The devastating events of October 7th, 2023, and the subsequent conflict have placed unprecedented demands on Shaare Zedek Medical Center and its staff. Despite these challenges, the hospital's extraordinary response and resilience have shone through.

Message from Shaare Zedek Medical Center's Director General

Dear Friends,

Israel finds itself in a period of unprecedented challenge and pain, circumstances that have profoundly touched every part of life at Shaare Zedek. Within our hospital family, we have endured tragic loss, witnessed hundreds of our staff and their loved ones called to the frontlines, and have been tasked with treating more than 600 injured victims of this horrific war.

Through it all, Shaare Zedek has stood at the forefront of Israel's medical response. Our expanded Trauma and Emergency Medicine facilities, together with our outstanding multidisciplinary teams, have enabled us to care for the wounded with skill, compassion, and resilience. Each remarkable recovery we witness reminds us of the vital role our hospital plays in the defence of our beloved nation.

When I began my role as Director General over five years ago, one of my first goals was the expansion of the Weinstock Family Department of Emergency Medicine (DEM), a critical gateway for patients across Jerusalem. At that time, the department was overcrowded and overstretched, unable to meet the growing demand. With the support of the Jerusalem Municipality, the Ministry of Health, and generous private donors, we raised over £10 million to make this vision a reality.

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Even as COVID-19 struck and parts of the new department were diverted to serve as Israel's first Corona ER, we pressed forward. Nearly a year ago, we celebrated the dedication of our new, expanded DEM. Last year alone, more than 100,000 patients passed through its doors, making it the largest and most central facility of its kind in Jerusalem. At the same time, our Trauma Unit has grown into the city's primary referral centre for emergency injuries.

Alongside the physical expansion, we have optimized processes from admission to discharge, shortening waiting times, improving outcomes and raising patient satisfaction. None of this would be possible without the dedication of our exceptional DEM staff, led by Dr. Todd Zalut and Naama Bagrish, whose professional leadership and compassionate care embody Shaare Zedek's values every single day.

We know, however, that this mission is not ours alone. We are deeply moved by the steadfast solidarity and support we continue to receive from our friends in the UK and around the world. Your partnership strengthens us, sustains us, and enables us to keep building the future of emergency and trauma care in Jerusalem.

As we pray for the safe return of our soldiers and hostages, and long for days of peace and healing, I thank you sincerely for your unwavering friendship. Together, we will continue to save lives, restore hope, and shape a stronger tomorrow.

With deep gratitude,

Professor Ofer Merin
Director General, Shaare Zedek Medical Center

Medical and Emergency Response

- Shaare Zedek treated over 1,000 patients in 2024, who were injured in conflict or war related incidents.
- The hospital rapidly opened a dedicated mental health care unit within the Emergency Department to support those suffering from trauma and subsequent PTSD.
- Over 200 staff members, including doctors and nurses, were called up to reserve army service and staff returned from retirement to support.
- The hospital's helipad, at a local sports field, adjacent to the hospital was reactivated for the first time in decades, underscoring its role as a critical national trauma centre.

Emergency Care

- The expanded Weinstock Department of Emergency Medicine, which opened in 2023 enabled improved triage, faster patient admissions and better care for over 100,000 patients in 2024. The upgrade was made possible thanks to the generosity of donors, including supporters from the UK.
- Shaare Zedek opened Jerusalem's first dedicated oncology emergency unit, providing urgent, specialised care for cancer patients experiencing complications from treatment, furthering the hospital's commitment to personalised patient-centred care.

Global Medical Leadership

- Shaare Zedek's Urology Department was recognised in *The Marker's Men's Health* magazine as a national leader in treating benign prostatic hyperplasia (BPH), performing hundreds of advanced procedures within its first year, including cutting-edge robotic surgeries.
- Shaare Zedek's Wilf Women and Infant Center played a leading role at the first European meeting of the American Society for Maternal-Fetal Medicine, with senior staff presenting research and serving on the organising committee, showcasing the hospital's international impact in obstetric care and innovation.

Groundbreaking Medicine

Shaare Zedek's Breast Health Center pioneered a new surgical technique allowing many breast surgeries to be performed without general anaesthesia, using advanced nerve blocks and sedation for faster recovery, reduced pain and minimal reliance on opioids.

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Hospital Recognition

In June 2024, Shaare Zedek's Helmsley Cancer Center was awarded first place in the "Design for Health and Wellness" category at the European Healthcare Design Congress.

The building, designed by Canadian architect Tye Farrow in collaboration with Shaare Zedek's Jerusalem-based architectural firm of Ofer Rubenstein, opened in November of 2022 and is increasingly regarded as one of Israel's landmark public healthcare buildings.

The design is intended to fuse medical function with a highly original design, using natural wood and light intended to create a warm and bright space to help uplift patients' emotional wellbeing throughout the challenging cancer care process.

UK Activities and Fundraising

In 2024 we raised £1,682,789 through events, campaigns, legacies and major gifts. These funds supported Shaare Zedek Medical Center to remain fully equipped and staffed to meet ongoing emerging needs.

Fundraising activity included participation in RideLondon and the Big Half Marathon, the distribution of our Heartbeat and Pulse publications, professional networking-organised events and general fundraising communications throughout the year. From the participation in challenge events, we are taking a strategic approach in this area for 2025 to grow engagement further.

Support from major donors continued to strengthen, with 29 individuals and charitable trusts contributing at this level. Our Friends and Patrons programmes expanded during the year, building a growing network of committed supporters.

In addition, UK donor visits to the hospital provided valuable opportunities for supporters to see the hospital's work directly, strengthening engagement and demonstrating the tangible impact of their contributions.

Governance and Growth

- We welcomed new Trustees and Honorary Patrons to the Board this year, including Rabbi Joseph Dweck, Claire Lemer, Margaret Rothem and Oliver Sloam.
- The Board remains committed to good governance, fundraising best practices, and ensuring Shaare Zedek UK remains a trusted and effective charity.

UK Financial Review

Shaare Zedek UK continues to operate with financial responsibility and transparency. In 2024:

- We have maintained a healthy financial position with closing balances totalling £1,075,168 (2023: £1,106,290).
- Income totalled £1,716,356 (2023: £2,251,821). This was largely from legacy income, trusts and foundations, individual giving, patronage and community fundraising.
- The total sent to the hospital from the UK office was £1,271,181 (2023: £1,708,473) which included funding for medical equipment and hospital infrastructure.
- The cost of raising funds totalled £363,695 (2023: 302,936) representing a cost ratio of 21%.
- The remaining expenditure related to other costs which totalled £22,429 (2023: £20,422).
- Income was largely affected by the economic climate however we were still thrilled to have raised a significant amount of money, sending 74% of our total income to the hospital.
- Expenditure was increased due to the appointment of a Fundraising Manager who was responsible for event and community fundraising activity and expanding our reach within the UK.
- Reserves remain within policy limits to ensure continuity of grant-making and operational stability.

Reserves policy and ongoing concern

It is the policy of the Charity to maintain unrestricted funds, which are the free reserve of the Charity, at a level that takes account of the likely administration costs of the Charity over the next 24-month period. The Board has the power to invest such assets in secure money market instruments.

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Risk management

The Board has assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and is satisfied that systems are in place to mitigate its exposure to those risks.

Structure, Governance and Management

Shaare Zedek UK is a registered charity governed by its Board of Trustees. The Board meets regularly to oversee the charity's strategy, performance and legal obligations. Daily operations are run by a dedicated team of professionals and volunteers.

We maintain strong communication with the hospital leadership in Jerusalem to ensure funds are deployed effectively and aligned with institutional priorities.

Plans for future periods

Looking ahead to 2025, we will:

- Increase investment in major donor development through our Patronage programme.
- Widen our strategic approach to challenge engagement for 2025.
- Expand our reach through young donor engagement, committee led fundraising and legacy giving.
- Develop new fundraising campaigns aligned with hospital priorities, including cancer care, maternal health and cardiology.
- Continue to support the hospital's response to the ongoing conflict and its aftermath.

Recruitment, Appointment and Terms of Office of Trustees

Trustees are appointed in accordance with the Charity's Memorandum and Articles of Association. In 2024, three new Trustees joined the Board.

All new Trustees receive a structured induction, which includes an overview of the charity's governance and organisational structure, as well as access to financial statements from the previous three years. As part of their onboarding, Trustees are also introduced to the operational work and impact of the charity to ensure they are fully informed and engaged in their role. Induction procedures are firmly established to support new appointees in contributing effectively from the outset.

Statement of Trustees' Responsibilities

The Trustees are responsible for preparing the Annual Report and Financial Statements in accordance with applicable law and United Kingdom Accounting Standards.

The Trustees confirm that they have complied with their duty under Section 17 of the Charities Act 2011 to have due regard to the Charity Commission's guidance on public benefit.

Safeguarding

Shaare Zedek UK has a Safeguarding Policy. The charity makes regular enquiries of the hospital with regard to its own robust safeguarding policies and notification of any relevant safeguarding issues of which we should be aware.

Strategic Report

The description under the headings "Achievements and performance" and "Financial review" meet the company law requirements for the Trustees to present a strategic report.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2024

The Board of Trustees

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr Michael Sorkin	(Resigned 1 October 2024)
Mr Anthony Rosenfelder	(Resigned 1 October 2024)
Mr Alain Stechler	
Mr Martin Paisner	
Mr Michael Sandler	
Mr Nigel Sloam	
Mr Jonathan Paull	
Mr Oliver Julian Sloam	(Appointed 1 October 2024)
Ms Margaret Rothem	(Appointed 1 October 2024)
Dr Claire Lemer	(Appointed 1 October 2024)

Related parties

Aggregate donations received from related parties without conditions amounted to £27,721 (2023: £520,740) for the year.

Aggregate remuneration of key management personnel in 2024 amounted to £83,750 (2023: £100,523).

None of the Trustees (or any persons connected with them) received any remuneration or benefits from the Charity during the year.

Auditor

The auditor, RDP Newmans LLP, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report, including the strategic report, was approved by the Board of Trustees.

Mr Jonathan Paull

Trustee

Dated: 29 September 2025

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees, who are also the directors of Shaare Zedek UK for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the charity and financial information. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF SHAARE ZEDEK UK

Opinion

We have audited the financial statements of Shaare Zedek UK (the 'charitable company') for the year ended 31 December 2024 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, including the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report and the strategic report prepared for the purposes of company law, is consistent with the financial statements; and
- the strategic report and the directors' report included within the Trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

The extent to which the audit was considered capable of detecting irregularities including fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with directors and other management, and from our commercial knowledge and experience of the charity sector.
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006 and The Charities Act 2011 together with the Charities SORP (FRS102), General Data Protection Regulation (GDPR), and employment legislation.
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed and tested journal entries to identify unusual transactions and other adjustments for appropriateness, and evaluating the business rationale of significant transactions outside the normal course of business;
- assessed whether judgements and assumptions made in determining the accounting estimates set out in note 2 were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- reviewing and agreeing financial statement disclosures and testing to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.
- reviewing correspondence with HMRC and bankers and reviewing minutes of board meetings.

No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity's controls, and the nature, timing and extent of the audit procedures performed. There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Paresh Radia FCA (Senior Statutory Auditor)

For and on behalf of RDP Newmans LLP, Statutory Auditor
Chartered Accountants
Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW
30 September 2025

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2024

	Notes	Unrestricted funds 2024 £	Restricted funds 2024 £	Endowment funds 2024 £	Total 2024 £	Total 2023 £
Income from:						
Donations and legacies	3	1,455,955	226,834	-	1,682,789	2,228,474
Investments	4	33,567	-	-	33,567	23,347
Total income		1,489,522	226,834	-	1,716,356	2,251,821
Expenditure on:						
Costs of raising funds	5	363,695	-	-	363,695	302,936
<u>Charitable activities</u>						
Payments to hospital	6	1,160,469	200,885	-	1,361,354	1,806,360
Total charitable expenditure		1,160,469	200,885	-	1,361,354	1,806,360
Other	11	22,429	-	-	22,429	20,422
Total resources expended		1,546,593	200,885	-	1,747,478	2,129,718
Net (outgoing)/incoming resources before transfers		(57,071)	25,949	-	(31,122)	122,103
Gross transfers between funds		82,289	(82,289)	-	-	-
Net income/(expenditure) for the year/ Net movement in funds		25,218	(56,340)	-	(31,122)	122,103
Fund balances at 1 January 2024		992,606	71,219	42,465	1,106,290	984,187
Fund balances at 31 December 2024		1,017,824	14,879	42,465	1,075,168	1,106,290

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET

AS AT 31 DECEMBER 2024

	Notes	2024		2023	
		£	£	£	£
Fixed assets					
Tangible assets	13		6,565		4,526
Investments	14		211		211
			<u>6,776</u>		<u>4,737</u>
Current assets					
Debtors	15	11,093		32,589	
Cash at bank and in hand		1,091,774		1,106,358	
		<u>1,102,867</u>		<u>1,138,947</u>	
Creditors: amounts falling due within one year	17	34,475		37,394	
Net current assets			<u>1,068,392</u>		<u>1,101,553</u>
Total assets less current liabilities			<u><u>1,075,168</u></u>		<u><u>1,106,290</u></u>
The funds of the charity					
Endowment funds	20		42,465		42,465
Restricted income funds	19		14,879		71,219
Unrestricted funds	21		1,017,824		992,606
			<u>1,075,168</u>		<u>1,106,290</u>

The financial statements were approved by the Trustees on 29 September 2025

Mr Alain Stechler
Trustee

Mr Jonathan Paull
Trustee

Company registration number 07469168 (England and Wales)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024

	Notes	2024 £	£	2023 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	27		(44,324)		86,820
Investing activities					
Purchase of tangible fixed assets		(3,827)		(1,525)	
Investment income received		33,567		23,347	
Net cash generated from investing activities			29,740		21,822
Net cash generated from financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(14,584)		108,642
Cash and cash equivalents at beginning of year			1,106,350		997,708
Cash and cash equivalents at end of year			1,091,766		1,106,350
Relating to:					
Cash at bank and in hand			1,091,774		1,106,358
Bank overdrafts included in creditors payable within one year			(8)		(8)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

Shaare Zedek UK is a private company limited by guarantee incorporated in England and Wales. The registered office is 4 Theobald Court, Theobald Street, Borehamwood, Hertfordshire, WD6 4RN, United Kingdom.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's memorandum and articles of association, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.

Income tax recoverable in relation to investment income or gift aid donations is recognised at the time the relevant income is receivable.

Legacy income is included in the SOFA when the Charity's entitlement has been established with a sufficient level of certainty, normally on receipt of the legacy or a letter confirming that it will be sent.

Grants received are accounted for as receivable as and when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. Income from charitable activities includes income received under contract.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies **(Continued)**

The charity is not registered for VAT.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure is recognised when a liability is incurred. Contractual arrangements and performance related grants are recognised as goods or services are supplied. Other grant payments are recognised when a constructive obligation arises that result in the payment being unavoidable.

Costs of generating funds are those costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities include both the direct and support costs relating to these activities.

Other costs include governance costs relating to legal, governance or constitutional matters, external accountancy and audit costs.

Support costs include central functions and have been allocated to the different categories of activities based on the time spent on each activity.

The charity is not registered for VAT so all expenses shown in the SOFA and notes to the accounts are shown gross (i.e. inclusive of VAT).

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Plant and machinery	25% straight line
Fixtures, fittings & equipment	10% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets .

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

1.13 Foreign exchange

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the statement of financial activities.

1.14 Volunteers

A substantial contribution to the activities of Shaare Zedek UK is supplied in the form of voluntary services for raising funds. The financial benefit of these non-cash donations have not been recognised in these accounts as by their nature it would be impractical to quantify in monetary terms.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Specifically, the Trustees have made judgements on the apportionment of support and governance costs across the various charitable activities (see note 7 for further details) - the basis of this apportionment has remained consistent to prior years.

In the view of the Trustees, with the exception to the above, there are no significant accounting estimates and judgements applied.

3 Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Donations and gifts	391,964	207,176	599,140	497,577	1,059,758	1,557,335
Legacies	1,063,991	19,658	1,083,649	473,779	197,360	671,139
	<u>1,455,955</u>	<u>226,834</u>	<u>1,682,789</u>	<u>971,356</u>	<u>1,257,118</u>	<u>2,228,474</u>

4 Income from investments

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Interest receivable	<u>33,567</u>	<u>23,347</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

5 Costs on raising funds

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Costs of generating donations and legacies		
Advertising	42,242	40,385
Other fundraising costs	31,573	14,797
Staff costs	242,863	199,255
Depreciation and impairment	545	723
Support costs	46,472	47,776
	<u>363,695</u>	<u>302,936</u>

6 Expenditure on charitable activities

	Payments to hospital 2024 £	Payments to hospital 2023 £
Direct costs		
Staff costs	21,578	24,694
Depreciation and impairment	545	723
Payments to hospital	1,271,181	1,708,473
	<u>1,293,304</u>	<u>1,733,890</u>
Share of support and governance costs (see note 7)		
Support	52,556	53,871
Governance	15,494	18,599
	<u>1,361,354</u>	<u>1,806,360</u>
Analysis by fund		
Unrestricted funds	1,160,469	550,142
Restricted funds	200,885	1,256,218
	<u>1,361,354</u>	<u>1,806,360</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

7 Support costs

	Support costs	Governance costs	2024		Governance costs	2023
	£	£	Support costs	Governance costs	£	£
			£	£		
Staff costs	37,071	15,494	52,565	43,293	18,599	61,892
Premises costs	44,917	-	44,917	29,380	-	29,380
Other costs	17,040	-	17,040	28,974	-	28,974
	<u>99,028</u>	<u>15,494</u>	<u>114,522</u>	<u>101,646</u>	<u>18,599</u>	<u>120,246</u>
Analysed between						
Fundraising	46,472	-	46,472	47,775	-	47,776
Charitable activities	52,556	15,494	68,050	53,871	18,599	72,470
	<u>99,028</u>	<u>15,494</u>	<u>114,522</u>	<u>101,646</u>	<u>18,599</u>	<u>120,246</u>

Support costs excluding staff costs which cannot be directly attributed have been apportioned equally between costs of raising funds and the charitable activity of payments to the hospital. Within support costs, other costs include telephone costs, postage costs, travel costs, computer running costs and staff training costs.

Governance costs include staff costs which have been apportioned on an estimated basis of the allocation of time spent on each specific activity.

8 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

	2024	2023
	£	£
Audit of the annual accounts	15,108	16,905
Non-audit services		
All other non-audit services	2,145	121

9 Trustees

None of the Trustees (or any persons connected with them) received any remuneration, nor reimbursement of travelling expenses during the year or prior year.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

10 Employees

The average monthly number of employees during the year was:

	2024	2023
	Number	Number
Administration	2	2
Fundraising	2	2
Finance	1	1
	<u> </u>	<u> </u>
Total	<u> </u> 5	<u> </u> 5

Employment costs

	2024	2023
	£	£
Wages and salaries	285,102	259,847
Social security costs	25,825	21,501
Other pension costs	6,081	4,495
	<u> </u>	<u> </u>
	<u> </u> 317,008	<u> </u> 285,843

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2024	2023
	Number	Number
Between £80,000 - £89,999	1	-
	<u> </u>	<u> </u>

Remuneration of key management personnel

The remuneration of key management personnel was as follows:

	2024	2023
	£	£
Aggregate remuneration	83,750	100,523
	<u> </u>	<u> </u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

11 Other

	Unrestricted funds	Unrestricted funds
	2024	2023
Net loss on disposal of tangible fixed assets	696	276
Audit fees	15,108	16,905
Legal and professional fees	6,625	3,241
	<u>22,429</u>	<u>20,422</u>

12 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

13 Tangible fixed assets

	Plant and machinery	Fixtures, fittings & equipment	Total
	£	£	£
Cost			
At 1 January 2024	7,401	6,945	14,346
Additions	3,644	183	3,827
Disposals	(1,270)	(2,330)	(3,600)
	<u>9,775</u>	<u>4,798</u>	<u>14,573</u>
Depreciation and impairment			
At 1 January 2024	6,703	3,117	9,820
Depreciation charged in the year	764	327	1,091
Eliminated in respect of disposals	(1,269)	(1,634)	(2,903)
	<u>6,198</u>	<u>1,810</u>	<u>8,008</u>
Carrying amount			
At 31 December 2024	<u>3,577</u>	<u>2,988</u>	<u>6,565</u>
At 31 December 2023	<u>698</u>	<u>3,828</u>	<u>4,526</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

14 Fixed asset investments

	Listed investments £
Cost or valuation	
At 1 January 2024 & 31 December 2024	211
Carrying amount	
At 31 December 2024	211
At 31 December 2023	211

15 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Other debtors	10,450	31,946
Prepayments and accrued income	643	643
	<u>11,093</u>	<u>32,589</u>

16 Loans and overdrafts

	2024 £	2023 £
Bank overdrafts	8	8
Payable within one year	8	8

17 Creditors: amounts falling due within one year

	Notes	2024 £	2023 £
Bank overdrafts	16	8	8
Other taxation and social security		8,221	8,808
Trade creditors		9,673	12,397
Other creditors		1,572	1,180
Accruals		15,001	15,001
		<u>34,475</u>	<u>37,394</u>

18 Members' liability

The company is limited by guarantee. In the event of the company being wound up while someone is a trustee, or within one year afterwards, in the event of there being a deficiency, each trustee will contribute a sum not exceeding £1.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

19 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds				Balance at 31 December 2024
	Balance at 1 January 2023	Incoming resources	Resources expended	Balance at 1 January 2024	Incoming resources	Resources expended	Transfers	
	£	£	£	£	£	£	£	£
Bikur Cholim Campus	3,560	156,822	(156,722)	3,660	5,025	(5,000)	(3,685)	-
Emergency Department	52	19,000	(18,500)	552	16,984	(17,536)	-	-
Neurosurgery and Neurology Department	1,272	-	-	1,272	15,300	(16,572)	-	-
Others	58,359	386,606	(386,606)	58,359	80,766	(52,950)	(71,296)	14,879
Paediatrics department	-	300	-	300	13,509	(13,577)	(232)	-
Neonatal Intensive Care Unit	6,857	10,000	(10,000)	6,857	-	-	(6,857)	-
Intensive Care Department	201	-	-	201	38,000	(38,000)	(201)	-
Coronavirus Department	18	-	-	18	-	-	(18)	-
Outpatient Clinic	-	393,991	(393,991)	-	-	-	-	-
Imaging, Biobanking and Sequencing Diagnosis Methods	-	290,400	(290,400)	-	57,250	(57,250)	-	-
	<u>70,319</u>	<u>1,257,118</u>	<u>(1,256,218)</u>	<u>71,219</u>	<u>226,834</u>	<u>(200,885)</u>	<u>(82,289)</u>	<u>14,879</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

19 Restricted funds

(Continued)

Bikur Cholim Campus is a separate campus hospital that merged with Shaare Zedek Medical Centre in Jerusalem. The fund is dedicated to fund the general running of the hospital. The remaining surplus of £3,685 was transferred to unrestricted funds as the project objectives are now completed.

The Emergency Department was set up to develop and extend the existing size of the old department. The fund is dedicated to cover running costs for the department.

The Neurosurgery and Neurology Department at the Shaare Zedek Medical Center treats a wide range of diseases involving the nervous system, with the aim of preserving and restoring brain and spine function and has a designated operating theatre which includes a new navigating system, intra-operation ultra-sound and an innovative robot enabling procedures such as tumor tissue biopsy with great precision. The fund is dedicated to provide equipment and cover general running costs for the department.

Included within Others are various smaller funds which relate to various activities including CT Scanner, various pieces of equipment, Haematology Department, Urology Department, pending allocation, Geriatrics Department, Cardiology Department and LDA Educational Institute. The Cardiology Department provides a comprehensive response to the gamut of cardiac and cellular diseases. Our team performs catheterization, installs stents in the coronary arteries and implants pacemakers, defibrillators and valves without open heart surgery. There is also a state-of-the-art Cardiac Imaging Institute which uses 3-D Echo, CT and MRI. We can also administer advanced treatment for congenital and structural disorders. The department stresses preventative care and accompanies patients throughout the post-heart attack rehabilitation process. A surplus of £19,879 is being carried forward to meet the project objectives of these departments. During the year, an amount of £71,296 was transferred to unrestricted funds as the project objectives are now completed.

The Paediatrics department surplus of £232 was transferred to unrestricted funds as the project objectives are now completed.

The Neonatal Intensive Care Unit (NICU) at the Shaare Zedek Medical Center treats infants born from week 24 of pregnancy. The complex includes 70 beds (with another 20 at the Bikur Cholim Campus), and state-of-the-art respiratory and monitoring equipment which provides precise data 24/7 on each of the babies in the unit. The fund is dedicated to provide equipment and cover general running costs for the department. The remaining surplus of £6,857 was transferred to unrestricted funds as the project objectives are now completed.

Our state of the art new ICU was upgraded in 2017 the first major upgrade and renovation of this Unit since the hospital moved to its current location in 1979. The Unit is now equipped with the latest technology and care methods in the most advanced setting possible. The risk of infection is a top priority for intensive care patients. The redesigned ICU gives each patient their own largely self-sufficient room to minimise the spread of infection. Almost all of the equipment is wall or ceiling mounted, meaning the room can be kept to a higher standard of cleanliness. There are 14 patient rooms in total, almost all of which are in constant use. Our Intensive Care Unit treats the most severe urgent care cases in the hospital. 70% of cases are post-surgery while others are complex cases referred from the Internal Medicine Departments. The remaining surplus of £201 was transferred to unrestricted funds as the project objectives are now completed.

The Coronavirus department resulted in a surplus of £18 which was transferred to unrestricted funds as the project objectives are now completed.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

19 Restricted funds

(Continued)

In terms of the outpatient clinic, out of the 800,000 patients who are treated at Shaare Zedek Medical Center each year, the vast majority are treated on an ambulatory basis in our more than 70 outpatient units and clinics. In general, the trend in modern medicine is to reduce the need for inpatient hospitalization wherever possible, as this increases costs, emotional and practical challenges for the patient and is also less desirable from a medical perspective. For all these reasons, outpatient care is the growing trend in modern hospital care and Shaare Zedek has firmly embraced this trend with increased investment in these services. The central area for the large majority of our ambulatory services is in the Margulies Outpatient Clinics which are divided between the Fourth and Fifth Floors of The Next Generation Building.

The trustees are satisfied that sufficient resources are held in an appropriate form to enable each fund to be applied in accordance with any restrictions.

20 Endowment funds

Endowment funds represent assets which must be held permanently by the charity. Income arising on the endowment funds can be used in accordance with the objects of the charity and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

	Movement in funds					Movement in funds					
	Balance at 1 January 2023	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at 1 January 2024	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at 31 December 2024
	£	£	£	£	£	£	£	£	£	£	£
Permanent endowments											
Rayne Endowment Fund	42,465	-	-	-	-	42,465	-	-	-	-	42,465
	<u>42,465</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>42,465</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>42,465</u>
	<u><u>42,465</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>42,465</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>42,465</u></u>

The Rayne Endowment Fund was donated by Lord Rayne to fund an international urology conference held at Shaare Zedek Medical Centre.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

21 Unrestricted funds

The income funds of the charity include unrestricted funds, within which designated funds have been set aside by the trustees for specific purposes:

	Movement in funds			Movement in funds					Balance at 31 December 2024
	Balance at 1 January 2023	Incoming resources	Resources expended	Balance at January 2024	Incoming resources	Resources expended	Transfers from Restricted Funds	Transfer to General Unrestricted Fund	
Designated - Neo-Natal Department	466	-	-	466	25	-	-	(491)	-
Designated - Paediatric Oncology	104	384	-	488	2,171	(2,659)	-	-	-
Designated - Bikur Campus	-	-	-	-	125	-	-	(125)	-
Designated - Emergency Department	-	-	-	-	1,984	(1,984)	-	-	-
Designated - Pending Allocation	14,597	-	-	14,597	206,237	(209,391)	-	(11,443)	-
Designated - Helmsley Cancer Centre	68,554	-	(68,554)	-	-	-	-	-	-
Designated - Nursing Scholarships	600	-	-	600	-	-	-	(600)	-
Designated funds- Trauma	-	-	-	-	40,083	(40,083)	-	-	-
Designated - Coronavirus Department	32	138	-	170	7	-	-	(177)	-
General Unrestricted Fund	787,050	994,182	(804,946)	976,286	1,238,890	(1,292,477)	82,289	12,836	1,017,824
	<u>871,403</u>	<u>994,703</u>	<u>(873,500)</u>	<u>992,606</u>	<u>1,489,522</u>	<u>(1,546,594)</u>	<u>82,289</u>	<u>-</u>	<u>1,017,824</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

21 Unrestricted funds

(Continued)

The Neo-natal and Paediatric Oncology funds were set up to support running costs for the department. The fund balance has been transferred to the general unrestricted fund.

Bikur Cholim Campus is a separate campus hospital that merged with Shaare Zedek Medical Centre in Jerusalem. The fund is dedicated to fund the general running of the hospital. The fund balance has been transferred to general unrestricted fund.

The Emergency Department was set up to develop and extend the existing size of the old department. The fund is dedicated to cover running costs for the department. The fund balance has been transferred to the general unrestricted fund.

The Pending Allocation Fund relates to donations which are yet to be remitted to the Shaare Zedek Medical Centre.

The Nursing Scholarships fund was set up to provide support and training for student nurses. The fund balance has been transferred to general unrestricted fund.

The Trauma unit was set up to treat a wide range of injuries, from minor wounds to complex, life-threatening trauma. The Trauma unit is within a new underground hospital with 70 adaptable beds which was completed during the year to ensure safe and continuous care during emergencies.

The Coronavirus Fund was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation. The fund balance has been transferred to the general unrestricted fund.

The General Unrestricted Fund relates to "free reserves" after allowing for all designated funds.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

22 Transfers

At the year end, the Trust transferred a total of £82,289 from restricted funds to unrestricted funds as detailed below:

At the year end, the Trust transferred a surplus of £3,685 arising on the Emergency Department from restricted funds to unrestricted funds to conclude the project objectives.

At the year end, the Trust transferred a surplus of £71,296 arising from various smaller funds (Haematology, Urology, Geriatrics, Cardiology Departments and the LDA Educational Institute) from restricted funds to unrestricted funds to conclude the project objectives.

At the year end, the Trust transferred a surplus of £232 arising on the Paediatrics department from restricted funds to unrestricted to conclude the project objectives.

At the year end, the Trust transferred a surplus of £6,857 arising on the Neonatal Intensive Care Unit from restricted funds to unrestricted to conclude the project objectives.

At the year end, the Trust transferred a surplus of £201 arising on the Intensive Care Unit from restricted funds to unrestricted to conclude the project objectives.

At the year end, the Trust transferred a surplus of £18 arising on the Coronavirus Department from restricted funds to unrestricted to conclude the project objectives.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

23 Analysis of net assets between funds

	Unrestricted funds	Designated funds	Restricted funds	Endowment funds	Total	Unrestricted funds	Designated funds	Restricted funds	Endowment funds	Total
	2024	2024	2024	2024	2024	2023	2023	2023	2023	2023
	£	£	£	£	£	£	£	£	£	£
Fund balances at 31 December 2024 are represented by:										
Tangible assets	6,565	-	-	-	6,565	4,526	-	-	-	4,526
Investments	211	-	-	-	211	211	-	-	-	211
Current assets/(liabilities)	1,011,048	-	14,879	42,465	1,068,392	971,549	16,320	71,219	42,465	1,101,553
	<u>1,017,824</u>	<u>-</u>	<u>14,879</u>	<u>42,465</u>	<u>1,075,168</u>	<u>976,286</u>	<u>16,320</u>	<u>71,219</u>	<u>42,465</u>	<u>1,106,290</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

24 Operating lease commitments

Lessee

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2024	2023
	£	£
Within one year	15,000	15,000
Between two and five years	12,500	27,500
	<u>27,500</u>	<u>42,500</u>

25 Related party transactions

Transactions with related parties

Aggregate donations received from related parties without conditions amounted to £27,721 (2023: £520,740) for the year.

26 Analysis of changes in net funds

The charity had no material debt during the year.

	2024	2023
	£	£
27 Cash (absorbed by)/generated from operations		
(Deficit)/surplus for the year	(31,122)	122,103
Adjustments for:		
Investment income recognised in statement of financial activities	(33,567)	(23,347)
Loss on disposal of tangible fixed assets	696	276
Depreciation and impairment of tangible fixed assets	1,091	1,447
Movements in working capital:		
Decrease/(increase) in debtors	21,496	(25,374)
(Decrease)/increase in creditors	(2,918)	11,715
Cash (absorbed by)/generated from operations	<u>(44,324)</u>	<u>86,820</u>

SHAARE ZEDEK UK

England & Wales - Charity number 1143272

Accounts

Charity registration number 1143272

Company registration number 07469168 (England and Wales)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees Mr Michael Sorkin
Mr Anthony Rosenfelder
Mr Alain Stechler
Mr Martin Paisner
Mr Michael Sandler
Mr Nigel Sloam
Mr Jonathan Paull

Charity number 1143272

Company number 07469168

Registered office 4 Theobald Court
Theobald Street
Borehamwood
Hertfordshire
United Kingdom
WD6 4RN

Auditor RDP Newmans LLP
Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW

Bankers HSBC Bank Plc
8 Canada Square
London
E14 5HQ

National Westminster Plc
135 Bishopgate
London
EC2M 3UR

Barclays Bank PLC
1 Churchill Place
London
E14 5HP

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) CONTENTS

	Page
Trustees' report	1 - 9
Statement of Trustees' responsibilities	10
Independent auditor's report	11 - 14
Statement of financial activities	15
Balance sheet	16
Statement of cash flows	17
Notes to the financial statements	18 - 32

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2023**

The Trustees present their annual report and financial statements for the year ended 31 December 2023.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Memorandum & Articles of Association, the Companies Act 2006 and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

In this context the Trustees have complied with the duty in section 17 (5) of the 2011 Charities Act in giving due consideration to the Charity Commission's guidance on Public Benefit. The report is prepared in accordance with the small companies' regime (Section 419(2) of the Companies Act 2006).

Principal aims and objectives

"To save a life is to save the world. Nowhere is this clearer than at Shaare Zedek. A hospital not just with a heart but with a soul that makes the world a better place."

Quote from a relative of a Shaare Zedek patient

Our mission is to support, by all such means as may be charitable in law and for exclusively charitable purposes, Shaare Zedek Medical Centre (Shaare Zedek) in providing world class care for all patients irrespective of their ability to pay, nationality, age, race or religion. We provide financial support to fund services, capital projects, research and the purchase of equipment for the hospital.

History

Founded in 1902, Shaare Zedek has been known as the "Hospital with a Heart" for more than a century. This reputation as a patient's first choice of hospitals stem from its unwavering commitment to all its patients, regardless of race, religion, political view or country of origin. All patients who are admitted receive the most advanced medical treatment available in a compassionate, supportive and nurturing environment. The hospital's ethos, "delivery of care and pioneering approaches to research", provides hope for us, hope for Israel and hope for the world.

Since it was founded, the Hospital has chartered the course of Jerusalem's modern development and has been instrumental in the city's growth. Over half of Jerusalem's children live below the poverty line. Shaare Zedek was one of the first hospitals in Israel to recognise the need for specialist paediatric medical facilities and is home to Jerusalem's only dedicated Women and Children's Hospital.

Shaare Zedek 2023

Today Shaare Zedek is a 1,500-bed facility with close to 100 departments, treating 800,000 patients annually. As the fastest growing hospital in the region, the hospital continues to respond to and plan for the needs of Jerusalem's uniquely diverse population. In 2023, the hospital opened its expanded Weinstock Department of Emergency Medicine. As home to a Level One Trauma Centre, the department stands as Jerusalem's foremost urgent response facility, annually admitting over 100,000 patients and experiencing a ten percent increase in admissions each year. The newly expanded department was meticulously designed with the patient at heart, aiming to make it much easier for them to move through each section, allowing for faster and more effective patient admission, triage and treatment.

Following the attacks on October 7th, Shaare Zedek also faced many other challenges, including staff shortages, as many professionals were called up for reserve army service. The team at the hospital responded immediately to the needs of the community by opening a mental health emergency centre very quickly, as they recognised there would be an immediate increase in the requirement of such a services. This was in addition to focusing on emergency preparedness and fundraising focused on building and equipping a 70 bed ICU ward in the basement of the Helmsley Cancer Centre, should there be a full scale attack which would require patients to be treated in safety underground.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

Message from Shaare Zedek Medical Centre's Director General

Dear Friends,

On the morning of Simchat Torah, as masses of Jews were about to rejoice and pray, the most bestial massacre in Israel's history was raging in the south. On that day, I was leading an Israeli rescue team in Armenia. As soon as I heard what was happening in Israel, I knew it was extremely serious and I got straight on a plane to Cyprus that flew over Iran and Iraq. I was tense the whole flight and by that evening I was already in the hospital.

In all my time of working at Shaare Zedek and in my time as the Director of Trauma during 2007-2019 I have never experienced such a large number of wounded patients admitted to our Trauma department in such a short space of time. To date we have treated over 600 patients since October 7th and this number increases daily. While the ground initiative in Gaza is still going on, our medical teams are ready for every eventuality.

The times we live in are deeply challenging and tragic, but we see it as a great source of personal and professional pride to know that Shaare Zedek is serving in so many ways to offer professional, advanced and compassionate care for the people of Jerusalem and Israel and we thank you, our friends in the UK for digging deep and supporting us at this incredibly challenging time.

We continue to pray for the safe and secure return of all the hostages and our soldiers.

Professor Ofer Merin

**Director General
Shaare Zedek Medical Centre**

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

Objectives and activities

In order to achieve our key objectives, Shaare Zedek UK (SZUK) employs a small office team led by a Chief Executive working in partnership with trustees and other lay leaders, supported by a small number of energetic volunteers.

SZUK promotes awareness of the activities of Shaare Zedek. We also seek to promote support of the charitable activities of the hospital, and in particular its charitable activities for the public benefit in health welfare, medical and scientific advancement and best practice in patient treatment. We raise funds through donations, legacies, solicited mailings, events, direct approaches and special appeals.

Achievements and Performance

The impact of our fundraising

Shaare Zedek relies on its donors to provide the funds to enable the standard of care and innovation for which the hospital is known. Every day at Shaare Zedek brings new challenges and achievements. Shaare Zedek prides itself on its ability to adapt to any situation and provide excellent care when it is most needed.

Hope for Israel

On October 7th we woke to the devastating news that Israel was under attack. Whilst communities were preparing to celebrate one of the most joyful dates in the Jewish calendar news emerged of the atrocities perpetrated by Hamas.

When news began to trickle through, in the early morning hours, Shaare Zedek was already preparing. Setting up an emergency centre, a family call centre, nurse and doctor planning was underway and all departments in the hospital were prepped with the sole aim of providing solutions to whatever challenges patients were about to face.

For the first time in decades a nearby sports field became the hospitals helipad and patients were transferred both by MDA (Magen David Adom) medivac and military helicopters straight to Shaare Zedek. The hospital started to receive many victims from the south of Israel who were evacuated to safety. Among them civilians and soldiers and many pain-filled stories of loss.

In one particularly heart-wrenching case, the hospital treated two young children found abandoned on the border fence after their mother was taken into captivity. Their father had survived and brought them directly to Shaare Zedek.

Within hours of the declaration of War the hospital opened a mental health care unit within the emergency room for individuals suffering from shock and other emotional issues.

The solidarity of our staff, from all races and populations of the Jerusalem population, has been extraordinary and is indicative of the remarkable spirit of unity that has always defined Shaare Zedek.

Tragically, some of our staff have experienced personal losses. Yet, amidst the grief, a sense of unity prevails. Over 200 dedicated individuals from Shaare Zedek, including doctors, nurses, and staff from various departments, seamlessly transitioned from their medical roles to don IDF uniforms, as they were called up for their reservist army duty. While retired staff, motivated by a sense of community, re-joined the hospital's ranks to support their Shaare Zedek family.

The hospital stands as a beacon of strength and resilience, providing crucial medical care and unwavering support to the community, even in the face of adversity.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

Hope for the World

Israeli Medical Team provides care in Armenia

On the 4th October 2023, Israel received a call from the Armenian government for help after hundreds of citizens were wounded after a fuel tank explosion.

Israel was the first country to land in Armenia with a medical delegation led by Professor Ofer Merin, Director General of Shaare Zedek. The delegation from Israel, made up of 14 medical professionals, were sent to provide intensive care treatment to hundreds of injured citizens including many burn victims.

Professor Merin shared "This is an unusual event on a global scale, with such a large number of burn victims. It is an honour and privilege to lead this worthy task, on behalf of the State of Israel, which is the first country to provide assistance."

"I would like to thank the Ministry of Health for their commitment and the teams of Shaare Zedek and Soroka who immediately mobilized to embark on this important mission. Our preparedness at Shaare Zedek Medical Center is for the benefit of everyone, everywhere."

Tanzanian partnership

The work of Shaare Zedek and our medical professionals extends far beyond the walls of the hospital in Jerusalem and something we are so proud of is how our doctors give hope to the world through their research and teaching.

Professor Gabriel Izbicki, Director of the Pulmonary Institute at Shaare Zedek visited Zanzibar, Tanzania with colleagues from Shaare Zedek to learn about the lack of basic medical equipment and knowledge about lung diseases in Zanzibar hospitals.

Professor Izbicki shared, "Our project began about a year-and-a-half ago. We visited two hospitals and gave lectures on lung diseases, mostly COVID-19, asthma, and chronic obstructive pulmonary disease (COPD)."

At the Al-Rahma Hospital in the capital city of Zanzibar, the Shaare Zedek team were impressed by the level of the staff's knowledge.

"They understood quite well the diseases, types of treatments, and the various inhalations, but when I asked them if they do tests to diagnose asthma and COPD, they said no. I was surprised and asked them if they referred patients to another hospital, and they again said no. I asked why, and they said that neither of them had the necessary medical equipment."

Professor Izbicki discovered that doctors did not even have a spirometer, a basic lung function device that measures the amount of air you can exhale in one second and the total volume of air you can exhale in one forced breath. 'It is impossible to distinguish between asthma and COPD without this device' and misdiagnoses due to inadequate equipment can lead to further problems.

Professor Izbicki was saddened by what he saw in Zanzibar, and upon his return to Israel, set about trying to help the people he met on his trip. After almost a year of planning, he arranged for a medical delegation to visit Israel for a week of essential learning. Not only that, he was also able to arrange donations of essential medical equipment to be taken back to the region.

Dr Bukoro Nestori who was among the group that came to Israel had never been on a plane before, but had dreamt of visiting Israel.

Professor Izbicki and his team were able to enrich Dr Bukoro's medical know how with valuable hands-on experience as well as impart important medical knowledge that Dr Bukoro was able to take back to Zanzibar.

A very special trip that will help change the future of Pulmonary care in Tanzania.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

Global first at Shaare Zedek

In August 2023, Shaare Zedek Medical Center became the first hospital in the world to perform a complex spinal surgery using augmented reality combined with robotic technology.

Dr Cezar J Mizrahi performed the incredible procedure on a 25-year-old patient who had been admitted to the hospital's Emergency Department after being seriously injured in a work-place fall. The trauma team at Shaare Zedek swiftly diagnosed an unstable spine fracture that put the man at immediate risk for paralysis and other severe neurological damage. He was quickly transferred into the care of Dr Mizrahi, a Spinal Neurosurgeon from the Spine Surgery Unit, and the Department of Neurosurgery.

The combination of AR (Augmented Reality) and robotics allowed Dr Mizrahi to perform a precise and minimally invasive procedure. "It made my life amazingly easy. I would even say a child could do a surgery with all this technology. The AR and robotics helped with positioning, trajectory, and planning," he said.

The combination of AR, which is an interactive experience that combines the real world and computer-generated content, with robotic technology, did not speed up the surgery, but rather made it more 'effective.'

The successful operation has given Dr Mizrahi hope that the technology may become an integral part of spinal surgeries going forward, but he knows that these things take time to get fully implemented.

"It is a slow process. If I had to speculate, I would say that in about 10 years it will be standard to use AR and robotics for complex cases," he said.

And although this technology is currently only used to perform spinal surgeries, Dr Mizrahi said he can see it being used for injuries on the entire body in the future.

UK funding

Donors choose to support any of the hospital's 100+ departments with which they have a personal affinity as well as responding to our appeals to support the needs of specific departments as dictated by the Board of the hospital. This year donors supported a variety of departments by funding equipment, rooms, facilities and scholarships.

There is a strong British footprint in every one of the hospital's 14 internationally recognised Centres of Excellence. Fundraising in the UK has always been conducted in close partnership with the leadership of the hospital in Jerusalem. Collaboration between professional colleagues and board members grows each year. This year our new Chief Executive made her first visit to the hospital. We have enjoyed a close working relationship with both the President and Director General of the hospital and their teams. This year the UK team once again joined a call bringing the international offices fundraising for Shaare Zedek together to discuss further collaboration. We look forward to a continued partnership with Professors Halevy and Merin and are indebted to them for their visionary leadership and continued service. We are grateful to the entire fundraising team at Shaare Zedek Medical Centre who support our fundraising efforts on the ground in Israel.

Strategic report

The description under the headings "Achievements and performance" and "Financial review" meet the company law requirements for the Trustees to present a strategic report.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

Financial review

The current economic climate continues to impact on our ability to raise new funds. Given the tough climate we were delighted to have raised £2,228,474 (2022: £1,641,822). We have maintained a healthy financial position with closing fund balances totalling £1,106,290 (2022: £984,187) of which £71,219 (2022: £70,319) relates to restricted funds and £42,465 (2022: £42,465) to general endowment fund. Furthermore, £16,320 (2022: £84,353) within the closing unrestricted fund balance is designated for specific purposes. Hence, the general unrestricted funds the charity holds amounts to £976,286 (2022: £787,050) at the end of the reporting period after making allowance for restricted and designated funds. We are delighted to have raised significant funds enabling us to send £1,708,473 (2022: £1,280,758) to Shaare Zedek in Jerusalem in relation to our charitable activities and support costs. This year we were in a position to send over 75% of our total income directly to the hospital, the balance being held in reserves in the UK.

Legacy gifts continue to be a vital source of income, with 30% of all donations this year being from legacy gifts in donors' wills. Legacies are unpredictable, at times materialising without our prior knowledge and we continue to maintain and develop this income whilst recognising the need for a diversification of income from other sources to maintain the level of support we currently provide to the hospital.

General donations, including major gifts, totalled £1,557,335 (2022: £1,041,396). Although we continue to enjoy the support of our loyal donors, the economic situation continues to be challenging. In common with other charities, we continue to find ways to engage new donors in a challenging climate. Some existing donors are lowering their donations due to reduced income to their Trusts or changes in personal circumstances, or because of the attacks on October 7th have chosen to support other Israeli charities.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

Reserves policy and going concern

It is the policy of the Charity to maintain unrestricted funds, which are the free reserves of the Charity, at a level that takes account of the likely administration costs of the Charity over the next 24-month period. The Board has the power to invest in such assets in secure money market instruments. The intention of the Charity is to make further payments to the Hospital in Israel as and when required in the future. This policy will provide adequate funds to meet current and anticipated future liabilities and provide financial flexibility in the event of an adverse drop in donations received.

Risk management

The Board has assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and is satisfied that systems are in place to mitigate its exposure to those risks. Significant risk areas include:

- **Financial risks** - the variability of incoming donations create risk that the Charity will not have sufficient funds to continue its charitable activities. The Trustees regularly review the financial performance and position of the charity to manage this risk, and have done so successfully historically by ensuring that planned charitable activities are in-line with anticipated donations and level of funds available.

Plans for the future

In May 2023 our Executive Director decided to leave the charity after dedicating herself to the role for 10 years. She finished working with us in July 2023. An experienced fundraiser was appointed as a successor in the post of CEO and started work in June. The trustees worked closely with our outgoing and incoming CEO's to ensure a smooth transition, which focused on the continuity of donor relationships.

In October 2023, we appointed a new Fundraising Manager, who will be working closely with the CEO and trustees, to develop a programme of fundraising events, as well as helping to raise the profile of SZUK across the community.

As an organisation, it was agreed that we would invest in our CRM and work to future proof our technologies, by further developing our website so that we can truly personalise our supporter journey. This will be implemented in 2024-2025.

Recruitment, appointment and terms of office of Trustees

Trustees are appointed in accordance with the Charity's Memorandum & Articles of Association. In 2023, three new Trustees were appointed.

Trustee induction and training

New trustees are made aware of the organisation structure of the charity and are shown financial statements of the charity for the three preceding years.

All trustees are now already familiar with the practical work of the charity. Induction procedures are in place for new trustees.

Safeguarding

Shaare Zedek UK has a Safeguarding Policy. The charity makes regular enquiries of the hospital with regard to its own robust safeguarding policies and notification of any relevant safeguarding issues of which we should be aware.

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 14 December 2010 and registered as a charity on 8 August 2011. The charity's reference and administrative details are as set out within these accounts. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

The Board of Trustees

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr Michael Sorkin
Mr Anthony Rosenfelder
Mr Alain Stechler
Mr Martin Paisner
Mr Michael Sandler
Mr Nigel Sloam
Mr Jonathan Paull

Key personnel

The following individuals whilst not statutory members of the charity were involved in an advisory capacity:

Dan Adler
David Bernstein
David Cohen
Geoffrey Goldkorn
Eva Greenspan
John Jay
Margot Lew
Angela Margolis-Raz
Marcus Margulies
Hilary Natoff
Jonathan Paull
Marcus Pearl
Margaret G Rothem
Simon Sackman
Nolan Wengrowe
Michael Ziff
Emma Pearl

Recruitment, appointment and terms of office of Trustees

Trustees are appointed in accordance with the Charity's Memorandum & Articles of Association.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2023

Trustee Induction and Training

New trustees are made aware of the organisational structure of the charity and are shown financial statements of the charity for the three preceding years.

All trustees are now already familiar with the practical work of the charity. Induction procedures are in place for new trustees.

Operations and staffing

Up until the end of July 2023, the trustees delegated day to day management of the charity to the Executive Director, Simona Bennett to deliver the aims and objectives of the charity. Oshrit Cowan, who started with the charity in June 2023, has now been appointed as Simona's successor.

Safeguarding

Shaare Zedek UK has a Safeguarding Policy. In 2019 the Executive Director completed safeguarding training with the NSPCC. The charity makes regular enquiries of the hospital with regard to its own robust safe-guarding policies and notification of any relevant safeguarding issues we should be aware of. All SZUK staff will now be required to undergo safeguarding training and DBS checks as we expand our outreach work into the community.

Related parties

Aggregate donations received from related parties without conditions amounted to £520,740 (2022: £421,374) for the year.

Aggregate remuneration of key management personnel in 2023 amounted to £100,523 (2022: £91,167).

None of the Trustees (or any persons connected with them) received any remuneration or benefits from the Charity during the year.

Auditor

In accordance with the company's articles, a resolution proposing that RDP Newmans LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report, including the strategic report, was approved by the Board of Trustees.

Mr Jonathan Paull

Trustee

Dated: 25 September 2024

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2023**

The Trustees, who are also the directors of Shaare Zedek UK for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the charity and financial information. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF SHAARE ZEDEK UK**

Opinion

We have audited the financial statements of Shaare Zedek UK (the 'charity') for the year ended 31 December 2023 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, including the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report and the strategic report prepared for the purposes of company law, is consistent with the financial statements; and
- the strategic report and the directors' report included within the Trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

The extent to which the audit was considered capable of detecting irregularities including fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with directors and other management, and from our commercial knowledge and experience of the charity sector.
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006 and The Charities Act 2011 together with the Charities SORP (FRS102), General Data Protection Regulation (GDPR), and employment legislation.
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed and tested journal entries to identify unusual transactions and other adjustments for appropriateness, and evaluating the business rationale of significant transactions outside the normal course of business;
- assessed whether judgements and assumptions made in determining the accounting estimates set out in note 2 were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- reviewing and agreeing financial statement disclosures and testing to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.
- reviewing correspondence with HMRC and bankers and reviewing minutes of board meetings.

No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity's controls, and the nature, timing and extent of the audit procedures performed. There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

**Paresh Radia FCA (Senior Statutory Auditor)
for and on behalf of RDP Newmans LLP**

25 September 2024

**Chartered Accountants
Statutory Auditor**

Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Endowment funds 2023 £	Total 2023 £	Total 2022 £
<u>Income from:</u>						
Donations and legacies	3	971,356	1,257,118	-	2,228,474	1,641,822
Investments	4	23,347	-	-	23,347	1,433
Total income		994,703	1,257,118	-	2,251,821	1,643,255
<u>Expenditure on:</u>						
Costs of raising funds	5	302,936	-	-	302,936	243,705
<u>Charitable activities</u>						
Payments to hospital	6	550,142	1,256,218	-	1,806,360	1,366,780
Total charitable expenditure		550,142	1,256,218	-	1,806,360	1,366,780
Other	11	20,422	-	-	20,422	15,387
Total resources expended		873,500	1,256,218	-	2,129,718	1,625,872
Net gains/(losses) on investments	12	-	-	-	-	(99)
Net movement in funds		121,203	900	-	122,103	17,284
Fund balances at 1 January 2023		871,403	70,319	42,465	984,187	966,903
Fund balances at 31 December 2023		992,606	71,219	42,465	1,106,290	984,187

The statement of financial activities includes all gains and losses recognised in the year.

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET
AS AT 31 DECEMBER 2023

	Notes	2023		2022	
		£	£	£	£
Fixed assets					
Tangible assets	14		4,526		4,725
Investments	15		211		211
			<u>4,737</u>		<u>4,936</u>
Current assets					
Debtors	16	32,589		7,215	
Cash at bank and in hand		1,106,358		997,716	
		<u>1,138,947</u>		<u>1,004,931</u>	
Creditors: amounts falling due within one year	18				
		<u>37,394</u>		<u>25,680</u>	
Net current assets			1,101,553		979,251
Total assets less current liabilities			<u>1,106,290</u>		<u>984,187</u>
The funds of the charity					
Endowment funds	20		42,465		42,465
Restricted income funds	19		71,219		70,319
Unrestricted funds	21		992,606		871,403
			<u>1,106,290</u>		<u>984,187</u>

The financial statements were approved by the Trustees on 25 September 2024

Mr Alain Stechler
Trustee

Mr Jonathan Paull
Trustee

Company registration number 07469168 (England and Wales)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	2023		2022	
		£	£	£	£
Cash flows from operating activities					
Cash generated from operations	26		86,820		26,366
Investing activities					
Purchase of tangible fixed assets		(1,525)		(525)	
Investment income received		23,347		1,433	
Net cash generated from investing activities			21,822		908
Net cash used in financing activities			-		-
Net increase in cash and cash equivalents			108,642		27,274
Cash and cash equivalents at beginning of year			997,708		970,434
Cash and cash equivalents at end of year			1,106,350		997,708
Relating to:					
Cash at bank and in hand			1,106,358		997,716
Bank overdrafts included in creditors payable within one year			(8)		(8)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Shaare Zedek UK is a private company limited by guarantee incorporated in England and Wales. The registered office is 4 Theobald Court, Theobald Street, Borehamwood, Hertfordshire, WD6 4RN, United Kingdom.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's memorandum and articles of association, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income or gift aid donations is recognised at the time the relevant income is receivable.

Legacy income is included in the SOFA when the Charity's entitlement has been established with a sufficient level of certainty, normally on receipt of the legacy or a letter confirming that it will be sent.

Grants received are accounted for as receivable as and when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. Income from charitable activities includes income received under contract.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies **(Continued)**

Trading income is recognised as and when monies are received and stated after trade discounts .

Trading income related to events is recognised in the year the events took place.

The charity is not registered for VAT.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure is recognised when a liability is incurred. Contractual arrangements and performance related grants are recognised as goods or services are supplied. Other grant payments are recognised when a constructive obligation arises that result in the payment being unavoidable.

Costs of generating funds are those costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities include both the direct and support costs relating to these activities.

Governance costs include the cost of any legal advice to trustees on governance or constitutional matters, external accountancy and audit costs.

Support costs include central functions and have been allocated to the different categories of activities based on the time spent on each activity.

The charity is not registered for VAT so all expenses shown in the SOFA and notes to the accounts are shown gross (i.e. inclusive of VAT).

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Plant and machinery	25% straight line
Fixtures, fittings & equipment	10% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies **(Continued)**

1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets .

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies (Continued)

1.13 Foreign exchange

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the statement of financial activities.

1.14 Volunteers

A substantial contribution to the activities of Shaare Zedek UK is supplied in the form of voluntary services for raising funds. The financial benefit of these non-cash donations have not been recognised in these accounts as by their nature it would be impractical to quantify in monetary terms.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Specifically, the Trustees have made judgements on the apportionment of support and governance costs across the various charitable activities (see note 8 for further details) - the basis of this apportionment has remained consistent to prior years.

In the view of the Trustees, with the exception to the above, there are no significant accounting estimates and judgements applied.

3 Income from donations and legacies

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Donations and gifts	497,577	1,059,758	1,557,335	195,291	846,105	1,041,396
Legacies receivable	473,779	197,360	671,139	440,976	159,450	600,426
	<u>971,356</u>	<u>1,257,118</u>	<u>2,228,474</u>	<u>636,267</u>	<u>1,005,555</u>	<u>1,641,822</u>

4 Income from investments

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Interest receivable	23,347	1,433
	<u>23,347</u>	<u>1,433</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

5 Costs on raising funds

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Costs of generating donations and legacies		
Advertising	40,385	35,679
Other fundraising costs	14,797	4,159
Staff costs	199,255	164,361
Depreciation and impairment	723	603
Support costs	47,776	38,903
	<u>302,936</u>	<u>243,705</u>

6 Expenditure on charitable activities

	Payments to hospital 2023 £	Payments to hospital 2022 £
Direct costs		
Staff costs	24,694	23,258
Depreciation and impairment	723	603
Payments to hospital	1,708,473	1,280,758
	<u>1,733,890</u>	<u>1,304,619</u>
Share of support and governance costs (see note 7)		
Support	53,871	45,229
Governance	18,599	16,932
	<u>1,806,360</u>	<u>1,366,780</u>
Analysis by fund		
Unrestricted funds	550,142	374,214
Restricted funds	1,256,218	992,566
	<u>1,806,360</u>	<u>1,366,780</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

7 Support costs

	Support costs	Governance costs	2023		Governance costs	2022
	£	£	Support costs	Governance costs	£	£
Staff costs	43,293	18,599	61,892	40,189	16,932	57,122
Premises costs	29,380	-	29,380	23,450	-	23,450
Other costs	28,974	-	28,974	20,493	-	20,493
	<u>101,646</u>	<u>18,599</u>	<u>120,246</u>	<u>84,132</u>	<u>16,932</u>	<u>101,065</u>
Analysed between						
Fundraising	47,775	-	47,776	38,903	-	38,903
Charitable activities	53,871	18,599	72,470	45,229	16,932	62,161
	<u>101,646</u>	<u>18,599</u>	<u>120,246</u>	<u>84,132</u>	<u>16,932</u>	<u>101,065</u>

Support costs excluding staff costs which cannot be directly attributed have been apportioned equally between costs of raising funds and the charitable activity of payments to the hospital. Within support costs, other costs include telephone costs, postage costs, travel costs, computer running costs and staff training costs.

Staff costs have been apportioned on an estimated basis of the allocation of time spent on each specific activity.

8 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

	2023	2022
	£	£
Audit of the annual accounts	<u>16,905</u>	<u>14,400</u>
Non-audit services		
All other non-audit services	<u>121</u>	<u>121</u>

9 Trustees

None of the Trustees (or any persons connected with them) received any remuneration, nor reimbursement of travelling expenses during the year or prior year.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

10 Employees

The average monthly number of employees during the year was:

	2023	2022
	Number	Number
Administration	2	1
Fundraising	2	3
Finance	1	1
	<u> </u>	<u> </u>
Total	5	5
	<u> </u>	<u> </u>

Employment costs	2023	2022
	£	£
Wages and salaries	259,847	219,075
Social security costs	21,501	20,225
Other pension costs	4,495	5,441
	<u> </u>	<u> </u>
	285,843	244,741
	<u> </u>	<u> </u>

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2023	2022
	Number	Number
Between £70,000 - £79,999	-	1
	<u> </u>	<u> </u>

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2023	2022
	£	£
Aggregate remuneration	100,523	91,167
	<u> </u>	<u> </u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

11 Other

	Unrestricted funds	Unrestricted funds
	2023	2022
Net loss on disposal of tangible fixed assets	276	378
Audit fees	16,905	14,400
Legal and professional fees	3,241	609
	<u>20,422</u>	<u>15,387</u>

12 Gains and losses on investments

	Unrestricted funds	Unrestricted funds
	2023	2022
	£	£
Gains/(losses) arising on:		
Revaluation of investments	-	(99)
	<u>-</u>	<u>(99)</u>

13 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

14 Tangible fixed assets

	Plant and machinery	Fixtures, fittings & equipment	Total
	£	£	£
Cost			
At 1 January 2023	6,471	6,819	13,290
Additions	930	594	1,524
Disposals	-	(468)	(468)
	<u>7,401</u>	<u>6,945</u>	<u>14,346</u>
At 31 December 2023	7,401	6,945	14,346
Depreciation and impairment			
At 1 January 2023	5,712	2,853	8,565
Depreciation charged in the year	991	456	1,447
Eliminated in respect of disposals	-	(192)	(192)
	<u>6,703</u>	<u>3,117</u>	<u>9,820</u>
At 31 December 2023	6,703	3,117	9,820
Carrying amount			
At 31 December 2023	<u>698</u>	<u>3,828</u>	<u>4,526</u>
At 31 December 2022	<u>759</u>	<u>3,966</u>	<u>4,725</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

15 Fixed asset investments

	Listed investments £
Cost or valuation	
At 1 January 2023 & 31 December 2023	211
Carrying amount	
At 31 December 2023	211
At 31 December 2022	211

16 Debtors

	2023 £	2022 £
Amounts falling due within one year:		
Other debtors	31,946	6,572
Prepayments and accrued income	643	643
	<u>32,589</u>	<u>7,215</u>

17 Loans and overdrafts

	2023 £	2022 £
Bank overdrafts	8	8
	<u>8</u>	<u>8</u>

18 Creditors: amounts falling due within one year

	Notes	2023 £	2022 £
Bank overdrafts	17	8	8
Other taxation and social security		8,808	6,023
Trade creditors		12,397	5,216
Other creditors		1,180	1,232
Accruals		15,001	13,201
		<u>37,394</u>	<u>25,680</u>

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

19 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 January 2022		Movement in funds			Balance at 1 January 2023			Movement in funds			Balance at 31 December 2023	
	£	£	Incoming resources	Resources expended	£	Incoming resources	Resources expended	Transfers	Investments gains/losses	£	£	£	£
Bikur Cholim Campus	3,515	12,045	156,822	(12,000)	3,560	156,822	(156,722)	-	-	-	-	3,660	
Children's Hospital	3,323	161,836	-	(165,159)	-	-	-	-	-	-	-	-	
Emergency Department	2,552	26,392	19,000	(28,892)	52	19,000	(18,500)	-	-	-	-	552	
Neurosurgery and Neurology Department	638	1,134	-	(500)	1,272	-	-	-	-	-	-	1,272	
Others	31,802	244,195	386,606	(217,639)	58,359	386,606	(386,606)	-	-	-	-	58,359	
Paediatrics department	-	-	300	-	-	300	-	-	-	-	-	300	
Neonatal Intensive Care Unit	7,433	53,516	10,000	(54,092)	6,857	10,000	(10,000)	-	-	-	-	6,857	
Nursing Scholarships	-	89,626	-	(89,626)	-	-	-	-	-	-	-	-	
Intensive Care Department	201	-	-	-	201	-	-	-	-	-	-	201	
Coronavirus Department	7,866	18	-	(7,866)	18	-	-	-	-	-	-	18	
Outpatient Clinic	-	416,793	393,991	(416,793)	-	393,991	(393,991)	-	-	-	-	-	
Imaging, Biobanking and Sequencing Diagnosis Methods	-	-	290,400	-	-	290,400	(290,400)	-	-	-	-	-	
	57,330	1,005,555	1,257,118	(992,567)	70,319	1,257,118	(1,256,218)	-	-	-	-	71,219	

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

19 Restricted funds

(Continued)

Bikur Cholim Campus is a separate campus hospital that merged with Shaare Zedek Medical Centre in Jerusalem. The fund is dedicated to fund the general running of the hospital. The surplus of £3,660 will be used next year to fulfil the objectives of the project.

The Emergency Department was set up to develop and extend the existing size of the old department. The fund is dedicated to cover running costs for the department. A surplus of £552 is being carried forward to next year.

The Neurosurgery and Neurology Department at the Shaare Zedek Medical Center treats a wide range of diseases involving the nervous system, with the aim of preserving and restoring brain and spine function and has a designated operating theatre which includes a new navigating system, intra-operation ultra-sound and an innovative robot enabling procedures such as tumor tissue biopsy with great precision. The fund is dedicated to provide equipment and cover general running costs for the department. The surplus of £1,272 is being forward to the following year.

Included within Others are various smaller funds which relate to various activities including CT Scanner, various pieces of equipment, Haematology Department, Urology Department, pending allocation, Geriatrics Department, Cardiology Department and LDA Educational Institute. A surplus of £58,359 is being carried forward to meet the project objectives of these departments.

Our state of the art new ICU was upgraded in 2017 the first major upgrade and renovation of this Unit since the hospital moved to its current location in 1979. The Unit is now equipped with the latest technology and care methods in the most advanced setting possible. The risk of infection is a top priority for intensive care patients. The redesigned ICU gives each patient their own largely self-sufficient room to minimise the spread of infection. Almost all of the equipment is wall or ceiling mounted, meaning the room can be kept to a higher standard of cleanliness. There are 14 patient rooms in total, almost all of which are in constant use.

The Cardiology Department provides a comprehensive response to the gamut of cardiac and cellular diseases. Our team performs catheterization, installs stents in the coronary arteries and implants pacemakers, defibrillators and valves without open heart surgery. There is also a state-of-the-art Cardiac Imaging Institute which uses 3-D Echo, CT and MRI. We can also administer advanced treatment for congenital and structural disorders. The department stresses preventative care and accompanies patients throughout the post-heart attack rehabilitation process.

Robotic surgery is a field which has developed in recent years, increasingly becoming a standard and indispensable approach to care in a variety of surgical disciplines. It allows extremely fine and complex movements in a tight space, without the need to open large cavities that can involve more complications and a longer, more painful recovery period. Appreciating that this represents the future of modern surgery, we are proud that Shaare Zedek Medical Centre, which currently sees around 35,000 surgical procedures performed each year, has been a local pioneer in introducing advanced robotic approaches to the Israeli medical community.

In terms of the outpatient clinic, out of the 800,000 patients who are treated at Shaare Zedek Medical Center each year, the vast majority are treated on an ambulatory basis in our more than 70 outpatient units and clinics. In general, the trend in modern medicine is to reduce the need for inpatient hospitalization wherever possible, as this increases costs, emotional and practical challenges for the patient and is also less desirable from a medical perspective. For all these reasons, outpatient care is the growing trend in modern hospital care and Shaare Zedek has firmly embraced this trend with increased investment in these services. The central area for the large majority of our ambulatory services is in the Margulies Outpatient Clinics which are divided between the Fourth and Fifth Floors of The Next Generation Building.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

19 **Restricted funds** (Continued)

The Paediatrics department has a surplus of £300 at the year end to be expended in the following year.

The Neonatal Intensive Care Unit (NICU) at the Shaare Zedek Medical Center treats infants born from week 24 of pregnancy. The complex includes 70 beds (with another 20 at the Bikur Cholim Campus), and state-of-the-art respiratory and monitoring equipment which provides precise data 24/7 on each of the babies in the unit. The fund is dedicated to provide equipment and cover general running costs for the department. A surplus of £6,857 is being carried forward to the following year.

Our Intensive Care Unit treats the most severe urgent care cases in the hospital. 70% of cases are post-surgery while others are complex cases referred from the Internal Medicine Departments. A surplus of £201 is being carried forward to the following year.

The Coronavirus department still has a surplus of £18 which is being carried forward to the following year.

The trustees are satisfied that sufficient resources are held in an appropriate form to enable each fund to be applied in accordance with any restrictions.

20 **Endowment funds**

Endowment funds represent assets which must be held permanently by the charity. Income arising on the endowment funds can be used in accordance with the objects of the charity and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

	Balance at 1 January 2022	Movement in funds				Incoming resources	Resources expended	Movement in funds				Incoming resources	Balance at January 2023	Investments gains/losses	Transfers	Resources expended	Investments gains/losses	Balance at 31 December 2023	
		£	£	£	£			£	£	£	£								£
Permanent endowments																			
Rayne Endowment Fund	42,465	-	-	-	-	-	42,465	-	-	-	-	-	-	-	-	-	-	-	42,465
	42,465	-	-	-	-	-	42,465	-	-	-	-	-	-	-	-	-	-	-	42,465

The Rayne Endowment Fund was donated by Lord Rayne to fund an international urology conference held at Shaare Zedek Medical Centre.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

21 Unrestricted funds

The income funds of the charity include unrestricted funds, within which designated funds have been set aside by the trustees for specific purposes:

	Movement in funds		Movement in funds		Movement in funds		Balance at 31 December 2023
	Balance at 1 January 2022	Incoming resources	Resources expended	Balance at 1 January 2023	Incoming resources	Resources expended	
Designated - Neo-Natal Department	-	466	-	466	-	-	466
Designated - Paediatric Oncology	-	104	-	104	384	-	488
Designated - Emergency Department	-	2,552	(2,552)	-	-	-	-
Designated - Pending Allocation	37,606	69,748	(92,757)	14,597	-	-	14,597
Designated - Helmsley Cancer Centre	-	259,326	(190,772)	68,554	-	(68,554)	-
Designated - Nursing Scholarships	-	2,000	(1,400)	600	-	-	600
Designated - Coronavirus Department	-	32	-	32	138	-	170
General Unrestricted Fund	829,502	303,472	(345,924)	787,050	994,182	(804,946)	976,286
	867,108	637,700	(633,405)	871,403	994,703	(873,500)	992,606

The Neo-natal and Paediatric Oncology funds were set up to support running costs for the department.

The Pending Allocation Fund relates to a single donation which is yet to be remitted to the Shaare Zedek Medical Centre for a specific department.

Hemsley Cancer Centre fund was set up to support running costs for the department.

The Nursing Scholarships fund was set up to provide support and training for student nurses.

The Coronavirus Fund was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation.

The General Unrestricted Fund relates to "free reserves" after allowing for all designated funds.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023**

22	Analysis of net assets between funds	Unrestricted funds		Designated funds		Restricted funds		Endowment funds		Total		Unrestricted funds		Designated funds		Restricted funds		Endowment funds		Total		
		2023	£	2023	£	2023	£	2023	£	2023	£	2023	£	2022	£	2022	£	2022	£	2022	£	2022
	Fund balances at 31 December 2023																					
	are represented by:																					
	Tangible assets	4,526		-		-		-		-		4,725		-		-		-		-		4,725
	Investments	211		-		-		-		-		211		-		-		-		-		211
	Current assets/(liabilities)	971,549		16,320		71,219		42,465		1,101,553		782,113		84,354		70,319		42,465		979,251		979,251
		976,286		16,320		71,219		42,465		1,106,290		787,049		84,354		70,319		42,465		984,187		984,187

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

23 Operating lease commitments

Lessee

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2023	2022
	£	£
Within one year	15,000	15,000
Between two and five years	27,500	42,500
	<u>42,500</u>	<u>57,500</u>

24 Related party transactions

Transactions with related parties

Aggregate donations received from related parties without conditions amounted to £520,740 (2022: £421,374) for the year.

25 Analysis of changes in net funds

The charity had no material debt during the year.

26 Cash generated from operations	2023	2022
	£	£
Surplus for the year	122,103	17,284
Adjustments for:		
Investment income recognised in statement of financial activities	(23,347)	(1,433)
Loss on disposal of tangible fixed assets	276	378
Fair value gains and losses on investments	-	99
Depreciation and impairment of tangible fixed assets and investments	1,447	1,206
Movements in working capital:		
(Increase)/decrease in debtors	(25,374)	3,891
Increase in creditors	11,715	4,942
Cash generated from operations	<u>86,820</u>	<u>26,367</u>

SHAARE ZEDEK UK

England & Wales - Charity number 1143272

Accounts

Charity registration number 1143272

Company registration number 07469168 (England and Wales)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Mr Michael Sorkin Mr Anthony Rosenfelder Mr Alain Stechler Mr Martin Paisner Mr Michael Sandler Mr Nigel Sloam Mr Jonathan Paull	(Appointed 9 September 2022)
Charity number	1143272	
Company number	07469168	
Registered office	4 Theobald Court Theobald Street Borehamwood Hertfordshire United Kingdom WD6 4RN	
Auditor	RDP Newmans LLP Lynwood House 373-375 Station Road Harrow Middlesex HA1 2AW	
Bankers	HSBC Bank Plc 8 Canada Square London E14 5HQ National Westminster Plc 135 Bishopgate London EC2M 3UR Barclays Bank PLC 1 Churchill Place London E14 5HP	

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) CONTENTS

	Page
Trustees' report	1 - 15
Statement of Trustees' responsibilities	16
Independent auditor's report	17 - 20
Statement of financial activities	21
Balance sheet	22
Statement of cash flows	23
Notes to the financial statements	24 - 41

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2022

The Trustees present their annual report and financial statements for the year ended 31 December 2022.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Memorandum & Articles of Association, the Companies Act 2006 and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2022).

In this context the Trustees have complied with the duty in section 17 (5) of the 2011 Charities Act in giving due consideration to the Charity Commission's guidance on Public Benefit. The report is prepared in accordance with the small companies' regime (Section 419(2) of the Companies Act 2006).

Principal aims and objectives

"To save a life is to save the world. Nowhere is this clearer than at Shaare Zedek, a hospital not just with a heart but with a soul that makes the world a better place."

Quote from a relative of a Shaare Zedek patient

Our mission is to support, by all such means as may be charitable in law and for exclusively charitable purposes, Shaare Zedek Medical Centre (SZMC) in providing world class care for all patients irrespective of their ability to pay, nationality, age, race or religion. We provide financial support to fund services, capital projects, research and the purchase of equipment for the hospital.

History

Founded in 1902, Shaare Zedek has been known as the "Hospital with a Heart" for more than a century. This reputation as a patient's first choice of hospitals stem from its unwavering commitment to all its patients, regardless of race, religion, political view or country of origin. All patients who are admitted receive the most advanced medical treatment available in a compassionate, supportive and nurturing environment. The hospital's ethos, "delivery of care and pioneering approaches to research", provides hope for us, hope for Israel and hope for the world.

Since 1902, the Hospital has chartered the course of Jerusalem's modern development and has been instrumental in the city's growth. Over half of Jerusalem's children live below the poverty line. Shaare Zedek was one of the first hospitals in Israel to recognise the need for specialist paediatric medical facilities and is home to Jerusalem's only dedicated Women and Children's Hospital.

Shaare Zedek 2022

Today Shaare Zedek is a 1,500-bed facility with close to 100 departments, treating 800,000 patients annually. As the fastest growing hospital in the region, the hospital continues to respond to and plan for the needs of Jerusalem's uniquely diverse population. In 2022 the new Radiotherapy Institute opened, providing a much-needed new facility to expand the support provided to patients from across the region. The most pressing expansion project is the doubling of the size of its Emergency Department. The daily growth in demand on its urgent care facilities in the region necessitates a bigger department with the latest technology to ensure that they are much better equipped to respond.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

Message from Shaare Zedek Medical Centre's Director General

Dear friends,

I welcome this chance to update all our friends of Shaare Zedek in the UK on the truly exciting and potential-filled developments which are ongoing here at Shaare Zedek Medical Centre.

As has always been our vision, progress is defined by our historic desire to respond to the growing needs of the community we are blessed to serve.

When Shaare Zedek opened its doors 120 years ago, the hospital consisted of 20 beds and 40 cows. Within a few years, we'll have grown to some 1,500 beds and be home to dozens of biotech and hi-tech companies. Our vision is to make Shaare Zedek into a centre of advanced technological development that combines the best of clinical medicine with innovative research and scientific accomplishment.

In November 2022 we began treating patients in our new Helmsley Cancer Centre, a remarkable building with an award-winning design. It has been designed to place the patient experience at the very centre and in 2023 we will be opening our newly expanded Department of Emergency Medicine. We know that Israel needs to already be planning to respond to the challenges that will define our national healthcare in twenty years from now. This is specifically what we at Shaare Zedek are involved with, with a strategic and ambitious plan to ensure that the people of the greater Jerusalem region will be afforded the medical response they need and deserve.

As always, I welcome the chance to salute our remarkable team of over 5,000 doctors, nurses, researchers, administrators and maintenance and support staff that call Shaare Zedek their professional home. They are the heart that allows this growth and we all owe them a great debt of gratitude for their dedication every day and night.

I also welcome the chance to express our thanks to you as our partners and caring for the people of Jerusalem and Israel.

On their behalf I want to share my gratitude and deepest thanks for your continued support. I wish you and your families all the best of health and happiness.

Professor Ofer Merin

Director General
Shaare Zedek Medical Centre

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Objectives and activities

Activities

In order to achieve our key objectives, Shaare Zedek UK (SZUK) employs a small office team led by an Executive Director working in partnership with trustees and other lay leaders, supported by a small number of energetic volunteers.

SZUK promotes awareness of the activities of Shaare Zedek. We also seek to promote support of the charitable activities of the hospital, and in particular its charitable activities for the public benefit in health welfare, medical and scientific advancement and best practice in patient treatment. We raise funds through donations, legacies, solicited mailings, events, direct approaches and special appeals.

Achievements and Performance

The impact of our fundraising

Shaare Zedek relies on its donors to provide the standard of care and innovation for which the hospital is known. Every day at Shaare Zedek brings new challenges and achievements. Shaare Zedek prides itself on its ability to adapt to any situation and provide excellent care when it is most needed. Our expertise in emergency preparedness has achieved global recognition during the fight against Covid-19. Below are some examples of the varied challenges and achievements in 2022, all of which would not have been possible without the support of our donors.

Hope for Israel: Ushering in a new era of cancer care

The new Helmsley Cancer Centre officially opened its doors to patients in November 2022. This momentous occasion marks a new era of cancer care in Jerusalem and one of the most momentous developments in Shaare Zedek's 120-year history.

The stunning building represents the culmination of years of planning and construction. Designed by Canadian-based architectural firm Farrow Partners and Jerusalem based Rubinstein-Ofer Architects it has already earned an international architecture award and is sure to become a Jerusalem icon.

The building has been designed to place the patient experience at the centre. Jonathan Halevy, President of Shaare Zedek shared, "The vision of this centre is inspired by our recognition that the emotional needs of cancer patients are often as important as their practical and medical ones."

Standing at six stories high, the large open spaces are infused with natural light from a massive skylight, allowing light to flood the treatment rooms and open spaces even when underground. The beautiful use of wood and the indoor garden bring natural elements and a softness in to the building which are calming and therapeutic. As the trees and plants grow, they will be seen from each level of the building, giving the feeling of outdoors, indoors.

Professor Ofer Merin, Director General of Shaare Zedek was among the first to welcome the patients into the new centre. "This is a truly emotional moment that can provide the countless people involved in making it happen with a sense of deep satisfaction. The greatest beneficiaries will be the medical community of Jerusalem and the surrounding areas who will be able to count our cancer care centre on par with the world's leading facilities."

Spread out over more than 12,000 square meters, the new cancer centre provides a wholly comprehensive approach to oncology care which begins with the Radiotherapy Institute, housed underground to accommodate the extremely heavy and specific engineering requirements for radiation care. The Institute also includes a CT Simulator which is a critical tool for mapping patient care. The upper floors house multiple treatment areas for outpatient care including an all new Oncology Day Hospital and multiple research and teaching facilities with seminar rooms and a dedicated auditorium.

Professor Nir Peled, Director of the Oncology Institute added, "This Centre positions Shaare Zedek to provide leading oncology care defined by advanced technology and compassionate medicine and we have worked to recruit some of the industry's leading physicians and technicians to staff this new facility. This truly ushers in a new era in care."

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

The new Cancer Centre has received a lot of support from British donors, who have provided equipment and room facilities.

Hope for Israel: Government Funding

In 2022 Shaare Zedek received the first round of government funding for core expenses. Over the past few years Shaare Zedek, alongside six other public Israeli hospitals, has been actively working to secure Government funding. These negotiations intensified since the onset of the Coronavirus pandemic. The underlying objective of their efforts has been on addressing the major imbalance between these seven hospitals and the medical centres owned by the government & HMOs. Whilst all hospitals provide a public service without discrimination, operating under the same economic ecosystem implemented by the Ministry of Health, the seven public hospitals have been historically deeply discriminated against when it comes to receiving necessary funding. While the government & HMO hospitals annual deficits were fully reimbursed, Shaare Zedek and others were left without any government support.

For decades this inequality was maintained, with Shaare Zedek and others receiving no government funding. But for many reasons, relating to the overall scope of our activities and the growth of the populations Shaare Zedek Medical Centre (SZMC) serves, this became an untenable situation. This new government support was only approved to help offset the sizable deficit which SZMC (and all the other hospitals now promised support), developed in recent years, exacerbated by the change in operations during the Coronavirus pandemic.

In January 2021, the seven Israeli public hospitals, including SZMC, announced an agreement with Israel's Ministry of Finance which has agreed to include allocations for these hospitals in the budget. The agreement also established that a committee will be created made up of representatives of the Ministry of Health, the Ministry of Finance and representatives of all public hospitals that will present their recommendations to the Government in advance of deliberations over the budget to describe the fiscal status of these hospitals – and with the specific goal of ensuring equal treatment alongside the governmental hospitals.

This followed an exhausting campaign led by Professor Merin and the Director's General of the six other public hospitals affected by the current inequality in the healthcare system and the financial crisis. The agreement from January 2021 was not immediately honoured. Following further negotiations, Shaare Zedek received its first round of Government funding in 2022.

Whilst we can no longer state that we don't receive government support, it is important that we all, and the donor community, appreciate that this doesn't change the critical nature of fundraising. The government funding will cover only 7% of our current operating budget and will need to be reapproved each year. As a hospital that is always moving forward in response to constantly expanding needs, donor funds are more important than ever for Shaare Zedek today and for the years ahead. There is no doubt that these changes are vital for our survival. SZMC is deeply indebted to the countless individuals led by Professor Ofer Merin who worked tirelessly to achieve this objective - and continue to work to address many ongoing obstacles.

Hope for Israel: Health Ministry Survey Ranks Shaare Zedek as Top Jerusalem Hospital in Patient Satisfaction

A Ministry of Health patient satisfaction survey ranked Shaare Zedek as the 'Top Jerusalem Hospital' with regard to patient satisfaction.

Following an intensive two years where Shaare Zedek was the most active Jerusalem hospital in treating cases of Coronavirus, the hospital once again earned the trust of the people of the city with 91% of the people surveyed responding that they feel in good hands at Shaare Zedek.

The survey, conducted by the Israeli Ministry of Health, questioned patients on a variety of factors relating to their treatment including consistency of care, accessibility to information and updates, communication skills of the staff, and overall satisfaction. In response to questions about the efficacy of the care they received, 89 percent of patients responded positively, an increase of 9 percent since the survey was first conducted in 2014.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

These results position Shaare Zedek among the national leaders in patient satisfaction. In particular, patients in the Internal Medicine departments reported an 83 percent level of satisfaction, and in the surgery departments 86 percent, both well above the national averages. The survey found that the most important factors for patients surrounded the availability of staff to communicate with patients and to provide ongoing information, to respond when patients were in pain and discomfort, and the high level of attention given to patient safety.

The results reflect the hospital's ongoing investment in upgrading the overall patient experience through increased staffing and the establishment of a patient advocacy service in all medical departments. The hospital is currently developing a digital platform that will further enhance this area of care and reduce bureaucracy for patient reporting and monitoring. Every morning, the hospital administration performs a review of patient activity with a focus on identifying areas where care can be improved.

Shaare Zedek Director General, Professor. Ofer Merin, responded to the survey results saying: "In 2021 we dealt with significant operational challenges emanating from the pandemic, combined with an escalation in security-related tensions. Despite those challenges, we were proud to be able to continue to see this increase in patient satisfaction which we know reflects our unprecedented investment in the relevant areas of care and in placing increased attention on the overall patient experience. We pledge to continue to enhance this central aspect of care and work to further enhance Shaare Zedek's reputation for advanced and compassionate medicine for the people of Jerusalem."

Hope for the World: Coronavirus: treating Jerusalem through a pandemic, globally relevant research and techniques

The Coronavirus pandemic continued to affect global communities in 2022. Hospitalisations at this stage in the pandemic were only the most severe of cases. In November 2021 Israel confirmed its first case of the omicron variant. Serious cases rose again towards the end of the year and early 2022. In January 2022, the number of seriously ill patients continued to rise. All Israeli hospitals including Shaare Zedek were forced to cut back on non-essential treatments to deal with the spread of the highly contagious Omicron variant.

This period of time has changed the world. Whilst nearly every aspect of our lives has been impacted by Covid-19, Shaare Zedek's role in responding to this disease has been not only the source of enormous challenge, but one of great pride.

The challenge has been in treating a disease that the medical world is only just beginning to understand, whilst being forced to overhaul much of the patient-care infrastructure. Compounding that challenge was the massive investment of financial and human resources placed into Shaare Zedek's Covid-19 response programme, and how the crisis forced the temporary closure of many other departments of the hospital.

The pride emanates from the fact that we quickly became Israel's second most active Covid-19 care hospital and we played a critical function in the care of thousands of Covid-19 patients. There is no doubt that the levels of preparedness that were put into place, some measures which were enacted months before the world had even heard the term Covid-19 were instrumental in the hospital's success.

Whilst treating Coronavirus cases has certainly been a significant focus over the last year at Shaare Zedek, the hospital has remained focused on the broader vision of comprehensive medical care. All major activities remained in place alongside the developmental projects. The crisis required tremendous investment for rapid construction and the purchase of new equipment. This was only possible thanks to the generosity and quick response of our donors. British donors responded generously to our Coronavirus Emergency Campaign, providing vital support for our essential services throughout the pandemic.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Hope for the World: Treating Ukrainian Refugees

In February 2022, the world watched in horror as Russia invaded and occupied parts of Ukraine. The invasion has so far resulted in tens of thousands of deaths on both sides, and instigated Europe's largest refugee crisis since World War II. Shaare Zedek has worked in partnership with medical and relief organisations to provide assistance whenever and wherever possible. Ukrainian refugees came by choice to Shaare Zedek after deciding to flee as tensions escalated, with one young mother giving birth on the day of the invasion. In March, Shaare Zedek took part in its first evacuation mission, working with Hatzolah Air to rescue three refugees including an 85 year old Holocaust survivor and a 97 year old woman. In May, Hatzolah Air, Magen David Adom and Shaare Zedek worked together again to evacuate an 18 Year old Israeli woman with a serious brain infection from a Ukrainian hospital. The mission was led by Dr. Todd Zalut, Director of Shaare Zedek's Department of Emergency Medicine. He was joined by other Shaare Zedek colleagues and Hatzolah Air. The team travelled with specific equipment loaned from the hospital to respond to her acute medical needs. Once in Israel, Magen David Adom had transferred her to the hospital, where Dr. Stefan Mausbach, Director of the Neurological ICU was waiting to take over her advanced care.

Shaare Zedek Director General Prof. Ofer Merin shared, "It is a source of pride to be called upon to treat these patients and to be a part of the international medical effort during these deeply trying times. Shaare Zedek is uniquely positioned to contribute to helping save lives wherever in the world the need exists, and I thank Hatzolah Air for their pivotal role in this mission and to all our staff who responded to the call."

Aaron Adler, CEO of Hatzolah Air commented, "The entire mission was performed in coordination with Shaare Zedek who we have a long-lasting relationship with and we know they will be treated with the care they need and deserve. We continue to rescue and evacuate more patients from the war-struck areas to ensure they are given passage to safe areas for treatment."

Dr. Zalut added that "Both in times of war and peace, Shaare Zedek is ready to respond to all types of medical emergencies. Our Emergency Department staff immediately committed themselves to this complex task which required the involvement of multiple arms of the hospital led by our Neurological and Neurosurgical ICU teams. We take considerable pride in the fact that we have the resources to provide the necessary medical response for this young woman and wish her a full recovery."

Whilst we did not specifically raise funds for the Ukrainian relief efforts, a number of British supporters made donations to our Emergency and Intensive Care departments to thank the staff for the humanitarian relief efforts.

Hope for the World: International collaboration:

In December, six complex heart surgeries were broadcast live from Shaare Zedek to the Innovation in Cardiovascular Interventions Conference (ICI), held in Tel Aviv.

Thousands of cardiologists from Israel and around the world joined the ICI and watched live whilst Dr Danny Dvir, director of the Interventional Cardiology Unit at Shaare Zedek and his medical team impressed the audience with treating each patient successfully.

Dr Danny Dvir shared "We are experienced in performing complex heart surgeries and were very happy to share our knowledge and experience at this important conference. We believe in innovation in cardiovascular surgery and take great pride in being able to treat patients who have previously needed open heart surgery through less invasive cardiovascular approaches."

British donors have funded equipment for the development of telemedicine at Shaare Zedek. British donations have also supported the development of the Cardiology Department.

Hope for Israel: Mass Casualty events: Hope for Israel Amidst a Wave of Terror

2022 is one of the deadliest years on record for victims of terror related incidents in Israel. In November, Shaare Zedek Medical treated a total of 23 victims in one day following a bombing.

Shaare Zedek provides immediate medical and psychological support to victims and their families. In the case of mass casualty events, a telephone and in person drop-in counselling services is set up to ensure anyone needing support can receive it.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022**

British donors have generously supported Shaare Zedek at time of emergency. We received further donations in response to terror attacks in 2022. The majority of funds were used for equipment in the Emergency Department.

Hope for the World: Innovative Procedure Helps Cure Woman Suffering from Two Decades of Tremors

Doctors in the Functional Surgery Program in the Helmsley Neurological Institute started to use a new surgical approach called Deep Brain Stimulation (DBS). This method helps address tremors related to a variety of neurological conditions and marks 'a first for the Israeli hospital and a breakthrough for the treatment of Parkinson's disorder'.

In one case the team treated a 70-year-old Jerusalem woman who had been suffering for over 20 years from Essential Tremors. This is a common symptom of a neurological disease resulting in shaking in the upper limbs, head and the vocal cords. In this case, the patient's condition had deteriorated to the point where she was unable to function normally.

Dr. Hazon explained, "In the case of functional neurosurgery procedures like DBS, we rely on very precise application of electrodes deep in the brain. Using advanced technology, we are able to target the area in question in a precise way, ensuring that the electrodes are placed exactly where needed. After implanting the electrodes, a pacemaker is inserted into the thoracic cavity to provide the electronic source for the electrodes.

The procedure went very well and the patient was able to go home 48 hours later. When the electrodes were activated doctors saw an improvement in her overall functioning which is remarkable. It is a great source of pride to be able to provide this type of life-altering care and we look forward to embracing new methodologies for treating neurological diseases in the future.

Hope for the World: World's thinnest 3D printed cornea implanted at Shaare Zedek

Patients who are blind or whose vision is severely impaired wait for many months to obtain a biological cornea taken from a cadaver. But now, ophthalmologists at Jerusalem's SZMC have achieved a medical breakthrough with the first implant of the thinnest 3D cornea made from synthetic acrylic material and attached to the inside of the patient's cornea.

The synthetic cornea was developed and produced by EyeYon, an Israeli start-up in Ness Ziona. The company has received Health Ministry approval for the use of the implant and has applied for similar approval from the US Food and Drug Administration. It has provided its breakthrough product to a few hospitals in Holland, India and China, but this was the first such surgery in Israel and the thinnest artificial cornea in the world.

The surgery is performed with a unique approach that speeds up recovery – the patient was in the hospital for only a day – and achieves very accurate results that prevent rejection of the implant.

The surgery is performed through an incision of about two millimetres in the wall of the eye, using advanced imaging that enables the attachment of the implant to the patient's endothelial tissue.

Hope for the World: Shaare Zedek Scientific

Shaare Zedek Scientific (SZS) had another year of rapid growth in 2022. It is SZS's goal to act as an innovation bridge between leading companies in the fields of medical research and the hospital. SZS is responsible for research and development collaborations between the Medical Centre and industry, including implementing new technologies in the field of digital health and providing access to medical data through Shaare Zedek's Innovation Centre.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

A central pillar of Shaare Zedek's vision is to promote the medical field by engaging in research at all levels. This mission has guided Shaare Zedek for over 120 years, to advance innovative modes of medical care that embrace new technologies and methods for the benefit of the community. Indeed, Shaare Zedek Scientific (SZS) encourages clinicians and scientists to maximize their innovation potential in industry and investigator-initiated research projects across a broad range of applied and theoretical topics and disciplines. This includes basic science, clinical trials, and practical innovation such as development of medical devices. This helps promote an always-expanding and increasingly productive collaboration with key industry players. SZS provides the professional support the investigators require to foster a fruitful interaction with industry players and other academic institutes. Today, through the dynamic infrastructure Shaare Zedek has created, it is increasingly positioned to push those goals even further and expand beyond boundaries for enhancing healthcare science all over the world.

SZS has formed many partnerships this year in researching Covid-19. The BioBank has become a resource to companies around the world.

SZS's partnership with Google continues through their life-science focused sister company, Verily. After more than two years of intensive research activity, the partnership is now focused on an ongoing study to apply AI technologies for gastroenterological diagnoses leading to the opening of Verily's new R&D centre in Haifa. Overseen and managed by SZS, the project is a historic recognition of our hospital's research capabilities enabling us to directly partner with world leaders in health-tech and data technologies.

A partnership with Sight Diagnostics has been formed to identify the possibility of blood cancer using a combination of images and data collected from Sight's OLO device and patient clinical information provided by the hospital. The research focuses on developing the capability to detect and classify white blood cells, and more specifically, to differentiate between different types of white blood cells in the immune system called lymphocytes, a procedure that has greatly challenged the global haematological community.

As Shaare Zedek enters into new areas of patient care, whilst developing new technologies and research focused on medicine for the future, Shaare Zedek believes its unique approach to integrated and personalised medicine will continue to cement its mark on Jerusalem, Israel and across the world.

SZS has joined the team of experts working with the biotech incubator incentive. Within the recently launched collaboration, Shaare Zedek's medical experts will work alongside teams from the incubator and their portfolio of companies to make the hospital's research resources and insights available for the benefit of relevant projects. Shaare Zedek will join the investment committee of the incubator, which is owned by Peregrine Ventures and help advance investments that are being promoted by the incubator. Dr. Renana Ofan, Director of Shaare Zedek Scientific said, "This partnership with Incentive is the next stage in the rapid growth Shaare Zedek is experiencing in the further embrace of groundbreaking technologies and innovation. We welcome this chance to collaborate with the remarkable teams at Incentive and Peregrine and look forward to working together on the many joint projects that lie ahead.

In a further effort to embrace the innovative and entrepreneurial spirit among our medical staff, SZS launched a program for some of our leading medical residents to educate them about the company and relevant opportunities. The course introduces the doctors to the worlds of commercial innovation and development with members of the company's marketing team providing individualized consulting. Medical residents participating in the program work alongside a senior member of our medical staff or a relevant executive from one of our industry partners to help them take their research and development ideas all the way from initial concept to implementation.

Research Conference Advancing healthcare solutions

In March 2022, SZS hosted their third conference on Medical Research and Innovation.

The conference entitled "The Next Generation of Researchers" highlighted the accomplishments of young researchers and innovators at both Shaare Zedek and among partner institutions and companies. The pace of medical research at Shaare Zedek is constantly rising and over the past year 600 studies were published involving Shaare Zedek researchers.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

The conference featured a variety of short presentations and lectures as well as the presentation of several achievement awards for some outstanding research programs and collaborations between scientists and physicians. Many studies focused on lessons learned from research into treatment of Covid-19 as well as clinical experience in response to the vaccination effort.

Shaare Zedek Director General Prof. Ofer Merin said, "Amidst the immense clinical and operational challenges which have defined public healthcare over the past two years, Shaare Zedek has forged ahead in defining ourselves as a leader in medical research. We take great pride in the role we play in advancing healthcare science both locally and around the world. As a hospital treating over one million medical cases each year in one of the world's most ethnically and genetically diverse population centres, we offer a clinical resource that can directly benefit scientific advancement in so many different areas. I salute all the many members of our Shaare Zedek team who are involved in further developing our accomplishments in this area and look forward to witnessing only continued achievements."

The keynote lecture was presented by Nobel Prize Laureate Prof. Aaron Ciechanover. He focused on his research into how the body's ability to breakdown proteins has become one of the most important areas of study in recent years, both for advancements in clinical care and pharmaceutical development.

The conference, which opened with remarks by Jerusalem Mayor Moshe Lion, was held in partnership with the Jerusalem Municipality, the Jerusalem Development Authority, BioJerusalem, the Hebrew University of Jerusalem and the Israel Ministry of Jerusalem and Heritage.

Hope for Israel: First in Israel Glaucoma Treatment

Shaare Zedek became the first hospital in Israel to perform a unique implant procedure for treatment of glaucoma that has been proven to significantly reduce the spread of the disease and prevent blindness.

The procedure was performed in the Glaucoma Treatment Unit and involved a highly complex and precise approach that had never been used before in Israel called Preserflo Microshunt. The microshunt has been proven to have excellent results in addressing intraocular pressure and significantly reduces the length of the surgery and the overall recovery time for the patient.

The procedure was performed by Dr. Motti Goldberg, Director of the Glaucoma Treatment Unit at Shaare Zedek who explained, "Glaucoma is the second most prevalent cause of blindness in the western world and becomes increasingly common with age. The disease is defined by damage to the optical nerve in ways that cannot always be felt, but can lead to irreversible blindness and is therefore often referred to as the "silent blinding disease."

"This Preserflo Microshunt is the most advanced of its type in the world today and is made up of a minuscule tube with a dimension of just 70 microns that is designed to significantly reduce and control the pressure in the eye in ways that make for safer surgeries."

The first patient to benefit from the new approach was 70 year old David Zuckerman, a resident of Beit El and father of 8 children and 40 grandchildren. Over the past year he needed to undergo cataract surgery which revealed that he was suffering from advanced glaucoma. As soon as he heard about the new approach, he welcomed the chance to be the first patient in Israel.

"Within three hours of the surgery I was already feeling good and I feel very appreciative that I was the first patient able to benefit from this procedure. I want to thank Dr. Goldberg and Dr. Strassman who cared for me with such professionalism and I hope that many other patients will be able to benefit from this innovative approach," Zuckerman said.

British donations have funded equipment in the Ophthalmology Department.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

UK funding

Donors choose to support any of the hospital's 100+ departments with which they have a personal affinity, as well as responding to our appeals to support the needs of specific departments as dictated by the Board of the hospital. This year donors supported a variety of departments by funding equipment, rooms, facilities and scholarships.

The hospital departments benefitting most from UK donations in 2022:-

Cleveland Clinic Fellowship, Coronavirus Equipment, Emergency Department, Lincoln David Abraham Paediatric Educational Institute, Neo-Natal Intensive Care Unit, Neurology & Neurosurgery, Outpatient Clinic, Paediatric Gastroenterology, Paediatric Nephrology, Paediatric Neurology, Paediatrics, Paediatric Ultrasound Suite, Radiotherapy Institute and Urology. In addition to this, several donors choose to fund Nursing Scholarships.

Donors in 2022 who asked for their donations to be used for most urgent needs of the hospital were allocated amongst these departments listed above. Where we receive donations without restriction, the UK office works with colleagues at Shaare Zedek to identify appropriate use of funds to ensure the maximum impact of UK donations.

There is a strong British footprint in every one of the hospital's 14 internationally recognised Centres of Excellence. Fundraising in the UK has always been conducted in close partnership with the leadership of the hospital in Jerusalem. In March 2019 Professor Ofer Merin became the Director-General of SZMC, with former Director-General Professor Jonathan Halevy becoming the President of the hospital. Professor Halevy continues to lead the fundraising strategy for the hospital in this role. Collaboration between professional colleagues and board members grows each year. This year our staff were able to visit the hospital in person for the first time since the pandemic ended. We have enjoyed a close working relationship with both the President and Director General of the hospital and their teams. This year the UK team once again joined a call bringing the international offices fundraising for Shaare Zedek together to discuss further collaboration. We look forward to a continued partnership with Professors Halevy and Merin and are indebted to them for their visionary leadership and continued service. We are grateful to the entire fundraising team at SZMC who support our fundraising efforts on the ground in Israel.

Objectives for 2022

These were the specific objectives in 2022 and how we performed to meet them:

Objective 1: Fundraising for Shaare Zedek Medical Centre

Financial and operational planning for 2022 was conservative. Without knowing how long the pandemic would last or the impact it would have on our work and the work of the hospital, our financial forecast was prepared for a scenario where appeal costs were covered and a small number of major gifts were received. Despite the uncertainty of the times, the generosity of our donors has resulted in us being able to raise £1,641,822 this year, with £1,366,780 already sent to the hospital.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Fundraising programmes and events

The most successful fundraising methods were part of our ongoing relationship with existing major donors, legacy gifts and in response to direct mail and email campaigns.

In early 2022 our Events Fundraiser left the team and as yet has not been replaced. Following the return of in-person events post-pandemic, we took part in a small number of events this year.

In 2019 we launched the Shaare Zedek Theatre Club. Planning for future theatre trips resumed in 2022. The first trip took place in 2022 once donors had shared their confidence in returning to theatres post-pandemic.

Sporting events and challenges pre-pandemic were traditionally an important source of income for us. We are very fortunate to have dedicated supporters who are willing to raise money for our cause. This included the Maccabi Fun Run, the Royal Parks Half Marathon and the London Marathon. Sporting challenges this year raised a total of £3,529. As life returns to normal, we expect to recruit more challenge participants and raise more funds in 2023.

We continued to hold online events focused on medical areas of Shaare Zedek's expertise. This included an online webinar in conjunction with UK fertility charity Chana. We look forward to more collaboration opportunities to share the expertise of the hospital to wider audiences. In 2023 we are seeking to recruit additional fundraising staff to the team to ensure our events activities can engage our existing and potential supporters in more impactful ways.

Our Lifecycle giving programme continues to be popular, offering certificates and personalised cards for those celebrating birthdays, anniversaries and festivals, and those who wish to support Shaare Zedek by asking family and friends to make donations to the hospital. Lifecycle giving also includes Yahrzeit donations and our Permanent Yahrzeit Programme, which provide comfort and connection for donors wishing to honour the memory of loved ones with a gift to support the health of future generations. We hope to invest in this income stream as part of our 2023 strategic review, with a view to significantly increasing income long-term.

Our marketing and communications strategy has continued to develop with an emphasis on personality and warmth, showing supporters the impact of their gifts and providing the living bridge between donors and the hospital. Our website, Facebook and Instagram pages and regular email updates allow donors to stay up to date with activities in the UK as well as at the hospital. Donors now have the ability to fundraise within our website, setting their own fundraising challenges and activities without the cost of using third party platforms, enabling all of the funds raised to benefit the charity directly. Our social media channels have been a central point through which we have engaged with supporters and wider audiences during the pandemic. The emotive stories from the hospital have provided much inspiration and motivation for donations.

Our four annual direct-mail campaigns continue to raise significant funds for the charity. We continue to see a pattern of more donors responding to appeals, but many are giving smaller donations, with an overall drop in income this year. With more donors choosing to give multiple times a year, it is essential for us to continue to produce engaging and meaningful content that connects donors to the hospital, demonstrating the impact of their support. We were expecting to see a larger decline in income after the strength of support without the urgency of the emergency campaign this year. Supporters were warm in their response to our direct mail campaigns and keen to do what they could, understanding the continued need for support during the pandemic.

Several synagogues, notably Edgware Adath Yisroel Synagogue, support our endeavours through their Kol Nidre Appeals. We are trying to develop relationships with more communities to increase awareness and fundraising capabilities.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Calendar advertising has been declining in recent years. The calendar is an effective marketing tool, particularly for legacies and as such, is still an important publication which is also profit making.

We receive a small but growing number of gifts in kind to support our work. We are grateful to donors who provide meeting rooms and venues free of charge in order for us to conduct our activities.

Payments to hospital

During the year the Charity remitted £1,366,780 (2021: £1,776,392) to Shaare Zedek Medical Centre in support of its activities and for related support and governance costs.

Improving our operations and strategic planning

A new Chairman was appointed in 2022. Working with the Executive Director and trustees, a strategic and operation review of the charity was conducted in late 2022 and presented to trustees in early 2023.

The organisational strategy continues to be implemented with a focus on key areas for organisational growth and fundraising opportunities based on our organisational strengths, key areas for improvement and new opportunities. All areas of activity are subject to regular evaluation and analysis.

We continue to develop contacts with other potential Members and a new committee of lay leaders is in the process of being recruited as part of succession planning by our trustees.

Supplier costs are regularly reviewed resulting in savings from renegotiating supplier contracts. As our communications materials continue to increase donor engagement, it is our intention to create sponsorship opportunities to meet these costs in order to keep administrative expenses as low as possible.

The CRM system used to manage donor records is regularly updated to comply with the GDPR legislative guidance to ensure we are fully compliant with the legislation. We continually update our donor records in advance of our appeals to ensure donors are contacted only when they wish to be, keeping good faith with our supporters and saving the charity unnecessary expenditure on producing and mailing appeals. We are registered with the Fundraising Regulator and the Fundraising Preference Service and to date have never received any complaints through either body.

Financial review

The current economic climate continues to impact on our ability to raise new funds. Given the tough climate we were delighted to have raised £1,641,822 (2021: £2,110,242). We have maintained a healthy financial position with closing fund balances totalling £984,187 (2021: £966,903) of which £70,319 (2021: £57,330) relates to restricted funds and £42,465 to general endowment fund. Furthermore, £84,353 (2021: £37,606) within the closing unrestricted fund balance is designated for specific purposes. Hence, the general unrestricted funds the charity holds amounts to £787,050 (2021: £829,502) at the end of the reporting period after making allowance for restricted and designated funds. We are delighted to have raised significant funds enabling us to send £1,366,780 (2021: £1,776,392) to Shaare Zedek in Jerusalem in relation to our charitable activities and support costs. This year we were in a position to send over 83% of our total income directly to the hospital, the balance being held in reserves in the UK.

Legacy gifts continue to be a vital source of income, with 37% of all donations this year being from legacy gifts in donors' wills. Legacies are unpredictable, at times materialising without our prior knowledge and we continue to maintain and develop this income whilst recognising the need for a diversification of income from other sources to maintain the level of support we currently provide to the hospital. We also recognise the importance of the connections we foster with our donors, and the value they place on our relationships in trusting us to be guardians of their legacies.

General donations, including major gifts, totalled £1,041,396 (2021: £1,291,883). Although we continue to enjoy the support of our loyal donors, the economic situation continues to be challenging. In common with other charities, we continue to find ways to engage new donors in a challenging climate. Some existing donors are lowering their donations due to reduced income to their Trusts or changes in personal circumstances.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Reserves policy and going concern

It is the policy of the Charity to maintain unrestricted funds, which are the free reserves of the Charity, at a level that takes account of the likely administration costs of the Charity over the next 24-month period. The Board has the power to invest in such assets in secure money market instruments.

Risk management

The Board has assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and is satisfied that systems are in place to mitigate its exposure to those risks.

Plans for the future

With our new Chair in post, a new strategic plan has been agreed to grow the charity. In May 2023 our Executive Director decided to leave the charity after dedicating herself to the role for 10 years. She finished working with us at the end of July 2023. An experienced fundraiser has been appointed as a successor and started working in June 2023. The trustees have worked closely with our outgoing and incoming CEO's to ensure a smooth transition, which has focussed on the continuity of donor relationships. The Chair is in discussions with Shaare Zedek's director General and President regarding their plans and priorities for the future. We are supporting the expansion of the Emergency Room and funding the remaining projects available in the new Cancer Centre in addition to the annual requests received from the hospital to upgrade existing equipment and facilities and purchase the latest new technology.

2022 has been a challenging and rewarding year for the charity in the UK and the hospital in Jerusalem. We hope to return to our regular programme of events and activities and use our ability to connect donors to our medical professionals through further online events. There is an acute need to obtain mid-level and major gifts on an annual basis or preferably a multi-year pledge basis. Efforts to increase major gift fundraising were planned to focus on applications to trusts and foundations, alongside our renewed efforts to engage new and existing mid-level donors. As a result of the Covid-19 pandemic and a reduction of staff, the expansion of our fundraising efforts has not yet been possible and this year has been focused on existing donor relationships and the recruitment and induction of our new Chair.

Our professional team has worked exceptionally hard in difficult circumstances to ensure that our levels of activity and donor engagement could support the hospital.

From the internal research we have conducted, the SZUK message is very strong with existing donors. We need to expand awareness of the hospital amongst the Jewish community and wider society to ensure that we can engage with future generations of supporters. The core brand message has informed new approaches to marketing, events and other activities that work towards this aim. Engaging new major donors will be a greater challenge in the current climate but we are working on creative ways to use the international resonance of a front-line hospital fighting a global pandemic to engage new supporters at all levels.

Recruitment, appointment and terms of office of Trustees

Trustees are appointed in accordance with the Charity's Memorandum & Article of Association. As stated above, In 2021 an active search for a new Chair of SZUK began. Jonathan Paull was appointed as Chair in late 2022. Trustees are actively recruiting for new trustees to ensure our board represents the diversity and breadth of our supporter base and wider society.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 14 December 2010 and registered as a charity on 8 August 2011. The charity's reference and administrative details are as set out within these accounts. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

The Board of Trustees

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr Michael Sorkin
Mr Anthony Rosenfelder
Mr Alain Stechler
Mr Martin Paisner
Mr Michael Sandler
Mr Nigel Sloam
Mr Jonathan Paull

(Appointed 9 September 2022)

Key personnel

The following individuals whilst not statutory members of the charity were involved in an advisory capacity:

Dan Adler
David Bernstein
David Cohen
Geoffrey Goldkorn
Eva Greenspan
John Jay
Margot Lew
Angela Margolis-Raz
Marcus Margulies
Hilary Natoff
Jonathan Paull
Marcus Pearl
Margaret G Rothem
Simon Sackman
Nolan Wengrowe
Michael Ziff
Emma Pearl

Recruitment, appointment and terms of office of Trustees

Trustees are appointed in accordance with the Charity's Memorandum & Articles of Association. As stated on page 13 above, we are delighted to welcome Jonathan Paull as a new trustee and chair, who was appointed on 9 September 2022.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

Trustee Induction and Training

New trustees are made aware of the organisational structure of the charity and are shown financial statements of the charity for the three preceding years.

All trustees are now already familiar with the practical work of the charity. Induction procedures are in place for new trustees.

Operations and staffing

Up until the end of July 2023, the trustees delegated day to day management of the charity to the Executive Director, Simona Bennett to deliver the aims and objectives of the charity. Oshrit Cowan, who started with the charity in June 2023, has now been appointed as Simona's successor.

Safeguarding

Shaare Zedek UK has a Safeguarding Policy. In 2019 the Executive Director completed safeguarding training with the NSPCC. The charity makes regular enquiries of the hospital with regard to its own robust safe-guarding policies and notification of any relevant safeguarding issues we should be aware of. All SZUK staff will now be required to undergo safeguarding training and DBS checks as we expand our outreach work into the community.

Related parties

Aggregate donations received from related parties without conditions amounted to £421,374 (2021: £595,956) for the year.

Aggregate remuneration of key management personnel amounted to £91,167 (2021: £78,000) for the year.

Auditor

A resolution proposing that RDP Newmans LLP be reappointed as auditors will be put to the members.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

The Trustees' report was approved by the Board of Trustees.

Mr Jonathan Paull

Trustee

Dated: 12 September 2023

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2022**

The Trustees, who are also the directors of Shaare Zedek UK for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the charity and financial information. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF SHAARE ZEDEK UK**

Opinion

We have audited the financial statements of Shaare Zedek UK (the 'charity') for the year ended 31 December 2022 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, including the trustees' report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

SHAARE ZEDEK UK

(A COMPANY LIMITED BY GUARANTEE)

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBERS OF SHAARE ZEDEK UK

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report prepared for the purposes of company law, is consistent with the financial statements; and
- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

The extent to which the audit was considered capable of detecting irregularities including fraud

We obtained an understanding of the legal and regulatory frameworks within which the charitable company operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006 and The Charities Act 2011 together with the Charities SORP (FRS102). We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company's ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and the group for fraud. The laws and regulations we considered in this context for the UK operations were, General Data Protection Regulation (GDPR), and employment legislation.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the charitable company through discussions with directors and other management, and from our commercial knowledge and experience of the charity sector.
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006 and The Charities Act 2011 together with the Charities SORP (FRS102), General Data Protection Regulation (GDPR), and employment legislation.
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed and tested journal entries to identify unusual transactions and other adjustments for appropriateness, and evaluating the business rationale of significant transactions outside the normal course of business;
- assessed whether judgements and assumptions made in determining the accounting estimates set out in note 2 were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF SHAARE ZEDEK UK**

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- reviewing and agreeing financial statement disclosures and testing to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity's controls, and the nature, timing and extent of the audit procedures performed. There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

**Paresh Radia FCA (Senior Statutory Auditor)
for and on behalf of RDP Newmans LLP**

12 September 2023

**Chartered Accountants
Statutory Auditor**

Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	Unrestricted funds 2022 £	Restricted funds 2022 £	Endowment funds 2022 £	Total 2022 £	Total 2021 £
<u>Income and endowments from:</u>						
Donations and legacies	3	636,267	1,005,555	-	1,641,822	2,110,242
Investments	4	1,433	-	-	1,433	92
Other	5	-	-	-	-	39,413
Total income		637,700	1,005,555	-	1,643,255	2,149,747
<u>Expenditure on:</u>						
Costs of raising funds	6	243,705	-	-	243,705	231,131
<u>Charitable activities</u>						
Payments to hospital	7	374,214	992,566	-	1,366,780	1,776,392
Total charitable expenditure		374,214	992,566	-	1,366,780	1,776,392
Other	12	15,387	-	-	15,387	24,816
Total resources expended		633,306	992,566	-	1,625,872	2,032,339
Net gains/(losses) on investments	13	(99)	-	-	(99)	11
Net movement in funds		4,295	12,989	-	17,284	117,419
Fund balances at 1 January 2022		867,108	57,330	42,465	966,903	849,484
Fund balances at 31 December 2022		871,403	70,319	42,465	984,187	966,903

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET

AS AT 31 DECEMBER 2022

	Notes	2022		2021	
		£	£	£	£
Fixed assets					
Tangible assets	14		4,725		5,783
Investments	15		211		310
			4,936		6,093
Current assets					
Debtors	17	7,215		11,106	
Cash at bank and in hand		997,716		970,437	
		1,004,931		981,543	
Creditors: amounts falling due within one year	19	(25,680)		(20,733)	
Net current assets			979,251		960,810
Total assets less current liabilities			984,187		966,903
Capital funds					
Endowment funds - general	21		42,465		42,465
Income funds					
Restricted funds	20		70,319		57,330
<u>Unrestricted funds</u>					
Designated funds	22	84,353		37,606	
General unrestricted funds		787,050		829,502	
			871,403		867,108
			984,187		966,903

The financial statements were approved by the Trustees on 12 September 2023

Mr Alain Stechler
Trustee

Mr Jonathan Paull
Trustee

Company registration number 07469168

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	2022 £	£	2021 £	£
Cash flows from operating activities					
Cash generated from operations	26		26,366		200,609
Investing activities					
Purchase of tangible fixed assets		(525)		(2,370)	
Proceeds on disposal of subsidiaries		-		100	
Investment income received		1,433		92	
Net cash generated from/(used in) investing activities					
			908		(2,178)
Net cash used in financing activities					
			-		-
Net increase in cash and cash equivalents					
			27,274		198,431
Cash and cash equivalents at beginning of year					
			970,434		772,103
Cash and cash equivalents at end of year					
			997,708		970,434
Relating to:					
Cash at bank and in hand					
			997,716		970,437
Bank overdrafts included in creditors payable within one year					
			(8)		(3)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

Charity information

Shaare Zedek UK is a private company limited by guarantee incorporated in England and Wales. The registered office is 4 Theobald Court, Theobald Street, Borehamwood, Hertfordshire, WD6 4RN, United Kingdom.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's memorandum and articles of association, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income or gift aid donations is recognised at the time the relevant income is receivable.

Legacy income is included in the SOFA when the Charity's entitlement has been established with a sufficient level of certainty, normally on receipt of the legacy or a letter confirming that it will be sent.

Grants received are accounted for as receivable as and when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. Income from charitable activities includes income received under contract.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Trading income is recognised as and when monies are received and stated after trade discounts .

Trading income related to events is recognised in the year the events took place.

The charity is not registered for VAT.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure is recognised when a liability is incurred. Contractual arrangements and performance related grants are recognised as goods or services are supplied. Other grant payments are recognised when a constructive obligation arises that result in the payment being unavoidable.

Costs of generating funds are those costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities include both the direct and support costs relating to these activities.

Governance costs include the cost of any legal advice to trustees on governance or constitutional matters, external accountancy and audit costs.

Support costs include central functions and have been allocated to the different categories of activities based on the time spent on each activity.

The charity is not registered for VAT so all expenses shown in the SOFA and notes to the accounts are shown gross (i.e. inclusive of VAT).

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Plant and machinery	25% straight line
Fixtures, fittings & equipment	10% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets .

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

1.13 Foreign exchange

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the statement of financial activities.

1.14 Volunteers

A substantial contribution to the activities of Shaare Zedek UK is supplied in the form of voluntary services for raising funds. The financial benefit of these non-cash donations have not been recognised in these accounts as by their nature it would be impractical to quantify in monetary terms.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Specifically, the Trustees have made judgements on the apportionment of support and governance costs across the various charitable activities (see note 8 for further details) - the basis of this apportionment has remained consistent to prior years.

In the view of the Trustees, there are no significant accounting estimates and judgements applied.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2022	2022	2022	2021	2021	2021
	£	£	£	£	£	£
Donations and gifts	195,291	846,105	1,041,396	262,186	1,029,697	1,291,883
Legacies receivable	440,976	159,450	600,426	808,359	10,000	818,359
	<u>636,267</u>	<u>1,005,555</u>	<u>1,641,822</u>	<u>1,070,545</u>	<u>1,039,697</u>	<u>2,110,242</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

4 Investments

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Interest receivable	1,433	92
	<u> </u>	<u> </u>

5 Other

	Total	Unrestricted funds
	2022	2021
	£	£
Coronavirus Job Retention Scheme grant	-	39,413
	<u> </u>	<u> </u>

6 Costs of raising funds

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Costs of generating donations and legacies		
Advertising	35,679	39,682
Other fundraising costs	4,159	4,251
Staff costs	164,361	147,373
Depreciation and impairment	603	619
Support costs	38,903	39,206
	<u> </u>	<u> </u>
Costs of generating donations and legacies	243,705	231,131
	<u> </u>	<u> </u>
	<u>243,705</u>	<u>231,131</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

7 Charitable activities

	Payments to hospital 2022 £	Payments to hospital 2021 £
Staff costs	23,258	19,980
Depreciation and impairment	603	619
Payments to hospital	1,280,758	1,696,607
	<u>1,304,619</u>	<u>1,717,206</u>
Share of support costs (see note 8)	45,229	44,734
Share of governance costs (see note 8)	16,932	14,452
	<u>1,366,780</u>	<u>1,776,392</u>
Analysis by fund		
Unrestricted funds	374,214	751,297
Restricted funds	992,566	1,025,095
	<u>1,366,780</u>	<u>1,776,392</u>

8 Support costs

	Support costs £	Governance costs £	2022 Support costs		Governance costs £	2021 £
	£	£	£	£	£	£
Staff costs	40,189	16,932	57,122	34,433	14,452	48,885
Impairment losses	-	-	-	100	-	100
Premises costs	23,450	-	23,450	32,660	-	32,660
Other costs	20,493	-	20,493	16,747	-	16,747
	<u>84,132</u>	<u>16,932</u>	<u>101,065</u>	<u>83,940</u>	<u>14,452</u>	<u>98,392</u>
Analysed between						
Fundraising	38,903	-	38,903	39,206	-	39,206
Charitable activities	45,229	16,932	62,161	44,734	14,452	59,186
	<u>84,132</u>	<u>16,932</u>	<u>101,065</u>	<u>83,940</u>	<u>14,452</u>	<u>98,392</u>

Support costs excluding staff costs which cannot be directly attributed have been apportioned equally between costs of raising funds and the charitable activity of payments to the hospital. Within support costs, other costs include telephone costs, postage costs, travel costs, computer running costs and staff training costs.

Staff costs have been apportioned on an estimated basis of the allocation of time spent on each specific activity.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

9 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

	2022	2021
	£	£
Audit of the annual accounts	14,400	13,200
Non-audit services		
All other non-audit services	121	109

10 Trustees

None of the Trustees (or any persons connected with them) received any remuneration, nor reimbursement of travelling expenses during the year or prior year.

11 Employees

The average monthly number of employees during the year was:

	2022	2021
	Number	Number
Administration	1	1
Fundraising	3	3
Finance	1	1
Total	5	5

Employment costs

	2022	2021
	£	£
Wages and salaries	219,075	195,439
Social security costs	20,225	15,979
Other pension costs	5,441	4,820
	244,741	216,238

The number of employees whose annual remuneration was £60,000 or more were:

	2022	2021
	Number	Number
Between £70,000 - £79,999	1	1

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

12 Other

	Unrestricted funds	Unrestricted funds
	2022	2021
Net loss on disposal of tangible fixed assets	378	11,327
Audit fees	14,400	13,200
Legal and professional fees	609	289
	<u>15,387</u>	<u>24,816</u>

13 Net gains/(losses) on investments

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Revaluation of investments	(99)	11
	<u>(99)</u>	<u>11</u>

14 Tangible fixed assets

	Plant and machinery	Fixtures, fittings & equipment	Total
	£	£	£
Cost			
At 1 January 2022	6,471	7,268	13,739
Additions	-	525	525
Disposals	-	(974)	(974)
	<u>6,471</u>	<u>6,819</u>	<u>13,290</u>
At 31 December 2022	6,471	6,819	13,290
Depreciation and impairment			
At 1 January 2022	4,948	3,008	7,956
Depreciation charged in the year	764	441	1,205
Eliminated in respect of disposals	-	(596)	(596)
	<u>5,712</u>	<u>2,853</u>	<u>8,565</u>
At 31 December 2022	5,712	2,853	8,565
Carrying amount			
At 31 December 2022	<u>759</u>	<u>3,966</u>	<u>4,725</u>
At 31 December 2021	<u>1,523</u>	<u>4,260</u>	<u>5,783</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

15 Fixed asset investments

	Listed investments £
Cost or valuation	
At 1 January 2022	310
Valuation changes	(99)
	<u>211</u>
At 31 December 2022	211
	<u>211</u>
Carrying amount	
At 31 December 2022	211
	<u>310</u>
At 31 December 2021	<u>310</u>

16 Financial instruments	2022 £	2021 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	211	310
	<u>211</u>	<u>310</u>

17 Debtors	2022 £	2021 £
Amounts falling due within one year:		
Other debtors	6,572	10,251
Prepayments and accrued income	643	855
	<u>7,215</u>	<u>11,106</u>

18 Loans and overdrafts	2022 £	2021 £
Bank overdrafts	8	3
	<u>8</u>	<u>3</u>
Payable within one year	8	3
	<u>8</u>	<u>3</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

19 Creditors: amounts falling due within one year

	Notes	2022 £	2021 £
Bank overdrafts	18	8	3
Other taxation and social security		6,023	5,279
Trade creditors		5,216	1,382
Other creditors		1,232	869
Accruals		13,201	13,200
		<u>25,680</u>	<u>20,733</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds			
	Balance at 1 January 2021	Incoming resources	Resources expended	Balance at 1 January 2022	Incoming resources	Resources expended	Balance at 31 December 2022
	£	£	£	£	£	£	£
Bikur Cholim Campus	665	5,350	(2,500)	3,515	12,045	(12,000)	3,560
Children's Hospital	7,591	10,786	(15,054)	3,323	161,836	(165,159)	-
Emergency Department	1,742	51,588	(50,778)	2,552	26,392	(28,892)	52
Neurosurgery and Neurology Department	638	50,400	(50,400)	638	1,134	(500)	1,272
Others	25,704	21,760	(15,662)	31,802	244,195	(217,638)	58,359
Flourescent Activated Cell Storage	-	145,800	(145,800)	-	-	-	-
Neonatal Intensive Care Unit	5,664	44,561	(42,792)	7,433	53,516	(54,092)	6,857
Nursing Scholarships	-	79,489	(79,489)	-	89,626	(89,626)	-
Helmsley Cancer Centre	-	194,130	(194,130)	-	-	-	-
Intensive Care Department	201	-	-	201	-	-	201
Coronavirus Department	523	23,515	(16,172)	7,866	18	(7,866)	18
Outpatient Clinic	-	315,118	(315,118)	-	416,793	(416,793)	-
IVF Research Department	-	97,200	(97,200)	-	-	-	-
	<u>42,728</u>	<u>1,039,697</u>	<u>(1,025,095)</u>	<u>57,330</u>	<u>(1,005,555)</u>	<u>(992,566)</u>	<u>70,319</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

(Continued)

Bikur Cholim Campus is a separate campus hospital that merged with Shaare Zedek Medical Centre in Jerusalem. The fund is dedicated to fund the general running of the hospital.

Children's Hospital was set up as a separate fund to support a new building designed specifically for Children. The work on this site began in 2008 and the Children's Hospital officially opened in August 2015. The fund is dedicated to provide equipment and cover general running costs for the department.

The Emergency Department was set up to develop and extend the existing size of the old department. The fund is dedicated to cover running costs for the department.

The Neurosurgery and Neurology Department at the Shaare Zedek Medical Center treats a wide range of diseases involving the nervous system, with the aim of preserving and restoring brain and spine function and has a designated operating theatre which includes a new navigating system, intra-operation ultra-sound and an innovative robot enabling procedures such as tumor tissue biopsy with great precision. The fund is dedicated to provide equipment and cover general running costs for the department.

Included within Others are various smaller funds which relate to various activities including CT Scanner, various pieces of equipment, Haematology Department, Urology Department, pending allocation, Geriatrics Department, Cardiology Department and LDA Educational Institute.

The Fluorescent Activated Cell Sorting, Flow Cytometry, is the laboratory modality used by a FACS machine, a versatile diagnostic tool to identify and sort cells by the use of laser equipment and fluidic/fluorescent dyes. The FACS classifies the cells by their size, granularity and fluorescence staining. This device has become the gold standard in haematology research and is therefore a critical diagnostic tool for a growing major medical centre such as Shaare Zedek.

The Neonatal Intensive Care Unit (NICU) at the Shaare Zedek Medical Center treats infants born from week 24 of pregnancy. The complex includes 70 beds (with another 20 at the Bikur Cholim Campus), and state-of-the-art respiratory and monitoring equipment which provides precise data 24/7 on each of the babies in the unit. The fund is dedicated to provide equipment and cover general running costs for the department.

The Nursing Scholarships Fund is dedicated to provide support and training for student nurses.

The Helmsley Cancer centre build was completed in 2022. The fund was dedicated to provide a Linear Accelerator for the Radiotherapy Institute.

Our Intensive Care Unit treats the most severe urgent care cases in the hospital. 70% of cases are post-surgery while others are complex cases referred from the Internal Medicine Departments.

The Assisted Reproduction service has proven itself as a leader in developing IVF procedures for the benefit of the community. Shaare Zedek is home to an internationally-renowned centre for Medical Genetics research and has been a pioneer in the advancement of pre-gestational screening of embryos for the purpose of initiating pregnancies of fetuses free of specific genetic diseases that affect their parents and previous generations.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

20 Restricted funds

(Continued)

Our state of the art new ICU was upgraded in 2017 the first major upgrade and renovation of this Unit since the hospital moved to its current location in 1979. The Unit is now equipped with the latest technology and care methods in the most advanced setting possible. The risk of infection is a top priority for intensive care patients. The redesigned ICU gives each patient their own largely self-sufficient room to minimise the spread of infection. Almost all of the equipment is wall or ceiling mounted, meaning the room can be kept to a higher standard of cleanliness. There are 14 patient rooms in total, almost all of which are in constant use.

Robotic surgery is a field which has developed in recent years, increasingly becoming a standard and indispensable approach to care in a variety of surgical disciplines. It allows extremely fine and complex movements in a tight space, without the need to open large cavities that can involve more complications and a longer, more painful recovery period. Appreciating that this represents the future of modern surgery, we are proud that Shaare Zedek Medical Centre, which currently sees around 35,000 surgical procedures performed each year, has been a local pioneer in introducing advanced robotic approaches to the Israeli medical community.

In terms of the outpatient clinic, out of the more than 1,000,000 patients who are treated at Shaare Zedek Medical Center each year, the vast majority are treated on an ambulatory basis in our more than 70 outpatient units and clinics. In general, the trend in modern medicine is to reduce the need for inpatient hospitalization wherever possible, as this increases costs, emotional and practical challenges for the patient and is also less desirable from a medical perspective. For all these reasons, outpatient care is the growing trend in modern hospital care and Shaare Zedek has firmly embraced this trend with increased investment in these services. The central area for the large majority of our ambulatory services is in the Margulies Outpatient Clinics which are divided between the Fourth and Fifth Floors of The Next Generation Building.

The Cardiology Department provides a comprehensive response to the gamut of cardiac and cellular diseases. Our team performs catheterization, installs stents in the coronary arteries and implants pacemakers, defibrillators and valves without open heart surgery. There is also a state-of-the-art Cardiac Imaging Institute which uses 3-D Echo, CT and MRI. We can also administer advanced treatment for congenital and structural disorders. The department stresses preventative care and accompanies patients throughout the post-heart attack rehabilitation process.

The Coronavirus Department was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation.

The trustees are satisfied that sufficient resources are held in an appropriate form to enable each fund to be applied in accordance with any restrictions.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

21 Endowment funds

Endowment funds represent assets which must be held permanently by the charity. Income arising on the endowment funds can be used in accordance with the objects of the charity and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

	Movement in funds					Movement in funds					
	Balance at 1 January 2021	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at January 2022	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at 31 December 2022
	£	£	£	£	£	£	£	£	£	£	£
Permanent endowments											
Rayne Endowment Fund	42,465	-	-	-	-	42,465	-	-	-	-	42,465
	<u>42,465</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>42,465</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>42,465</u>

The Rayne Endowment Fund was donated by Lord Rayne to fund an international urology conference held at Shaare Zedek Medical Centre.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

22 Unrestricted funds

The income funds of the charity include unrestricted funds, within which designated funds have been set aside by the trustees for specific purposes:

	Movement in funds				Movement in funds			
	Balance at 1 January 2021	Incoming resources	Resources expended	Transfers	Balance at 1 January 2022	Incoming resources	Resources expended	Balance at 31 December 2022
Designated - Neo-Natal Department	16,224	-	-	(16,224)	-	466	-	466
Designated - Paediatric Oncology	-	-	-	-	-	104	-	104
Designated - Emergency Department	-	-	-	-	-	2,552	(2,552)	-
Designated - Pending Allocation	76,794	632,323	(671,511)	-	37,606	69,748	(92,757)	14,597
Designated - Helmsley Cancer Centre	-	-	-	-	-	259,326	(190,772)	68,554
Designated - Nursing Scholarships	-	-	-	-	-	2,000	(1,400)	600
Designated - Coronavirus Department	-	-	-	-	-	32	-	32
General Unrestricted Fund	671,273	477,727	(335,722)	16,224	829,502	303,472	(345,924)	787,050
	<u>764,291</u>	<u>1,110,050</u>	<u>(1,007,233)</u>	<u>-</u>	<u>867,108</u>	<u>637,700</u>	<u>(633,405)</u>	<u>871,403</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

22 Unrestricted funds

(Continued)

The Neo-Natal Department Fund had been set up to allow the legacy of one of our donors to contribute to the work they had supported throughout their life.

Paediatric Oncology fund was set up to support running costs for the department.

The Emergency Department was set up to develop and extend the existing size of the old department. The fund is dedicated to cover running costs for the department.

The Pending Allocation Fund relates to a single donation which is yet to be remitted to the Shaare Zedek Medical Centre, as the trustees have not yet confirmed what the donation should be used for.

Hemsley Cancer Centre fund was set up to support running costs for the department.

The Nursing Scholarships fund was set up to provide support and training for student nurses.

The Coronavirus Fund was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation.

The General Unrestricted Fund relates to "free reserves" after allowing for all designated funds.

23 Analysis of net assets between funds

	Unrestricted funds 2022 £	Designated funds 2022 £	Restricted funds 2022 £	Endowment funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Designated funds 2021 £	Restricted funds 2021 £	Endowment funds 2021 £	Total 2021 £
Fund balances at 31 December 2022 are represented by:										
Tangible assets	4,725	-	-	-	4,725	5,783	-	-	-	5,783
Investments	211	-	-	-	211	310	-	-	-	310
Current assets/(liabilities)	782,113	84,354	70,319	42,465	979,251	823,409	37,606	57,330	42,465	960,810
	<u>787,049</u>	<u>84,354</u>	<u>70,319</u>	<u>42,465</u>	<u>984,187</u>	<u>829,502</u>	<u>37,606</u>	<u>57,330</u>	<u>42,465</u>	<u>966,903</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

24 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2022	2021
	£	£
Within one year	15,000	-
Between two and five years	42,500	-
	<u>57,500</u>	<u>-</u>

25 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2022	2021
	£	£
Aggregate compensation	<u>91,167</u>	<u>78,000</u>

Transactions with related parties

Aggregate donations received from related parties without conditions amounted to £421,374 (2021: £595,956) for the year.

26 Cash generated from operations

	2022	2021
	£	£
Surplus for the year	17,284	117,419
Adjustments for:		
Investment income recognised in statement of financial activities	(1,433)	(92)
Loss on disposal of tangible fixed assets	378	11,327
Fair value gains and losses on investments	99	(11)
Depreciation and impairment of tangible fixed assets and investments	1,206	1,338
Movements in working capital:		
Decrease in debtors	3,891	75,074
Increase/(decrease) in creditors	4,942	(4,446)
Cash generated from operations	<u>26,367</u>	<u>200,609</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022

27 Analysis of changes in net funds

The charity had no debt during the year.

SHAARE ZEDEK UK

England & Wales - Charity number 1143272

Accounts

Charity registration number 1143272

Company registration number 07469168 (England and Wales)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
LEGAL AND ADMINISTRATIVE INFORMATION

Trustees Mr Michael Sorkin
Mr Anthony Rosenfelder
Mr Alain Stechler
Mr Martin Paisner
Mr Michael Sandler
Mr Nigel Sloam

Charity number 1143272

Company number 07469168

Registered office 4 Theobald Court
Theobald Street
Borehamwood
Hertfordshire
United Kingdom
WD6 4RN

Auditor RDP Newmans LLP
Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW

Bankers HSBC Bank Plc
8 Canada Square
London
E14 5HQ

National Westminster Plc
135 Bishopgate
London
EC2M 3UR

Barclays Bank PLC
1 Churchill Place
London
E14 5HP

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) CONTENTS

	Page
Trustees' report	1 - 16
Statement of Trustees' responsibilities	17
Independent auditor's report	18 - 21
Statement of financial activities	22
Summary income and expenditure account	23
Balance sheet	24 - 25
Statement of cash flows	26
Notes to the financial statements	27 - 46

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)
FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees present their annual report and financial statements for the year ended 31 December 2021.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity 's Memorandum & Articles of Association , the Companies Act 2006 and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

In this context the Trustees have complied with the duty in section 17 (5) of the 2011 Charities Act in giving due consideration to the Charity Commission's guidance on Public Benefit. The report is prepared in accordance with the small companies' regime (Section 419(2) of the Companies Act 2006).

Principal aims and objectives

"To save a life is to save the world. Nowhere is this clearer than at Shaare Zedek, a hospital not just with a heart but with a soul that makes the world a better place."

Quote from a relative of a Shaare Zedek patient

Our mission is to support, by all such means as may be charitable in law and for exclusively charitable purposes, Shaare Zedek Medical Centre (Shaare Zedek) (Jerusalem) in providing world class care for all patients irrespective of their ability to pay, nationality, age, race or religion. We provide financial support to fund services, capital projects, research and the purchase of equipment for the hospital.

History

Founded in 1902, Shaare Zedek has been known as the "Hospital with a Heart" for nearly 120 years. This reputation as a patient's first choice of hospitals stem from its unwavering commitment to all its patients, regardless of race, religion, political view or country of origin. All patients who are admitted receive the most advanced medical treatment available in a compassionate, supportive and nurturing environment. The hospital's ethos, "delivery of care and pioneering approaches to research", provides hope for us, hope for Israel and hope for the world.

Since 1902, the Hospital has chartered the course of Jerusalem's modern development and has been instrumental in the city's growth. Over half of Jerusalem's children live below the poverty line. Shaare Zedek was one of the first hospitals in Israel to recognise the need for specialist paediatric medical facilities and is home to Jerusalem's only dedicated Women and Children's Hospital.

Shaare Zedek 2021

Today Shaare Zedek is a 1,000-bed facility with close to 100 departments, treating 800,000 patients annually. As the fastest growing hospital in the region, the hospital continues to respond to and plan for the needs of Jerusalem's uniquely diverse population. Its current major expansion projects include the completion of the Radiotherapy Institute, a much-needed new facility to support patients from across the region. The most pressing expansion is the doubling of the size of its Emergency Department. The daily growth in demand on its urgent care facilities in the region necessitates a bigger department with the latest technology to ensure that they are much better equipped to respond.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Message from Shaare Zedek Medical Centre's Director General

Dear friends,

As we entered 2022, we found ourselves in a time of continued and in many ways unprecedented challenge. While we have been operating at the forefront of Israel's COVID-19 response since early 2020, this latest wave presented a level of operational difficulty very different from any previous wave.

Most challenging has been the high number of staff members who were either testing positive or in isolation due to infected family members. At times, as many as 15% of our workforce were unable to come into work. Responding to this challenge in a way that ensures our high level of care is never compromised has required extensive shuffling of shifts and responsibilities. All of this at the very time when our Corona Care Service was treating the highest numbers of patients since the start of the pandemic – a number which surpassed 200 patients, many of whom were in serious and critical condition.

Celebrating Shaare Zedek's 120th anniversary in 2022, we have been witness to many difficult periods throughout that remarkable history and we know that we will similarly grow stronger as a community and a hospital out of this current crisis. I am hopeful and confident that by the time many of you read this message we will be in a far better situation but whatever the challenge and whatever the need we are prepared to respond.

The coming months promise to be ones of exciting development and progress for our hospital. We will be opening the expanded Department of Emergency Medicine as well as the new Helmsley Cancer Centre, two projects that we know will significantly enhance our ability to provide the advanced and compassionate care that has always defined our hospital.

Coping with these challenges has necessitated the strong support of our friends around the world. We are deeply thankful for your generosity and welcome the chance to only further strengthen those partnerships on behalf of the people of Jerusalem and Israel.

Wishing you and your families only good health and happiness.

Professor Ofer Merin

Director General
Shaare Zedek Medical Centre

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Objectives and activities

Activities

In order to achieve our key objectives, Shaare Zedek UK (SZUK) employs a small office team led by an Executive Director working in partnership with trustees and other lay leaders, supported by a small number of energetic volunteers.

SZUK promotes awareness of the activities of Shaare Zedek. We also seek to promote support of the charitable activities of the hospital, and in particular its charitable activities for the public benefit in health welfare, medical and scientific advancement and best practice in patient treatment. We raise funds through donations, legacies, solicited mailings, events, direct approaches and special appeals.

Achievements and Performance

The impact of our fundraising

Shaare Zedek relies on its donors to provide the standard of care and innovation for which the hospital is known. Every day at Shaare Zedek brings new challenges and achievements. Shaare Zedek prides itself on its ability to adapt to any situation and provide excellent care when it is most needed. Our expertise in emergency preparedness has achieved global recognition during the fight against Covid-19. Below are some examples of the varied challenges and achievements in 2021, all of which would not have been possible without the support of our donors.

Historic budget negotiations with the Government

Over the past few years Shaare Zedek alongside six other public Israeli hospitals has been actively working to secure government funding. These negotiations intensified since the onset of the Coronavirus pandemic. The underlying objective of their efforts has been to address the major imbalance between these seven hospitals and the medical centres owned by the government and HMOs. Whilst all hospitals provide a public service without discrimination, operating under the same economic ecosystem implemented by the Ministry of Health, the seven public hospitals have been historically deeply discriminated against when it comes to receiving necessary funding. While the government and HMO hospitals' annual deficits were fully reimbursed, Shaare Zedek and others were left without any government support.

For decades this inequality was maintained; with Shaare Zedek and others receiving no government funding, but for many reasons, relating to the overall scope of our activities and the growth of the populations Shaare Zedek Medical Centre (SZMC) serves, this became an untenable situation. This new government support was only approved to help offset the sizable deficit which SZMC (and all the other hospitals now promised support), developed in recent years, exacerbated by the change in operations during the Coronavirus pandemic.

In January 2021, following intensive negotiations, the seven Israeli public hospitals, including Shaare Zedek Medical Centre, announced an agreement with Israel's Ministry of Finance, which has agreed to include allocations for these hospitals in the budget for the year 2021. The agreement also established that a committee will be created made up of representatives of the Ministry of Health, the Ministry of Finance and representatives of all public hospitals. This Committee will present its recommendations to the Government in advance of deliberations over the 2021 budget to describe the fiscal status of these hospitals – and with the specific goal of ensuring equal treatment alongside the governmental hospitals.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

This followed an exhaustive campaign led by Professor Merin and the Director Generals of the six other public hospitals affected by the current inequality in the healthcare system and the financial crisis. The agreement from January 2021 was not immediately honoured. Following further negotiations, we expect Shaare Zedek to receive its first round of government funding in 2022.

Whilst we can no longer state that we do not receive government support, it is important that all of us, including the donor community, appreciate that this does not change the critical nature of fundraising. The government funding will cover only 7% of our current operating budget and will need to be reapproved each year. As a hospital that is always moving forward in response to constantly expanding needs, donor funds are more important than ever for Shaare Zedek today and for the years ahead. There is no doubt that these changes are vital for our survival. SZMC is deeply indebted to the countless individuals led by Professor Merin who worked tirelessly to achieve this objective - and continue to work to address many ongoing obstacles.

Coronavirus: treating Jerusalem through a pandemic, globally relevant research and techniques

The Coronavirus pandemic continued to affect global communities in 2021. Government enforced lockdowns remained in place across Israel until April 2021. The vaccination campaign began in December of 2020, with hospital workers amongst the first group of citizens to receive the vaccine. Between June and September, case numbers and hospitalisations increased, although at this stage in the pandemic only the most severe of cases were hospitalised. In November Israel confirmed its first case of the Omicron variant. Serious cases rose again towards the end of the year and early into 2022.

This period of time has changed the world. Whilst nearly every aspect of our lives has been impacted by Covid-19, Shaare Zedek's role in responding to this disease has been not only the source of enormous challenge, but one of great pride.

The challenge has been in treating a disease that the medical world is only just beginning to understand, whilst being forced to overhaul much of the patient-care infrastructure. Compounding that challenge was the massive investment of financial and human resources placed into Shaare Zedek's Corona response programme, and how the crisis forced the temporary closure of many other departments of the hospital.

This pride emanates from the fact that we quickly became Israel's second most active Corona care hospital and we played a critical function in the care of thousands of Covid-19 patients. There is no doubt that the levels of preparedness that were put into place, some of which were enacted months before the world had even heard the term Covid, were instrumental in the hospital's success.

Whilst treating Coronavirus cases has certainly been a significant focus over the last year at Shaare Zedek, the hospital has remained focused on the broader vision of comprehensive medical care. All major activities remained in place alongside the developmental projects. The crisis required tremendous investment for rapid construction and the purchase of new equipment. This was only possible thanks to the generosity and quick response of our donors.

Coronavirus Family Social Support Hotline

In April, nearly a year after first opening, Shaare Zedek officially closed the Corona Family Social Support Hotline. Staffed by a team of social workers and volunteers, the Hotline connected families and Corona patients being treated in the hospital. The Hotline processed over 1,500 direct requests from family members on behalf of patients. The staff managed requests in multiple languages ensuring constant open communication between families, patients and medical staff. With a very significant reduction in the number of patients being treated in the Keter (Corona) Ward, the Department of Social Work continued to process requests from families with direct communication with the Ward's social workers.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Coronavirus Research

The focus of Shaare Zedek's research work is clinical. This means Shaare Zedek researchers and clinicians are able to evaluate the effectiveness of their current work and develop techniques and treatments for the needs of their current patients as well as those in the future. Having treated so many Covid-19 patients gave Shaare Zedek an opportunity to learn quickly and share their findings with the global health community. Shaare Zedek research into the effectiveness of Covid-19 vaccines on pregnant women gained international prominence as medical communities urged pregnant women to get vaccinated. As a result of a study led by Prof. David Zadok, Director of Shaare Zedek's Department of Ophthalmology, the medical community is now more aware of a potential complication associated with a linkage between the COVID-19 vaccine and corneal transplants. In addition to identifying the issue, the authors have presented recommendations for a pharmaceutical fix.

An example of how our research is directly applied to our clinical work with patients is the opening of the Sports Medicine Rehabilitation Program for Post-Corona Patients. In February 2021, a Shaare Zedek research study indicated that 95% of recovered Corona patients showed no evidence of irreversible respiratory or cardiac damage after a period of three months and that the majority of symptoms had dissipated by six months. Professor Gabriel Izbicki, Director of the Louzoun Pulmonary Institute at Shaare Zedek who was responsible for the study noted that the results were certainly encouraging, "Almost all the patients we studied after six months reported a marked improvement in their overall conditions and the test results reflected that. We found that regular fitness activities of three to four times a week were direct contributors to helping the patient recover that much more quickly."

Following these findings, the Heidi Rothberg Sports Medicine Centre at Shaare Zedek developed a dedicated program for individuals suffering from the long-term effects of the disease. The program was designed to offer an individualized response for patients with each case accompanied by doctors, dieticians, and physiotherapists who provided the relevant, comprehensive response that was needed. Many of these patients are worried about resuming physical activity and do not believe that they are able to do so. The dedicated fitness facility is specifically designed to help patients with medical histories under the guidance of sports medicine specialists and support personnel. The professional confidence and training that is offered through this rehabilitation process allows patients to improve their health and overall quality of life."

World First Mitral Valve Record

In April, Shaare Zedek became the first hospital in the world to perform three mitral valve replacement procedures in one day via catheterization using the Tendyne Valve System.

The procedure was performed for the first time earlier that week, and provides a medical response for patients experiencing leakages in the mitral valve of the heart who, until now, had no effective options other than invasive open-chest procedures that comes with significant risks and extensive recovery times. This new approach presents many new options for all types of patients with complex cardiac disease.

Shaare Zedek takes great pride in serving as a local and international leader in advancing these procedures and embracing new technologies on behalf of our patients and the community.

Emergency Drills

In November, Shaare Zedek's emergency preparedness teams took part in a national home front command drill, simulating a military-style attack in the north of the country.

In the event of war breaking out in the north, this would likely result in significantly increased patient traffic to hospitals in other parts of the country. The drill, which was carried out in partnership with the IDF Homefront Command and Magen David Adom, simulated Shaare Zedek absorbing a large number of injured and ill patients from the hospitals in the north.

In light of our extensive experience in absorbing large numbers of patients and following the hospital's recent designation as a Level 1 Trauma Centre, Shaare Zedek was chosen as the first Israeli hospital for this specific drill. The exercise required the participation of teams from throughout the hospital and was coordinated by Sarah Goldberg, Shaare Zedek's Disaster Preparedness Coordinator and Dr. Ariel Rokach, Director of Shaare Zedek's Emergency Response Centre.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Mass Casualty events: Givat Ze'ev Synagogue bleacher collapse

As the festival of Shavuot began, Shaare Zedek provided comprehensive mass casualty response following the collapse of a crowded set of bleachers at a synagogue in Jerusalem's Givat Ze'ev neighbourhood. Despite the timing of the event on the holiday, over 200 hospital staff members from all relevant medical, paramedical and administrative departments arrived to support the hospital response.

Over the course of the evening, the emergency departments treated 115 patients. 8 were admitted in serious to critical condition and required life-saving surgeries. In addition to the direct medical care provided, our social work team responded to the developing and ongoing needs of patients and their families.

National support after Meron tragedy

Whilst the events of the deadly Lag BaOmer crush in Meron were being reported, Shaare Zedek created a dedicated emergency service for those suffering from mental trauma associated with the events. The service was run in coordination with the Ministry of Health and other relevant services in the Jerusalem area. Shaare Zedek was able to provide a service staffed by our social work and trauma team, who have extensive experience in dealing with traumatic events.

A model of Coexistence during heightened tensions

During the pandemic, the stories of Arab doctors or nurses helping Jewish patients to say Shema Yisrael or the prayers that accompany the departure of a soul offered a ray of hope in a bleak time. A few weeks after lockdown ended, riots spread across several cities throughout Israel with mixed Arab and Jewish populations. In addition to treating the people injured in these attacks, our medical team- together with medics across Israel- responded by sharing messages of unity from what the Israeli press called our "Island of coexistence" at Shaare Zedek.

Speaking to the press at the time, Shaare Zedek's President, Professor Jonathan Halevy said "Between 20% and 25% of our 5,000 employees are Arab, which is about the same rate of Arab patients we have. I believe that our multi-ethnic, multi-cultural group well represents our multi-ethnic multi-cultural city. We are all united by the mission to work for the patients. I know it sounds very banal but it is true. Politics remains outside the hospital."

Professor Halevy described these times as "very trying. I don't think there is a single Israeli citizen today who is not worried for this unprecedented situation. Medical staff are no different except that no matter what, they always report for duty." Professor Halevy pointed out that the head of Shaare Zedek's corona department was an Arab doctor from East Jerusalem, while his head nurse was a Charedi (ultra-Orthodox) mother of seven. "They worked hand in hand," he said.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Sinkhole collapse

On 7th June, a large sinkhole opened up in a parking area adjacent to the hospital's main entrance. The incident occurred due to a tunnel collapse: the affected area sits atop a worksite where the Route 16 tunnel was under active construction. While seven cars were damaged in the collapse, thankfully there were no injuries. Following the collapse, a complete engineering and safety survey was performed throughout the hospital campus. The comprehensive review was carried out in cooperation with engineers from the Jerusalem Municipality, the Homefront Command, the Israel Police and other relevant professional agencies. The review confirmed that the affected area was completely beyond the structure of the hospital itself and was no danger to the safety of any of the buildings.

Democracy in times of pandemic

In March, amidst an unprecedented election, where Shaare Zedek's main Corona Unit remained in operation, a dedicated voting station was set up within the Unit allowing COVID-19 patients to exercise their democratic voting rights. In addition, three other voting stations were in place across the hospital to serve both patients and staff who would be unable to vote close to their homes. Havatzelet Daniel, who coordinates the election process within the hospital said, "We have made every effort to ensure that all patients are able to vote and of course this year we had the additional challenges surrounding the Corona ward. The election process in the hospital will once again be carried out with professionalism and respect for the democratic process."

New 800 space car park opened

In April Shaare Zedek opened its new parking complex. With over 800 parking spaces, the underground complex responds to what we know has been a major challenge for those wanting to visit the hospital. Multiple floors of expansive and well-lit parking areas feed into a series of elevator banks allowing easy and quick access to the main entrance of the hospital. The complex includes a dedicated parking area for radiotherapy patients, with their own entrance into the new Cancer Centre, minimising their exposure to sick patients and shortening the distance for them to get to their appointments.

National and International Impact: Partnerships, collaboration and awards

This year as in other years, Shaare Zedek's work with technology and bio-tech companies, hospitals, governments and charities has helped it to provide better care for its own patients as well as sharing best practice around the world. This only serves to grow its global reputation for excellence and innovation. These achievements in clinical excellence, pioneering research and collaboration with its international counterparts have generated public benefit with local and global impact, attracting the attention of world media and praise in international journals. These partnerships provide huge benefits to its patients, often enabling Shaare Zedek to embrace cutting-edge technology and equipment at no cost to the hospital.

Teams across the hospital are regularly involved in supporting medical provision and infrastructure in developing countries. One such initiative is its Cardiology partnership in Ethiopia, training two new specialists every year to strengthen Ethiopia's expertise in Paediatric medicine. This year the hospital has hosted several international governmental and medical delegations to share its expertise in adapting to the Covid-19 global pandemic. Our medical experts have also visited other countries at their request to help build robust infrastructure and systems in facing the ongoing pandemic.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Professor Bornstein appointed Chair of special commission on neurological care

In June, Professor Natan Bornstein, Director of the Helmsley Neurological Institute and an internationally respected expert in Neurology, was appointed to serve as Chair of an Israeli Ministry of Health special commission on Neurological care. The creation of the commission comes in light of an increase in neurological morbidity cases throughout the country. The commission is designed to provide overall recommendations that can then be implemented to improve neurological care across the national health system.

According to Professor Bornstein, there has been a noticeable increase in brain disease in Israel which demands a systemic response – both on the level of hospital-based medicine and with increased awareness and training on the community-medicine level. “This commission which I will chair will create a detailed assessment of the increase that we are witnessing, and map the existing infrastructure so we can better determine where we need to invest in additional resources. I welcome this opportunity and thank the Health Ministry for placing their confidence in me to lead this effort to enhance and improve the level of neurological care throughout Israel.”

Professor Halevy awards and appointments

In October, Shaare Zedek’s President, Professor Halevy, was reappointed as Chair of the Public Committee of the National Basket of Health Services. The Chair is largely viewed as one of the most prominent and influential positions in the Israeli healthcare system as it oversees the body responsible for selecting the pharmaceuticals and medical technologies that are included in the “basket” of coverage within the country’s public health insurance structure.

Professor Halevy said, “I am honoured to once again be charged with helping guide Israel’s public healthcare infrastructure and helping our nation to serve as a leader in advanced and compassionate medicine on behalf of our citizens. I view this appointment as a signal of the important place that Shaare Zedek has come to play for our nation and this is certainly not just an honour for me but for the Shaare Zedek family at large.”

During the pandemic, Professor Halevy became a leading trusted public figure that the populace looked to for medical advice. In recognition of more than three decades of service in leadership, and for his specific role during the pandemic, Professor Halevy was honoured as a Yakir Yerushalayim (Worthy Citizen of Jerusalem.) The award is the city’s highest civilian honour and bestowed on individuals who have made a historic contribution to the development of Jerusalem. In accepting the honour Professor Halevy said, “I can think of no other city in the world that is more fitting to raise ones children and to instil within them the values of our heritage and traditions. In 1988 when I came to Shaare Zedek, it was a small and humble hospital lacking many of the major departments that define modern medicine. My successor, Professor Ofer Merin, inherited a hospital with over 1,000 beds, that is able to offer the people of Jerusalem everything that advanced medicine has to offer. Today we are the city’s largest hospital, so I take great pride in my life’s work which has allowed this hospital to achieve these heights while always preserving the traditions that make it so special.”

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Gold-Level Certification in Preventing SIDS, a first for Israel

In November, Shaare Zedek became the first Israeli hospital to receive Gold-Level Certification Awarded by ATID, the Israeli Foundation for the Study and the Prevention of Sudden Infant Death in an Effort to Prevent Sudden Infant Deaths and Sleep-related Deaths. Shaare Zedek's Wilf Children's Hospital sees over 22,000 births annually, the most of any Israeli hospital, and among the highest in the Western world.

To receive the certification, Shaare Zedek implemented an educational program developed by Dr. Shatz and ATID whereby all maternity nurses are trained to educate new parents on the measures known to reduce the incidence of SIDS. Dr. Shatz explained that "Every staff member who undergoes this course and then passes along these lessons to parents has the ability to directly save a child's life." Over a year ago, as part of the certification process, Shaare Zedek began putting all infants in the hospital to sleep in specially designed "sleep sacks" that can reduce the risks associated with SIDS and sets an important example for parents and other hospitals.

Dr. Shatz said that ATID's surveys indicate that 82 percent of parents described the hospital staff as the most important resource for learning how to care for a new-born infant. "For that reason, those first 48 hours in the hospital are critical for educating parents on how to reduce the incidence of sudden death and that is why this hospital-based initiative is so important for the more than 185,000 babies that are born in Israel every year."

Shaare Zedek Scientific

Shaare Zedek Scientific (SZS) had another year of rapid growth in 2021. It is SZS's goal to act as an innovation bridge between leading companies in the fields of medical research and the hospital. SZS is responsible for research and development collaborations between the Medical Centre and industry, including implementing new technologies in the field of digital health and providing access to medical data through Shaare Zedek's Innovation Centre.

A central pillar of Shaare Zedek's vision is to promote the medical field by engaging in research at all levels. This mission has guided Shaare Zedek for nearly 120 years, to advance innovative modes of medical care that embrace new technologies and methods for the benefit of the community. Indeed, SZS encourages clinicians and scientists to maximize their innovation potential in industry and investigator-initiated research projects across a broad range of applied and theoretical topics and disciplines. This includes basic science, clinical trials, and practical innovation such as development of medical devices. This helps promote an always-expanding and increasingly productive collaboration with key industry players. Shaare Zedek Scientific provides the professional support the investigators require to foster a fruitful interaction with industry players and other academic institutes. Today, through the dynamic infrastructure Shaare Zedek has created, it is increasingly positioned to push those goals even further and expand beyond boundaries for enhancing healthcare science all over the world.

SZS has formed many partnerships this year in researching Covid-19. Our BioBank has become a resource to companies around the world. A partnership with Sight Diagnostics has focused on early detection and fighting Covid-19. Throughout the year it has been mutually benefiting from a close partnership in researching early diagnosis methodologies for Covid-19 patients. Utilizing Shaare Zedek's BioBank, home to one of the world's largest resources of bio-data related to Coronavirus, SZS together with Shaare Zedek is continuously advancing its understanding of this virus and enhanced methods for diagnosis and treatment. Sight Diagnostics won the Genesis Prize for this work in early 2021.

Its partnership with Google continues through their life-science focused sister company, Verily. SZS recently announced a collaboration on a clinical study of AI-powered colonoscopy.

Another partnership with Sight Diagnostics has been formed to identify the possibility of blood cancer using a combination of images and data collected from Sight's OLO device and patient clinical information provided by the hospital. The research focuses on developing the capability to detect and classify white blood cells, and more specifically, to differentiate between different types of white blood cells in the immune system called lymphocytes, a procedure that has greatly challenged the global haematological community.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

As Shaare Zedek enters into new areas of patient care, whilst developing new technologies and research focused on medicine for the future, Shaare Zedek believes its unique approach to integrated and personalised medicine will continue to cement its mark on Jerusalem, Israel and across the world.

UK funding

Donors choose to support any of the hospital's 100+departments with which they have a personal affinity, as well as responding to our appeals to support the needs of specific departments as dictated by the Board of the hospital. This year donors support returned to a more varied use across the hospital departments, compared to 2020 where the majority of donations were in support of our emergency coronavirus appeal.

The hospital departments benefitting most from UK donations in 2021 were the Emergency Department, Radiotherapy Institute, Neurology & Neurosurgical Department, Fertility and IVF Department and the Neonatal Intensive Care Unit, Outpatient clinics, Coronavirus "Keter" Unit, Bikur Cholim Campus, Paediatric Dialysis, Sleep lab, Maternity, Paediatric Educational Institute and Paediatrics. In addition to this, several donors choose to fund Nursing Scholarships. We also had many donors respond to our small but important campaign to fund self-care package for any staff self-isolating due to Covid-19.

In 2021, donations from supporters who had asked for their donations to be used for most urgent needs of the hospital were allocated throughout the departments listed above. Where we receive donations without restriction, the UK office works with colleagues at Shaare Zedek to identify appropriate use of funds to ensure the maximum impact of UK donations. The majority of these funds were used for the Coronavirus Departments and general equipment, such as surgical gloves, which are used across the hospital.

There is a strong British footprint in every one of the hospital's 14 internationally recognised Centres of Excellence. Fundraising in the UK has always been conducted in close partnership with the leadership of the hospital in Jerusalem. In March 2019 Professor Ofer Merin became the Director-General of Shaare Zedek Medical Centre, with former Director-General Professor Jonathan Halevy becoming the President of the hospital. Professor Halevy continues to lead the fundraising strategy for the hospital in his new role. Collaboration between professional colleagues and board members grows each year.

This year our Executive Director and a number of our lay leaders attended the online board meeting of the International Board of Governors of the hospital. We have enjoyed a close working relationship with both the President and Director General of the hospital and their teams. This year the UK team joined a call bringing together the international offices fundraising for Shaare Zedek to discuss further collaboration. We look forward to a continued partnership with Professors Halevy and Merin and are indebted to them for their visionary leadership and continued service. We are grateful to Uri Schwarz and the entire fundraising team at Shaare Zedek Medical Centre who support our fundraising efforts on the ground in Israel.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Objectives for 2021- a difficult year

These were the specific objectives in 2021 and how we performed to meet them:

Objective 1: Fundraising for Shaare Zedek Medical Centre

Financial and operational planning for 2021 was conservative. Without knowing how long the pandemic would last or the impact it would have on our work and the work of the hospital, our financial forecast was prepared for a scenario where appeal costs were covered and a small number of major gifts were received. Despite the uncertainty of the times, the generosity of our donors has resulted in us being able to raise £2,110,242 this year, with £1,696,607 already sent to the hospital.

Fundraising programmes and events

The most successful fundraising methods were part of our ongoing relationship with existing major donors, legacy gifts and in response to direct mail and email campaigns.

As in 2020, the impact of Coronavirus meant a continued suspension of in-person events. The increased interest in online events is an opportunity for us as we seek to find ways to connect donors in the UK to the hospital in Israel. A unique online event held this year was the 50 year reunion for our young committee. The event was held on the date of the anniversary of their first ever committee event. Some of the committee members have remained involved with the charity throughout the 50 years. For some of them this was the first time they had seen each other since their time on the committee. Thanks to the 1971 committee, we raised £4,970. We hope to arrange an in-person event with the committee in the future.

The work of our staff team during this period has been exemplary and inspirational. In addition to our responsibilities to fundraise for the hospital we felt a responsibility to our donors. As well as this, fundraising staff spent a huge amount of time looking after our donors, signposting them where they needed professional support and providing a sounding board for donors who value a relationship with the team on a personal level.

Our Lifecycle giving programme continues to be popular, offering certificates and personalised cards for those celebrating birthdays, anniversaries and festivals, and those who wish to support Shaare Zedek by asking family and friends to make donations to the hospital. Lifecycle giving also includes Yahrzeit donations and our Permanent Yahrzeit Programme, the latter providing comfort and connection for donors wishing to honour the memory of loved ones with a gift to support the health of future generations. Lifecycle giving income has stayed at a similar level to last year. We hope to invest in this income stream as part of our 2023 strategic review.

Our marketing and communications strategy has continued to develop with an emphasis on personality and warmth, showing supporters the impact of their gifts and providing the living bridge between donors and the hospital. Our website, Facebook page and regular email updates allow donors to stay up to date with activities in the UK as well as at the hospital. Donors now have the ability to fundraise within our website, setting their own fundraising challenges and activities without the cost of using third party platforms, enabling all of the funds raised to benefit the charity directly. Our social media channels have been a central point through which we have engaged with supporters and wider audiences during the pandemic. The emotive stories from the hospital have provided much inspiration and motivation for donations.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Other than a nominal decrease, income from appeals has stayed at a similar level to 2020. We were expecting to see a larger decline in income following the strength of support for and urgency of the Covid Emergency campaign. Supporters were warm in their response to our direct mail campaigns and keen to do what they could, understanding the continued need for support during the pandemic.

Several synagogues, notably Edgware Adath Yisroel Synagogue and Mill Hill United Synagogue, support our endeavours through their Kol Nidre Appeals. We are trying to develop relationships with more communities to increase awareness and fundraising capabilities.

Calendar advertising has been declining in recent years. The calendar is an effective marketing tool, particularly for legacies and as such, is still an important publication which is also profit making. In order to maximise profits, we hope in 2022 or in 2023 to recruit an advertising committee who can work on bringing in calendar advertisements throughout the year.

Several donations of goods in kind have allowed us to expand our community outreach work at very little additional cost. For each of the Jewish festivals during lockdown, we marketed an activity pack for children. The packs contained age appropriate activities to keep children entertained during the festivals. Each pack purchased paid for a self-care package for a member of hospital staff self-isolating due to Covid-19. The support from UK donors in funding the Covid-19 Care Packs has been greatly received by everyone at Shaare Zedek. The packs proved very popular and cost effective for us to sell and raised £4,571 in 2021. This initiative has now ceased as it is no longer required.

Objective 2: Payments to hospital

During the year the Charity remitted £1,776,392 (2020: £4,312,281) to Shaare Zedek Medical Centre in support of its activities and for related support and governance costs.

This is a huge achievement for our professional team. With a small staff all working from home during lockdown, we faced many challenges ranging from school closures and no childcare for half the team to one member of staff being hospitalised with Covid-19, and suffering a bereavement due to the virus. Despite the large challenges every staff member faced during this period, the charity still raised a significant sum this year. At various times during the pandemic we made use of the Government Coronavirus Job Retention Scheme ('furlough'). One member of staff was furloughed from the beginning of the scheme and others made use of the scheme when it became a flexible arrangement.

Objective 3: Improving our operations and strategic planning

The organisational strategy continues to be implemented with a focus on key areas for organisational growth and fundraising opportunities based on our organisational strengths, key areas for improvement and new opportunities. All areas of activity are subject to regular evaluation and analysis. The global pandemic had an unforeseen impact on our operations in 2021. As such we are in the process of regularly reviewing strategic planning and income forecasts in light of the ever-changing landscape. We anticipate a full strategic review in early 2023 once a new Chair is in post.

We continue to develop contacts with other potential Members and a new committee of lay leaders is in the process of being recruited as part of succession planning by our trustees.

Supplier costs are regularly reviewed resulting in savings from renegotiating supplier contracts. As our communications materials continue to increase donor engagement, it is our intention to create sponsorship opportunities to meet these costs in order to keep administrative expenses as low as possible.

The CRM system used to manage donor records is regularly updated to comply with the GDPR guidance to ensure we are fully compliant with relevant legislation. We continually update our donor records in advance of our appeals to ensure donors are contacted only when they wish to be, keeping good faith with our supporters and saving the charity unnecessary expenditure on producing and mailing appeals. We are registered with the Fundraising Regulator and the Fundraising Preference Service and to date have only received one request for record removal (in 2017) and no complaints from either agency.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Financial review

The current economic climate continues to impact on our ability to raise new funds. Given the tough climate we were delighted to have raised £2,110,242 (2020: £4,492,953). We have maintained a healthy financial position with closing fund balances totalling £966,903 (2020: £849,484) of which £57,330 (2020: £42,728) relates to restricted funds. Furthermore, £37,606 (2020: £93,018) within the closing unrestricted fund balance is designated for specific purposes. Hence, the general unrestricted funds the charity holds amounts to £829,502 (2020: £671,273) at the end of the reporting period after making allowance for restricted and designated funds. We are delighted to have raised significant funds enabling us to send £1,696,607 (2020: £4,244,962) to Shaare Zedek in Jerusalem in relation to our charitable activities and support costs. This year we were in a position to send over 80% of our total income directly to the hospital, the balance being held in reserves in the UK.

Legacy gifts continue to be a vital source of income, with 39% of all donations this year being from legacy gifts in donors' wills and one large gift of £449,232. Legacies are unpredictable, at times materialising without our prior knowledge and we continue to maintain and develop this income whilst recognising the need for a diversification of income from other sources to maintain the level of support we currently provide to the hospital. We also recognise the importance of the connections we foster with our donors, and the value they place on our relationships in trusting us to be guardians of their legacies.

General donations, including major gifts, totalled £1,291,883 (2020: £3,477,771). Although we continue to enjoy the support of our loyal donors, the economic situation continues to be challenging. In common with other charities, we continue to find ways to engage new donors in a challenging climate. Existing donors too are lowering their donations due to reduced income to their Trusts or changes in their personal circumstances due to the pandemic.

Reserves policy and going concern

It is the policy of the charity to maintain unrestricted funds, which are the free reserves of the charity, at a level that takes account of the needs of the likely administration costs of the charity over the next 24 month period. The Board has the power to invest in such assets in secure money market instruments.

Risk management

The Board has assessed the major risks to which the charity is exposed, in particular those relating to the operations and finances of the Charity. The Board is satisfied that systems are in place to mitigate its exposure to those risks.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Plans for the future

With a new Director General now in post at Shaare Zedek, our Executive Director and trustees are in discussions with the hospital regarding their plans and priorities for the future. We are supporting the Emergency Room and Radiotherapy Institute capital building projects in addition to the annual requests received from the hospital to upgrade existing equipment and facilities and to purchase the latest new technology.

2021 has been a challenging and rewarding year for the charity in the UK and the hospital in Jerusalem. We hope to return to our regular programme of events and activities and use our ability to connect donors to our medical professionals through further online events. There is an acute need to obtain mid-level and major gifts on an annual basis or preferably, on a multi-year pledge basis. Efforts to increase major gift fundraising were planned to focus on applications to trusts and foundations, alongside our renewed efforts to engage new and existing mid-level donors. As a result of the Covid-19 pandemic, fundraising has largely been focused on supporting the efforts of the hospital to fight the pandemic, whilst ensuring key capital projects did not fall behind schedule.

Our professional team has worked exceptionally hard in difficult circumstances to ensure that our levels of activity and donor engagement could continue to support the hospital. Our financial forecast for the year has been impacted by the pandemic but none-the-less, we managed to finish 2021 with a higher level of unrestricted funds than anticipated.

From the internal research we have conducted, the SZUK message is very strong with existing donors. We need to expand awareness of the hospital amongst the Jewish community and wider society to ensure that we can engage with future generations of supporters. The core brand message has informed new approaches to marketing, events and other activities that work towards this aim. Engaging new major donors will be a greater challenge in the current climate but we are working on creative ways to use the international resonance of a front-line hospital fighting a global pandemic to engage new supporters at all levels.

On 9 September 2022, Michael Sorokin stepped down as Chairman of the charity and we wish to thank him for his invaluable dedication, support and direction during his chairmanship over many years. However, we are delighted to welcome Jonathan Paull, who joined our board as the new trustee and Chairman of the charity on 9 September 2022. Jonathan will now be leading the charity in a strategic review of our work with a view to a clear operational plan to develop all the areas of income and supporter generation.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 14 December 2010 and registered as a charity on 8 August 2011. The charity's reference and administrative details are as set out within these accounts. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

The Board of Trustees

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr Michael Sorkin
Mr Anthony Rosenfelder
Mr Alain Stechler
Mr Martin Paisner
Mr Michael Sandler
Mr Nigel Sloam

Key personnel

The following individuals whilst not statutory members of the charity were involved in an advisory capacity:

Dan Adler
David Bernstein
David Cohen
Geoffrey Goldkorn
Eva Greenspan
John Jay
Margot Lew
Angela Margolis-Raz
Marcus Margulies
Hilary Natoff
Jonathan Paull
Marcus Pearl
Margaret G Rothem
Simon Sackman
Nolan Wengrowe
Michael Ziff
Emma Pearl

Recruitment, appointment and terms of office of Trustees

Trustees are appointed in accordance with the Charity's Memorandum & Articles of Association. As stated on page 14 above, we are delighted to welcome Jonathan Paull as a new trustee, who was appointed on 9 September 2022.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

Trustee Induction and Training

New trustees are made aware of the organisational structure of the charity and are shown financial statements of the charity for the three preceding years.

All trustees are now already familiar with the practical work of the charity. Induction procedures are in place for new trustees.

Operations and staffing

The trustees delegate day to day management of the charity to the Executive Director, Simona Bennett to deliver the aims and objectives of the charity.

Safeguarding

Shaare Zedek UK has a Safeguarding Policy. In 2019 the Executive Director completed safeguarding training with the NSPCC. The charity makes regular enquiries of the hospital with regard to its own robust safe-guarding policies and notification of any relevant safeguarding issues we should be aware of. All SZUK staff will now be required to undergo safeguarding training and DBS checks as we expand our outreach work into the community.

Related parties

Included within other creditors is an amount of £nil (2020: £83) due to Sharzed Advertising Limited, a 100% owned subsidiary which was struck off after the balance sheet date.

Aggregate donations received from related parties without conditions amounted to £595,956 (2020: £265,925) for the year.

Aggregate remuneration of key management personnel amounted to £78,000 (2020: £72,600) for the year.

Auditor

A resolution proposing that RDP Newmans LLP be reappointed as auditors will be put to the members.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

The Trustees' report was approved by the Board of Trustees.

Mr Michael Sorkin

Trustee

Dated: 28 September 2022

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees, who are also the directors of Shaare Zedek UK for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT
TO THE TRUSTEES OF SHAARE ZEDEK UK**

Opinion

We have audited the financial statements of Shaare Zedek UK (the 'charity') for the year ended 31 December 2021 which comprise the statement of financial activities, the summary income and expenditure account, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF SHAARE ZEDEK UK**

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report [or the strategic report] included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept; or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF SHAARE ZEDEK UK**

The extent to which the audit was considered capable of detecting irregularities including fraud

We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006 and The Charities Act 2011 together with the Charities SORP (FRS102). We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company's ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and the group for fraud. The laws and regulations we considered in this context for the UK operations were, General Data Protection Regulation (GDPR), and employment legislation.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed and tested journal entries to identify unusual transactions and other adjustments for appropriateness, and evaluating the business rationale of significant transactions outside the normal course of business;
- assessed whether judgements and assumptions made in determining the accounting estimates set out in note 2 were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- reviewing and agreeing financial statement disclosures and testing to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity's controls, and the nature, timing and extent of the audit procedures performed. There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF SHAARE ZEDEK UK**

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

RDP Newmans LLP

29 September 2022

**Chartered Accountants
Statutory Auditor**

Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW

RDP Newmans LLP is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Endowment funds 2021 £	Total 2021 £	Total 2020 £
<u>Income and endowments from:</u>						
Donations and legacies	3	1,070,545	1,039,697	-	2,110,242	4,492,241
Other trading activities	4	-	-	-	-	712
Investments	5	92	-	-	92	7,322
Other	6	39,413	-	-	39,413	9,682
Total income		1,110,050	1,039,697	-	2,149,747	4,509,957
<u>Expenditure on:</u>						
Costs of raising funds	7	231,131	-	-	231,131	219,394
<u>Charitable activities</u>						
Payments to hospital	8	751,297	1,025,095	-	1,776,392	4,312,281
Total charitable expenditure		751,297	1,025,095	-	1,776,392	4,312,281
Other	13	24,816	-	-	24,816	17,698
Total resources expended		1,007,244	1,025,095	-	2,032,339	4,549,373
Net gains/(losses) on investments	14	11	-	-	11	(124)
Net movement in funds		102,817	14,602	-	117,419	(39,540)
Fund balances at 1 January 2021		764,291	42,728	42,465	849,484	889,024
Fund balances at 31 December 2021		867,108	57,330	42,465	966,903	849,484

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
SUMMARY INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2021

	All income funds	
	2021	2020
	£	£
Gross income	2,149,747	4,509,957
Gains/(losses) on investments	11	(124)
	<hr/>	<hr/>
Total income in the reporting period	2,149,758	4,509,833
Total expenditure from income funds	2,032,339	4,549,373
	<hr/>	<hr/>
Net income/(expenditure) for the year	117,419	(39,540)
	<hr/> <hr/>	<hr/> <hr/>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET

AS AT 31 DECEMBER 2021

	Notes	2021		2020	
		£	£	£	£
Fixed assets					
Tangible assets	15		5,783		15,977
Investments	16		310		399
			<u>6,093</u>		<u>16,376</u>
Current assets					
Debtors	18	11,106		86,181	
Cash at bank and in hand		970,437		772,103	
		<u>981,543</u>		<u>858,284</u>	
Creditors: amounts falling due within one year	20	(20,733)		(25,176)	
Net current assets			960,810		833,108
Total assets less current liabilities			<u>966,903</u>		<u>849,484</u>
Capital funds					
Endowment funds - general	22		42,465		42,465
Income funds					
Restricted funds	21		57,330		42,728
<u>Unrestricted funds</u>					
Designated funds	23	37,606		93,018	
General unrestricted funds		829,502		671,273	
			<u>867,108</u>		<u>764,291</u>
			<u>966,903</u>		<u>849,484</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2021

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2021, although an audit has been carried out under section 144 of the Charities Act 2011. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these accounts under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 28 September 2022

Mr Michael Sorkin
Trustee

Mr Alain Stechler
Trustee

Company registration number 07469168

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	2021 £	£	2020 £	£
Cash flows from operating activities					
Cash generated from/(absorbed by) operations	27		200,609		(64,528)
Investing activities					
Purchase of tangible fixed assets		(2,370)		(3,053)	
Investment income received		92		7,322	
Net cash (used in)/generated from investing activities			(2,278)		4,269
Net cash used in financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			198,331		(60,259)
Cash and cash equivalents at beginning of year			772,103		832,362
Cash and cash equivalents at end of year			970,434		772,103
Relating to:					
Cash at bank and in hand			970,437		772,103
Bank overdrafts included in creditors payable within one year			(3)		-

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

Charity information

Shaare Zedek UK is a private company limited by guarantee incorporated in England and Wales. The registered office is 4 Theobald Court, Theobald Street, Borehamwood, Hertfordshire, WD6 4RN, United Kingdom.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's memorandum and articles of association, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income or gift aid donations is recognised at the time the relevant income is receivable.

Legacy income is included in the Statement of Financial Activities when the Charity's entitlement has been established with a sufficient level of certainty, normally on receipt of the legacy or a letter confirming that it will be sent.

Grants received are accounted for as receivable as and when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. Income from charitable activities includes income received under contract.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

(Continued)

Trading income is recognised as and when monies are received and stated after trade discounts .

Trading income related to events is recognised in the year the events took place.

The charity is not registered for VAT.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure is recognised when a liability is incurred. Contractual arrangements and performance related grants are recognised as goods or services are supplied. Other grant payments are recognised when a constructive obligation arises that result in the payment being unavoidable.

Costs of generating funds are those costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities include both the direct and support costs relating to these activities.

Governance costs include the cost of any legal advice to trustees on governance or constitutional matters, external accountancy and audit costs.

Support costs include central functions and have been allocated to the different categories of activities based on the time spent on each activity.

The charity is not registered for VAT so all expenses shown in the SOFA and notes to the accounts are shown gross (i.e. inclusive of VAT).

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Plant and machinery	25% straight line
Fixtures, fittings & equipment	10% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies **(Continued)**

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

A subsidiary is an entity controlled by the charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies **(Continued)**

1.11 Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets .

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13 Foreign exchange

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the statement of financial activities.

1.14 Group accounts

The financial statements present information about the charity as an individual undertaking and not about its group. The company and its subsidiary undertaking comprise a small-sized group. The company has therefore taken advantage of the exemptions provided by section 399 of the Companies Act 2006 not to prepare group accounts.

1.15 Volunteers

A substantial contribution to the activities of Shaare Zedek UK is supplied in the form of voluntary services for raising funds. The financial benefit of these non-cash donations have not been recognised in these accounts as by their nature it would be impractical to quantify in monetary terms.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Specifically, the Trustees have made judgements on the apportionment of support and governance costs across the various charitable activities (see note 9 for further details) - the basis of this apportionment has remained consistent to prior years.

In the view of the Trustees, there are no significant accounting estimates and judgements applied.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2021	2021	2021	2020	2020	2020
	£	£	£	£	£	£
Donations and gifts	262,186	1,029,697	1,291,883	253,181	3,224,590	3,477,771
Legacies receivable	808,359	10,000	818,359	968,970	45,500	1,014,470
	<u>1,070,545</u>	<u>1,039,697</u>	<u>2,110,242</u>	<u>1,222,151</u>	<u>3,270,090</u>	<u>4,492,241</u>

4 Other trading activities

	Total	Unrestricted funds
	2021	2020
	£	£
Non-charitable trading income	-	712
	<u>-</u>	<u>712</u>

5 Investments

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Interest receivable	92	7,322
	<u>92</u>	<u>7,322</u>

6 Other

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Coronavirus Job Retention Scheme grant	39,413	9,682
	<u>39,413</u>	<u>9,682</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

7 Costs of raising funds

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
<u>Costs of generating donations and legacies</u>		
Advertising	39,682	38,922
Other fundraising costs	4,251	4,551
Staff costs	147,373	146,194
Depreciation and impairment	619	1,404
Support costs	39,206	27,990
	<u>231,131</u>	<u>219,061</u>
<u>Fundraising trading: costs of goods sold</u>		
Other trading activities	-	304
Staff costs	-	24
Support costs	-	5
	<u>-</u>	<u>333</u>
Fundraising trading: costs of goods sold	-	333
	<u>231,131</u>	<u>219,394</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

8 Charitable activities

	Payments to hospital 2021 £	Payments to hospital 2020 £
Staff costs	19,980	18,961
Depreciation and impairment	619	1,404
Payments to hospital	1,696,607	4,244,962
	<u>1,717,206</u>	<u>4,265,327</u>
Share of support costs (see note 9)	44,734	33,518
Share of governance costs (see note 9)	14,452	13,436
	<u>1,776,392</u>	<u>4,312,281</u>
Analysis by fund		
Unrestricted funds	751,297	1,046,755
Restricted funds	1,025,095	3,265,150
Endowment funds - general	-	376
	<u>1,776,392</u>	<u>4,312,281</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

9 Support costs

	Support costs	Governance costs	2021	Support costs	Governance costs	2020
	£	£	£	£	£	£
Staff costs	34,433	14,452	48,885	32,397	13,436	45,833
Impairment losses	100	-	100	-	-	-
Premises costs	32,660	-	32,660	26,837	-	26,837
Other costs	16,747	-	16,747	2,279	-	2,279
	<u>83,940</u>	<u>14,452</u>	<u>98,392</u>	<u>61,513</u>	<u>13,436</u>	<u>74,949</u>
Analysed between						
Fundraising	39,206	-	39,206	27,990	-	27,990
Trading	-	-	-	5	-	5
Charitable activities	44,734	14,452	59,186	33,518	13,436	46,954
	<u>83,940</u>	<u>14,452</u>	<u>98,392</u>	<u>61,513</u>	<u>13,436</u>	<u>74,949</u>

Support costs excluding staff costs which cannot be directly attributed have been apportioned equally between costs of raising funds and the charitable activity of payments to the hospital. Within support costs, other costs include telephone costs, postage costs, travel costs, computer running costs and staff training costs.

Staff costs have been apportioned on an estimated basis of the allocation of time spent on each specific activity.

10 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

	2021	2020
	£	£
Audit of the annual accounts	13,200	15,230
Non-audit services		
All other non-audit services	109	1,189

11 Trustees

None of the Trustees (or any persons connected with them) received any remuneration, nor reimbursement of travelling expenses during the year or prior year.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

12 Employees

The average monthly number of employees during the year was:

	2021	2020
	Number	Number
Administration	1	1
Fundraising	3	3
Finance	1	1
	<u> </u>	<u> </u>
Total	<u> </u>	<u> </u>
	<u> </u>	<u> </u>

Employment costs	2021	2020
	£	£
Wages and salaries	195,439	191,462
Social security costs	15,979	14,940
Other pension costs	4,820	4,610
	<u> </u>	<u> </u>
	<u>216,238</u>	<u>211,012</u>
	<u> </u>	<u> </u>

The number of employees whose annual remuneration was £60,000 or more were:

	2021	2020
	Number	Number
Between £70,000 - £79,999	1	1
	<u> </u>	<u> </u>

13 Other

	Unrestricted	Unrestricted
	funds	funds
	2021	2020
Net loss on disposal of tangible fixed assets	11,327	2,354
Audit fees	13,200	15,230
Legal and professional fees	289	114
	<u> </u>	<u> </u>
	<u>24,816</u>	<u>17,698</u>
	<u> </u>	<u> </u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

14 Net gains/(losses) on investments

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Revaluation of investments	11	(124)
	<u>11</u>	<u>(124)</u>

15 Tangible fixed assets

	Plant and machinery	Fixtures, fittings & equipment	Total
	£	£	£
Cost			
At 1 January 2021	6,471	24,650	31,121
Additions	-	2,370	2,370
Disposals	-	(19,751)	(19,751)
	<u>6,471</u>	<u>7,269</u>	<u>13,740</u>
At 31 December 2021	6,471	7,269	13,740
Depreciation and impairment			
At 1 January 2021	4,184	10,960	15,144
Depreciation charged in the year	764	473	1,237
Eliminated in respect of disposals	-	(8,424)	(8,424)
	<u>4,948</u>	<u>3,009</u>	<u>7,957</u>
At 31 December 2021	4,948	3,009	7,957
Carrying amount			
At 31 December 2021	<u>1,523</u>	<u>4,260</u>	<u>5,783</u>
At 31 December 2020	<u>2,287</u>	<u>13,690</u>	<u>15,977</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

16 Fixed asset investments

	Listed investments £	Other investments	Total £
Cost or valuation			
At 1 January 2021	299	100	399
Valuation changes	11	-	11
	<u>310</u>	<u>100</u>	<u>410</u>
At 31 December 2021	310	100	410
	<u>-</u>	<u>-</u>	<u>-</u>
Impairment			
At 1 January 2021	-	-	-
Impairment losses	-	100	100
	<u>-</u>	<u>100</u>	<u>100</u>
At 31 December 2021	-	100	100
	<u>-</u>	<u>100</u>	<u>100</u>
Carrying amount			
At 31 December 2021	310	-	310
	<u>299</u>	<u>100</u>	<u>399</u>
At 31 December 2020	299	100	399
	<u>299</u>	<u>100</u>	<u>399</u>

	Notes	2021 £	2020 £
Other investments comprise:			
Investments in subsidiaries	26	-	100
		<u>-</u>	<u>100</u>

17 Financial instruments

	2021 £	2020 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	310	299
	<u>310</u>	<u>299</u>

18 Debtors

	2021 £	2020 £
Amounts falling due within one year:		
Other debtors	10,251	8,361
Prepayments and accrued income	855	77,820
	<u>11,106</u>	<u>86,181</u>
	<u>11,106</u>	<u>86,181</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

19 Loans and overdrafts		2021	2020
		£	£
Bank overdrafts		3	-
		<u>3</u>	<u>-</u>
Payable within one year		3	-
		<u>3</u>	<u>-</u>
 20 Creditors: amounts falling due within one year			
	Notes	2021	2020
		£	£
Bank overdrafts	19	3	-
Other taxation and social security		5,279	5,313
Trade creditors		1,382	5,310
Amounts owed to subsidiary undertakings		-	83
Other creditors		869	751
Accruals and deferred income		13,200	13,719
		<u>20,733</u>	<u>25,176</u>
		<u>20,733</u>	<u>25,176</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

21 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds			
	Balance at 1 January 2020	Incoming resources	Resources expended	Balance at 1 January 2021	Incoming resources	Resources expended	Balance at 31 December 2021
	£	£	£	£	£	£	£
Bikur Cholim Campus	7,485	680	(7,500)	665	5,350	(2,500)	3,515
Children's Hospital	3,344	11,581	(7,334)	7,591	10,786	(15,054)	3,323
Emergency Department	1,742	374,199	(374,199)	1,742	51,588	(50,778)	2,552
Neurosurgery and Neurology Department	638	50,000	(50,000)	638	50,400	(50,400)	638
Others	19,105	13,307	(6,708)	25,704	21,760	(15,662)	31,802
Flourescent Activated Cell Storage	-	-	-	-	145,800	(145,800)	-
Neonatal Intensive Care Unit	5,323	66,893	(66,552)	5,664	44,561	(42,792)	7,433
Nursing Scholarships	-	77,439	(77,439)	-	79,489	(79,489)	-
Obstetric Department	-	153,974	(153,974)	-	-	-	-
Radiotherapy Institute	-	181,233	(181,233)	-	194,130	(194,130)	-
Intensive Care Department	151	35,250	(35,200)	201	-	-	201
Robotic Surgery	-	1,223,581	(1,223,581)	-	-	-	-
Cardiology Department	-	3,420	(3,420)	-	-	-	-
Coronavirus Department	-	1,078,533	(1,078,010)	523	23,515	(16,172)	7,866
Outpatient Clinic	-	-	-	-	315,118	(315,118)	-
IVF Research Department	-	-	-	-	97,200	(97,200)	-
	<u>37,788</u>	<u>3,270,090</u>	<u>(3,265,150)</u>	<u>42,728</u>	<u>1,039,697</u>	<u>(1,025,095)</u>	<u>57,330</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

21 Restricted funds

(Continued)

Bikur Cholim Campus is a separate campus hospital that merged with Shaare Zedek Medical Centre in Jerusalem. The fund is dedicated to fund the general running of the hospital.

Children's Hospital was set up as a separate fund to support a new building designed specifically for Children. The work on this site began in 2008 and the Children's Hospital officially opened in August 2015. The fund is dedicated to provide equipment and cover general running costs for the department.

The Emergency Department was set up to develop and extend the existing size of the old department. The fund is dedicated to cover running costs for the department.

The Neurosurgery and Neurology Department at the Shaare Zedek Medical Center treats a wide range of diseases involving the nervous system, with the aim of preserving and restoring brain and spine function and has a designated operating theatre which includes a new navigating system, intra-operation ultrasound and an innovative robot enabling procedures such as tumor tissue biopsy with great precision. The fund is dedicated to provide equipment and cover general running costs for the department.

Included within Others are various smaller funds which relate to various activities including CT Scanner, various pieces of equipment, Haematology Department, pending allocation, Geriatrics Department, Cardiology Department and LDA Educational Institute.

The Neonatal Intensive Care Unit (NICU) at the Shaare Zedek Medical Center treats infants born from week 24 of pregnancy. The complex includes 70 beds (with another 20 at the Bikur Cholim Campus), and state-of-the-art respiratory and monitoring equipment which provides precise data 24/7 on each of the babies in the unit. The fund is dedicated to provide equipment and cover general running costs for the department.

The Nursing Scholarships Fund is dedicated to provide support and training for student nurses.

The Obstetric Department includes the delivery rooms, the maternity wards, the High-Risk Pregnancy Unit and the Obstetric Ultrasound Unit. The fund is dedicated to provide equipment and cover general running costs for the department.

The Radiotherapy Institute is currently being built and is due for completion in 2022. The fund is dedicated to provide a Linear Accelerator for the Radiotherapy Institute.

Our Intensive Care Unit treats the most severe urgent care cases in the hospital. 70% of cases are post-surgery while others are complex cases referred from the Internal Medicine Departments.

The Fluorescent Activated Cell Sorting, Flow Cytometry, is the laboratory modality used by a FACS machine, a versatile diagnostic tool to identify and sort cells by the use of laser equipment and fluidic/fluorescent dyes. The FACS classifies the cells by their size, granularity and fluorescence staining. This device has become the gold standard in haematology research and is therefore a critical diagnostic tool for a growing major medical centre such as Shaare Zedek.

The Assisted Reproduction service has proven itself as a leader in developing IVF procedures for the benefit of the community. Shaare Zedek is home to an internationally-renowned centre for Medical Genetics research and has been a pioneer in the advancement of pre-gestational screening of embryos for the purpose of initiating pregnancies of foetuses free of specific genetic diseases that affect their parents and previous generations.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

21 Restricted funds

(Continued)

Our state of the art new ICU was upgraded in 2017 the first major upgrade and renovation of this Unit since the hospital moved to its current location in 1979. The Unit is now equipped with the latest technology and care methods in the most advanced setting possible. The risk of infection is a top priority for intensive care patients. The redesigned ICU gives each patient their own largely self-sufficient room to minimise the spread of infection. Almost all of the equipment is wall or ceiling mounted, meaning the room can be kept to a higher standard of cleanliness. There are 14 patient rooms in total, almost all of which are in constant use.

Robotic surgery is a field which has developed in recent years, increasingly becoming a standard and indispensable approach to care in a variety of surgical disciplines. It allows extremely fine and complex movements in a tight space, without the need to open large cavities that can involve more complications and a longer, more painful recovery period. Appreciating that this represents the future of modern surgery, we are proud that Shaare Zedek Medical Centre, which currently sees around 35,000 surgical procedures performed each year, has been a local pioneer in introducing advanced robotic approaches to the Israeli medical community.

In terms of the outpatient clinic, out of the more than 1,000,000 patients who are treated at Shaare Zedek Medical Center each year, the vast majority are treated on an ambulatory basis in our more than 70 outpatient units and clinics. In general, the trend in modern medicine is to reduce the need for inpatient hospitalization wherever possible, as this increases costs, emotional and practical challenges for the patient and is also less desirable from a medical perspective. For all these reasons, outpatient care is the growing trend in modern hospital care and Shaare Zedek has firmly embraced this trend with increased investment in these services. The central area for the large majority of our ambulatory services is in the Margulies Outpatient Clinics which are divided between the Fourth and Fifth Floors of The Next Generation Building.

The Cardiology Department provides a comprehensive response to the gamut of cardiac and cellular diseases. Our team performs catheterization, installs stents in the coronary arteries and implants pacemakers, defibrillators and valves without open heart surgery. There is also a state-of-the-art Cardiac Imaging Institute which uses 3-D Echo, CT and MRI. We can also administer advanced treatment for congenital and structural disorders. The department stresses preventative care and accompanies patients throughout the post-heart attack rehabilitation process.

The Coronavirus Department was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation.

The trustees are satisfied that sufficient resources are held in an appropriate form to enable each fund to be applied in accordance with any restrictions.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

22 Endowment funds

Endowment funds represent assets which must be held permanently by the charity. Income arising on the endowment funds can be used in accordance with the objects of the charity and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

	Movement in funds					Movement in funds					
	Balance at 1 January 2020	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at 1 January 2021	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at 31 December 2021
	£	£	£	£	£	£	£	£	£	£	£
Permanent endowments											
Rayne Endowment Fund	42,841	-	(376)	-	-	42,465	-	-	-	-	42,465
	<u>42,841</u>	<u>-</u>	<u>(376)</u>	<u>-</u>	<u>-</u>	<u>42,465</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>42,465</u>
	<u><u>42,841</u></u>	<u><u>-</u></u>	<u><u>(376)</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>42,465</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>42,465</u></u>

The Rayne Endowment Fund was donated by Lord Rayne to fund an international urology conference held at Shaare Zedek Medical Centre.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

23 Unrestricted funds

The income funds of the charity include unrestricted funds, within which designated funds have been set aside by the trustees for specific purposes:

	Movement in funds			Movement in funds				Balance at 31 December 2021
	Balance at 1 January 2020	Incoming resources	Resources expended	Balance at 1 January 2021	Incoming resources	Resources expended	Transfers	
Designated - Neo-Natal Department	16,224	-	-	16,224	-	-	(16,224)	-
Designated - Pending Allocation	-	76,794	-	76,794	632,323	(671,511)	-	37,606
Designated - Coronavirus Department	-	802,000	(802,000)	-	-	-	-	-
General Unrestricted Fund	792,171	361,073	(481,971)	671,273	477,727	(335,722)	16,224	829,502
	<u>808,395</u>	<u>1,239,867</u>	<u>(1,283,971)</u>	<u>764,291</u>	<u>1,110,050</u>	<u>(1,007,233)</u>	<u>-</u>	<u>867,108</u>

The Neo-Natal Department Fund had been set up to allow the legacy of one of our donors to contribute to the work they had supported throughout their life. The Trustees have now decided to transfer the balance held in the fund to the General Unrestricted Fund to support the running costs of the charity.

The Pending Allocation Fund relates to a single donation which is yet to be remitted to the Shaare Zedek Medical Centre, as the trustees have not yet confirmed what the donation should be used for.

The Coronavirus Fund was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation.

The General Unrestricted Fund relates to "free reserves" after allowing for all designated funds.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2021

24 Analysis of net assets between funds

	Unrestricted funds 2021 £	Designated funds 2021 £	Restricted funds 2021 £	Endowment funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Designated funds 2020 £	Restricted funds 2020 £	Endowment funds 2020 £	Total 2020 £
Fund balances at 31 December 2021 are represented by:										
Tangible assets	5,783	-	-	-	5,783	15,977	-	-	-	15,977
Investments	310	-	-	-	310	399	-	-	-	399
Current assets/(liabilities)	823,409	37,606	57,330	42,465	960,810	654,897	93,018	42,728	42,465	833,108
	<u>829,502</u>	<u>37,606</u>	<u>57,330</u>	<u>42,465</u>	<u>966,903</u>	<u>671,273</u>	<u>93,018</u>	<u>42,728</u>	<u>42,465</u>	<u>849,484</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

25 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2021	2020
	£	£
Aggregate compensation	78,000	72,600
	<u>78,000</u>	<u>72,600</u>

Transactions with related parties

Included within other creditors is an amount of £nil (2020: £83) due to Sharzed Advertising Limited, a 100% owned subsidiary, which was struck off after the balance sheet date.

Aggregate donations received from related parties without conditions amounted to £595,956 (2020: £265,925) for the year.

26 Subsidiaries

The financial statements below are separate from the charity's financial statements.

Details of the charity's subsidiaries at 31 December 2021 are as follows:

Name of undertaking	Registered office	Nature of business	Class of shares held	% Held	
				Direct	Indirect
Sharzed Advertising Limited	England and Wales	Advertising	Ordinary	100.00	

The principal activity of the subsidiary undertaking during the year was that of advertising and promoting fund raising for Shaare Zedek UK. The subsidiary was struck off after the balance sheet date.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2021

27 Cash generated from operations	2021	2020
	£	£
Surplus/(deficit) for the year	117,419	(39,540)
Adjustments for:		
Investment income recognised in statement of financial activities	(92)	(7,322)
Loss on disposal of tangible fixed assets	11,327	2,354
Fair value gains and losses on investments	(11)	124
Depreciation and impairment of tangible fixed assets and investments	1,338	2,808
Movements in working capital:		
Decrease/(increase) in debtors	75,074	(24,138)
(Decrease)/increase in creditors	(4,446)	1,186
Cash generated from/(absorbed by) operations	<u>200,609</u>	<u>(64,528)</u>
28 Analysis of changes in net funds		

The charity had no debt during the year.

SHAARE ZEDEK UK

England & Wales - Charity number 1143272

Accounts

Charity Registration No. 1143272

Company Registration No. 07469168 (England and Wales)

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Mr Michael Sorkin Mr Anthony Rosenfelder Mr Alain Stechler Mr Martin Paisner Mr Michael Sandler Mr Nigel Sloam	(Appointed 6 August 2020)
Charity number	1143272	
Company number	07469168	
Registered office	5 Technology Park Colindeep Lane London NW9 6BX	
Auditor	RDP Newmans LLP Lynwood House 373-375 Station Road Harrow Middlesex HA1 2AW	
Bankers	HSBC Bank Plc 8 Canada Square London E14 5HQ	
	Bank Leumi (UK) Plc 20 Stratford Place London W1C 1BG	
	National Westminster Plc 135 Bishopgate London EC2M 3UR	
	Barclays Bank Plc 1 Churchill Place London E14 5HP	

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) CONTENTS

	Page
Trustees' report	1 - 13
Statement of Trustees' responsibilities	14
Independent auditor's report	15 - 18
Statement of financial activities	19
Summary income and expenditure account	20
Balance sheet	21 - 22
Statement of cash flows	23
Notes to the financial statements	24 - 42

SHAARE ZEDEK UK

(A COMPANY LIMITED BY GUARANTEE)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees present their report and financial statements for the year ended 31 December 2020.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's Memorandum & Articles of Association, the Companies Act 2006 and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

In this context the Trustees have complied with the duty in section 17 (5) of the 2011 Charities Act in giving due consideration to the Charity Commission's guidance on Public Benefit. The report is prepared in accordance with the small companies' regime (Section 419(2) of the Companies Act 2006).

Principal aims and objectives

"To save a life is to save the world. Nowhere is this clearer than at Shaare Zedek. A hospital not just with a heart but with a soul that makes the world a better place."

Quote from a relative of a Shaare Zedek patient

Our mission is to support, by all such means as may be charitable in law and for exclusively charitable purposes, Shaare Zedek Medical Centre (Shaare Zedek) in providing world class care for all patients irrespective of their ability to pay, nationality, age, race or religion. We provide financial support to fund services, capital projects, research and the purchase of equipment for the hospital.

History

Founded in 1902, Shaare Zedek has been known as the "Hospital with a Heart" for more than a century. This reputation as a patient's first choice of hospitals stem from its unwavering commitment to all its patients, regardless of race, religion, political view or country of origin. All patients who are admitted receive the most advanced medical treatment available in a compassionate, supportive and nurturing environment. The hospital's ethos, "delivery of care and pioneering approaches to research", provides hope for us, hope for Israel and hope for the world.

Since 1902, the Hospital has chartered the course of Jerusalem's modern development and has been instrumental in the city's growth. Over half of Jerusalem's children live below the poverty line. Shaare Zedek was one of the first hospitals in Israel to recognise the need for specialist paediatric medical facilities and is home to Jerusalem's only dedicated Women and Children's Hospital.

Shaare Zedek 2020

Today Shaare Zedek Medical Centre is a 1,000-bed facility with close to 100 departments, treating 800,000 patients annually. As the fastest growing hospital in the region, the hospital continues to respond to and plan for the needs of Jerusalem's uniquely diverse population. Its current major expansion projects include the Radiotherapy Institute, a much-needed new facility to support patients from across the region. The most pressing expansion is the doubling of the size of its Emergency Department. The daily growth in demand on its urgent care facilities in the region necessitates a bigger department with the latest technology to ensure they are much better equipped to respond.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2020

Message from our New Director General

I begin by expressing my hope that all is well with you and your families in what continues to be a trying time. We are currently in a period that has literally changed the world. While nearly every aspect of our lives has been impacted by Covid-19 Shaare Zedek's role in responding to this disease has been not only the source of enormous challenge, but one of great pride.

The challenge has been in treating a disease that the medical world is only just beginning to understand, while being forced to overhaul much of our patient-care infrastructure. Compounding that challenge was the massive investment of financial and human resources placed into our Covid-19 response program and how the crisis forced the temporary closure of many other departments of the hospital.

The pride emanates from the fact that we quickly became Israel's second most active Covid-19 Care hospital and we played a critical function in the care of thousands of Covid-19 patients. There is no doubt that the levels of preparedness that we put into place – some measures which were enacted many months before the world had even heard the term Covid-19 – were instrumental in our success.

While treating Coronavirus cases has certainly been a significant focus over the last year at Shaare Zedek, we have remained focused on our broader vision of comprehensive medical care. All major activities remained in place alongside our developmental projects.

We thank you, our friends in the UK, for digging deep and supporting us at this uniquely challenging time for Shaare Zedek. The crisis required a tremendous investment for rapid construction and the purchase of new equipment so I extend my sincere thanks and look forward to our continued partnership in caring for the people of Jerusalem and Israel.

Professor Ofer Merin, MD
Director General, Shaare Zedek Medical Centre

SHAARE ZEDEK UK

(A COMPANY LIMITED BY GUARANTEE)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)

(CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Objectives and activities

Activities

In order to achieve our key objectives, Shaare Zedek UK employs a small office team led by an Executive Director working in partnership with trustees and other lay leaders, supported by a small but growing number of energetic volunteers.

Shaare Zedek UK promotes awareness of the activities of Shaare Zedek Medical Centre. We also seek to promote support of the charitable activities of the hospital, and in particular its charitable activities for the public benefit in health welfare, medical and scientific advancement and best practice in patient treatment. We raise funds through donations, legacies, solicited mailings, events, direct approaches and special appeals.

Achievements and Performance

Achievements on the ground: The impact of our fundraising

An unprecedented year: Shaare Zedek's fight against Covid-19

As Jerusalem's only centrally-located major hospital, Shaare Zedek takes its responsibility to be ready for any circumstance very seriously. From biohazard drills to mass casualty events, its teams undertake regular training to ensure that facilities, equipment, systems and staff are all ready for any eventuality.

In early 2019, the hospital ran an emergency scenario for a pandemic. This resulted in purchasing additional equipment and strengthening of protocols for such an event. No-one could have foreseen that these would be put to use as quickly as early 2020 when the Covid-19 virus arrived in Israel. Having prepared for such a scenario, its teams were already confident in their processes and procedures for treating patients in an isolation environment. Consequently, its efforts could be more usefully focused on adapting the facilities to meet the growing needs as patient numbers increased.

The Covid-19 response began in early March when the pandemic first arrived in Israel with its medical teams trained and ready to confront the crisis with comprehensive and compassionate care. Immediately upon recognizing the scope of the challenge, its medical and support teams began setting up multiple Keter (Covid-19) units including a dedicated ICU, a large biological patient absorption unit, a paediatric Keter unit and various other support and treatment facilities. The hospital has sampled more than 2,500 Covid-19 patients, establishing Biobank – one of the world's largest Covid-19 databases that allows researchers to characterize the disease, identify complications, find novel diagnostic methods, vaccines and even contribute to testing new treatments. More than 65 Coronavirus studies have already been performed at the hospital and it has been used extensively for local and international research purposes.

A comprehensive testing system was set up by its Laboratory Department and they operate numerous clinics for the ongoing monitoring of prior Covid-19 patients – both children and adults.

In mid-December the hospital began intensive vaccination efforts in the very physical space where the first Covid-19 patients were treated. In the first 5 days of the vaccination programme over 2,000 staff- the majority of our staff team- had been vaccinated.

Research efforts focused on early detection of Covid-19 through non-invasive means including a collaborative study with Israel's Biological Research Institute for a breathalyser test for Covid-19. One of the many benefits of patient-based research work is its ability to report patterns and anomalies quickly. As one of Israel's busiest Covid-19 hospitals, Shaare Zedek have treated a large volume of patients and as such were able to contribute to global learning about the virus in real time. Shaare Zedek's findings have been shared and used by the scientific community around the world, and have been reported widely in the international press. Its global reputation for excellence and pioneering treatment has been significantly bolstered by its response to this pandemic.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2020

Since the first patient arrived for treatment for Coronavirus until the end of 2020, our Covid-19 Unit recorded:

- 69,316 Hospitalisations
- 3,432 Patients in inpatient care
- 1,225,284 Hours of assisted respiration
- 142,041 Face shields
- 1,121,276 Protective gowns
- 2,082,144 Masks
- 50,950 Full body suits
- 140,423 Pairs of gloves

Other achievements in 2020

Treating Jerusalem through a pandemic

2020's activities were defined by the Covid-19 crisis which affected all aspects of the hospital's operations. This included a temporary reduction of services in some areas of the hospital as a result of government-imposed departmental closures as well as an overall reduction in patients due to lockdowns and other factors outside of the hospital's control. Below is a summary of Shaare Zedek's key patient statistics for 2020:

- 1,000 patient beds
- 262,289 imaging scans
- 406,936 hospitalisation days
- 21,878 babies born
- 34,944 surgeries
- 846,017 outpatient clinic visits
- 138,043 Emergency Department cases
- 2,310 cardiac procedures
- 1,325 neurological procedures
- 3,432 Covid-19 patients treated
- 69,316 Covid-19 hospitalisation days
- 1,225,284 hours of assisted respiration (Covid-19 wards)
- 1,175 physicians
- 1,959 nurses
- 613 paramedical staff

While Covid-19 certainly defined the year for the medical centre, there were many other accomplishments and developments recorded. Most significantly, the hospital is positioned to significantly increase in size and scope in the coming year with the projected completion of the first phase of the Cancer Care Centre. This is all part of the "master plan" to be completed over the next decade and a half and designed to triple our patient care areas.

Alongside this, all its "general" medical services went on at all hours of the day and night with surgeries, outpatient visits and of course births once again recording impressive annual numbers.

Among its proudest accomplishments for the year:

- Active construction moved ahead on its new Radiotherapy Institute and parking tower as well as building commencing on the expanded Emergency Department.

- The Department of Medical Genetics advanced new research for the early detection of the BRCA 1 and 2 mutations allowing for identification before the onset of cancer and significantly increasing patient survival rates.

- The Wilf Woman and Infant Centre became the first maternity program in Israel to adopt a new protocol promoted by the International Paediatric Association to use specially designed "sleeping bags" known to be safer and address risks of Sudden Infant Death Syndrome (SIDS).

SHAARE ZEDEK UK

(A COMPANY LIMITED BY GUARANTEE)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)

(CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

- Shaare Zedek became the first hospital in Israel to use an innovative surgical technique to address a congenital kidney malformation in a one-and-a-half-month-old baby.
- The hospital recorded high marks in standard reviews by the Israel Ministry of Health which credited Shaare Zedek with providing the highest levels of service, delivered with professionalism in standing at the forefront of medical care for the people of Israel.
- The medical staff once again contributed to IDF relief efforts including leading a major international field hospital drill.
- Internationally renowned ethicist and Paediatric Neurologist at Shaare Zedek Professor Avraham Steinberg received the prestigious Yakir Yerushalayim Award.
- A beloved and long-time volunteer at the hospital, Reina Abitbul, was selected for the high honour to light one of the torches at the annual national Independence Day celebration.
- Yirah Levy, a National Service volunteer who serves in the Covid-19 ward was honoured with an award for her service by Israel's President.
- Dr. Ramzi Kurd, Head of Covid-19 Department at Shaare Zedek Medical Centre was selected as one of the top 40 promising people in Israel under the age of 40.

Shaare Zedek once again welcomes the chance to renew its commitment to the people of Jerusalem and Israel, as it has done for nearly 120 years, to serve its community with compassion, dedication and looks forward to a new year defined by happiness and health.

Global Impact: Partnerships and collaboration

This year as in other years, Shaare Zedek's work with technology and bio-tech companies, hospitals, governments and charities has helped it to provide better care for its own patients as well as sharing best practice around the world, and only serves to grow its global reputation for excellence and innovation. The achievements in clinical excellence, pioneering research and collaboration with its international counterparts have generated public benefit with local and global impact, attracting the attention of world media and praise in international journals. These partnerships provide huge benefits to its patients, often enabling Shaare Zedek to embrace cutting-edge technology and equipment at no cost to the hospital.

Teams across the hospital are regularly involved with supporting medical provision and infrastructure in developing countries. One such initiative is its Cardiology partnership in Ethiopia, training two new specialists every year to strengthen Ethiopia's expertise in paediatric medicine. This year the hospital has hosted several international governmental medical delegations to share its expertise in adapting to the Covid-19 global pandemic. This included a visit from the Ambassador of Kosovo to Israel who pledged to establish medical cooperation efforts between the two countries and invited Shaare Zedek to lead a medical exchange delegation to Kosovo.

Professor Natan Bornstein, Director of the Helmsley Neurological Institute and an internationally respected expert in Neurology, has been appointed to serve as Chair of an Israeli Ministry of Health special commission on neurological care. The creation of the commission comes in light of an increase in neurology cases throughout the country. The commission is designed to provide overall recommendations that can then be implemented to improve neurology care across the national health system.

Professor Bornstein, who holds the David B. Keidan Chair in Neurology, heads Shaare Zedek's comprehensive neurology program, which was set up five years ago as an umbrella service named the Helmsley Neurological Institute. The Institute includes dedicated programs for stroke care, general and paediatric neurosurgery and interventional neuro-radiology.

The services have become nationally and internationally known for embracing increasingly ground-breaking methods and technologies for the diagnosis and treatment of a wide variety of neurological conditions and injuries to the brain and spinal column.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2020

Additional medical units have been set up for treatment of related conditions like motor diseases and chronic headaches. According to Professor Bornstein, there has been a noticeable increase in brain disease in Israel which demands a systemic response – both on the level of hospital-based medicine and with increased awareness and training on the community-medicine level. *“This commission which I will chair will create a detailed assessment of the increase that we are witnessing, and map the existing infrastructure so we can better determine where we need to invest in additional resources. I welcome this opportunity and thank the Health Ministry for placing their confidence in me to lead this effort to enhance and improve the level of neurological care throughout Israel.”*

Shaare Zedek Scientific (SZC) had another year of rapid growth in 2020. It is SZC’s goal to act as an innovation bridge between leading companies in the fields of medical research and our hospital. SZC is responsible for research and development collaborations between the Medical Centre and industry, including implementing new technologies in the field of digital health and providing access to medical data through Shaare Zedek’s Innovation Centre.

A central pillar of Shaare Zedek’s vision is to promote the medical field by engaging in research at all levels. This mission has guided Shaare Zedek for nearly 120 years, to advance innovative modes of medical care that embrace new technologies and methods for the benefit of the community. Indeed, SZC encourages clinicians and scientists to maximize their innovation potential in industry and investigator-initiated research projects across a broad range of applied and theoretical topics and disciplines. This includes basic science, clinical trials, and practical innovation such as development of medical devices. This helps promote an always-expanding and increasingly productive collaboration with key industry players. Shaare Zedek Scientific provides the professional support the investigators require to foster a fruitful interaction with industry players and other academic institutes. Today, through the dynamic infrastructure Shaare Zedek has created, it is increasingly positioned to push those goals even further and expand beyond boundaries for enhancing healthcare science all over the world.

SZC has formed many partnerships this year in researching Covid-19. Our BioBank has become a resource to companies around the world. A partnership with Sight Diagnostics has focused on early detection and fighting Covid-19. Throughout the year it has been mutually benefiting from a close partnership in researching early diagnosis methodologies for Covid-19 patients. Utilizing Shaare Zedek’s BioBank, home to one of the world’s largest resources of bio-data related to Coronavirus, together it is continuously advancing its understanding of this virus and enhanced methods for diagnosis and treatment. Sight Diagnostics won the Genesis Prize for this work in early 2021.

Its partnership with Google continues through their life-science focused sister company, Verily. SZC recently announced a collaboration on a clinical study of AI-powered colonoscopy.

Another partnership with Sight Diagnostics has been formed to identify the possibility of blood cancer using a combination of images and data collected from Sight’s OLO device and patient clinical information provided by the hospital. The research focuses on developing the capability to detect and classify white blood cells, and more specifically, to differentiate between different types of white blood cells in the immune system called lymphocytes, a procedure that has greatly challenged the global haematological community.

As Shaare Zedek enters into new areas of patient care, whilst developing new technologies and research focused on medicine for the future, Shaare Zedek believes its unique approach to integrated and personalised medicine will continue to cement its mark on Jerusalem, Israel and across the world.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2020

UK funding

Most of our donors in 2020 responded to the Emergency Coronavirus appeal. The hospital started dealing with patients suffering with Coronavirus symptoms in early March 2020 and this is when we launched our Emergency Appeal at Shaare Zedek UK. Shaare Zedek's medical teams were trained and ready to confront the crisis with their usual comprehensive and compassionate care. However very early on the hospital recognised the huge challenge in front of them and launched an international emergency appeal to meet the challenge. Within weeks UK donors had raised thousands and by the end of 2020 we had sent £1,880,010 to Shaare Zedek Medical Centre specifically to support the fight on Covid-19.

The statistics do not explain the human toll the virus has taken on our teams. All of the staff, from doctors to cleaners found themselves working in a new potentially life-threatening environment. The hospital management took the decision not to make anyone work in the Keter units and asked staff to volunteer. The incredible efforts of these staff who voluntarily put themselves on the line are nothing short of heroic. Their experiences were captured by members of the team who wrote public diaries of daily life in the Keter wards, art exhibitions were displayed in the hospital entrance. A news crew made a short film about life in the Shaare Zedek ward which is available to view on our website. It is proud of the zero infection rates amongst staff from the hospital wards, but many staff were infected whilst outside of work, or self-isolating with their families. On Erev Rosh Hashanah, there were 40 staff members sick with Coronavirus, two weeks later the number jumped to 56 (an increase of 40%). At one point in time there were more than 200 staff members in isolation. In the UK we launched a Covid-19 care package scheme to fund self-care package for any staff self-isolating.

Other donors responded to our emergency appeal by completing pledges early, redirecting funds to the emergency appeal or making large donation to other departments in need of urgent funds, such as the Emergency Department. In total, UK donors generosity enabled us to send £4,244,962 to the hospital in 2020.

In solidarity with colleagues in Israel, Our Executive Director voluntarily took a salary sacrifice at the height of the pandemic, following the example of the senior leadership team at the hospital who took similar action.

In addition to the emergency appeal for Covid-19, gifts have been made across many of the 100+ departments at the hospital. Donors choose to support departments with which they have a personal affinity as well as responding to our appeals to support the needs of specific departments as dictated by the Board of the hospital. The UK office has designated unrestricted funds to the departments most in need of support to ensure the maximum impact of UK donations. This year donations have been restricted and designated to support Intensive Care, Neurology & Neurosurgery, Obstetrics and Gynaecology, Neonatal Intensive Care, Cardiology, Oncology, Radiotherapy Institute, Emergency and Paediatric Emergency, Robotic Surgery, Paediatric Oncology & Haematology, and various other departments within our dedicated Children's Hospital. In addition, a small number of donors have chosen to support training opportunities for doctors and nursing scholarships.

There is a strong British footprint in every one of the hospital's 14 internationally recognised Centres of Excellence. Fundraising in the UK has always been conducted in close partnership with the leadership of the hospital in Jerusalem. In March 2019 Professor Ofer Merin became the Director-General of Shaare Zedek Medical Centre, with former Director-General Professor Jonathan Halevy becoming the President of the hospital. Professor Halevy continues to lead the fundraising strategy for the hospital in his new role. Collaboration between professional colleagues and board members grows each year. This year our Executive Director and Chairman attended the online board meeting of the International Board of Governors of the hospital. We have enjoyed a close working relationship with both the President and Director General of the hospital and their teams. This year the UK team joined a call bringing the international offices fundraising for Shaare Zedek together to discuss further collaboration. We look forward to a continued partnership with Professors Halevy and Merin and are indebted to them for their visionary leadership and continued service. We are grateful to Uri Schwarz and the entire fundraising team at Shaare Zedek Medical Centre who support our fundraising efforts on the ground in Israel.

SHAARE ZEDEK UK (A COMPANY LIMITED BY GUARANTEE) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Strategic report

The description under the headings "Achievements and performance" and "Financial review" meet the company law requirements for the Trustees to present a strategic report.

Organisational Objectives for 2020 - a difficult year

These were the specific objectives in 2020 and how we performed to meet them:

Objective 1: Fundraising for Shaare Zedek Medical Centre

Our planned activity for the year and all charitable operations and administration were disrupted and hugely impacted by the global pandemic. Despite this, the generosity of our donors has resulted in us being able to raise £4,492,953 this year, with £4,244,962 already sent to the hospital directly.

Fundraising programmes and events

The majority of funds raised in 2020 were received in response to our Emergency Coronavirus Appeal. The most successful fundraising methods were part of our ongoing relationship with existing major donors, individual interactions with prospective donors and in response to direct mail and email campaigns as well as legacy gifts.

The work of our staff team during this period has been exemplary and inspirational. In addition to our responsibilities to fundraise for the hospital we felt a responsibility to our donors. In addition fundraising staff spent a huge amount of time looking after our donors, contacting all the donors we know personally to ensure everyone was safe and to offer support if it was needed. The team provided various forms of support, from buying groceries and collecting medications to signposting people for additional support required.

All events and challenges planned for 2020 were cancelled due to pandemic. We were very fortunate to be able to run Zoom briefings direct from Shaare Zedek on topics from 'Corona through the eyes of sick children' to Compassion from Behind the Mask'. To date our most popular briefing was held by President of Shaare Zedek, Professor Jonathan Halevy on the Covid-19 vaccination. This was a topic of major interest and we had over 250 attendees from around the world. Many more have viewed the recording since the live briefing which was made available to watch on our website. We hope to be able to continue to make use of online events connecting our donors directly to our doctors and nurses in the future. Whilst they cannot replace a visit to the hospital, these events allow us to connect with donors and potential supporters who may otherwise not have the opportunity to hear about our work. These events were free of charge to attend and open to all as it was felt this was a public service we could provide during the global pandemic. Many of the donors from the UK who attended the calls had already contributed to our emergency appeal and a few did so after the events.

We continue to follow Government guidance closely and keep up to date with announcements from the providers of the challenge events we usually participate in. We take a decision on a case by case basis as to whether we will participate in any challenge events. In the first half of 2021 we have not held any events. At our board meeting later in the year we will discuss if any in person events are possible in 2021 or if we should wait until 2022.

Our Celebrations programme continues to be popular, offering certificates and personalised cards for those celebrating birthdays, anniversaries and festivals, and those who wish to support Shaare Zedek by asking family and friends to make donations to the hospital. Our income from celebrations this year includes a matched funding gift to encourage bar and bat mitzvah aged teenagers to raise funds for us. Celebrations income has declined this year as many supporters cancelled or postponed their celebrations due to the pandemic. We expect to see an increase in these gifts as lockdown restrictions ease.

In 2020 we registered with Benevity, the workplace giving programme. There are over 600 companies that match employee charitable gifts through this programme. We are grateful to one of our donors who suggested our registration with Benevity. We are promoting the programme through our publications and website and hope to be able to engage with employers offering matched-giving programmes in the year ahead.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Our marketing and communications strategy has continued to develop with an emphasis on personality and warmth, showing supporters the impact of their gifts and providing the living bridge between donors and the hospital. Our website allows donors to stay up to date with activities in the UK as well as at the hospital. Donors now have the ability to fundraise within our website, setting their own fundraising challenges and activities without the cost of using third party platforms, enabling all of the funds raised to benefit the charity directly. Our social media channels have been a central point through which we have engaged with supporters and wider audiences during the pandemic. The emotive stories from the hospital have provided much inspiration and motivation for donations.

Appeals income has increased in 2020. Supporters were warm in their response to our direct mail campaigns and keen to do what they could as hospitals were at the forefront of the pandemic. We expect that this will decline in 2021 as the wider effects of the pandemic have taken effect and hospitals are no longer the only urgent priority.

Several synagogues, notably Edgware Adath Yisroel Synagogue, support our endeavours through their Kol Nidre Appeals. We are trying to develop relationships with more communities to increase awareness and fundraising capabilities.

Calendar advertising has been declining in recent years. The calendar is an effective marketing tool, particularly for legacies and as such is still an important publication which is also profit making. In order to maximise profits we hope in 2021 or in 2022 to recruit an advertising committee who can work on bringing in calendar adverts throughout the year.

Several donations of goods in kind have allowed us to expand our community outreach work at very little cost to the charity. For each of the Jewish festivals during lockdown, we marketed an activity pack for children to keep busy. The packs contained age appropriate activities to keep children entertained during the festivals. Each pack purchased provided a self care package for a member of hospital staff self-isolating due to Covid-19. The support from UK donors in funding the Covid-19 Care Packs has been greatly received by everyone at Shaare Zedek. The packs proved very popular and cost effective for us to sell and raised £1,637 in 2020 and we expect to raise more from this initiative in 2021.

Objective 2: Payments to hospital

During the year the Charity remitted £4,244,962 (£1,265,056) directly to the Shaare Zedek Medical Centre and incurred additional staff, support and governance costs amounting to £67,319 (2019: £91,597) in relation to the charitable activity.

This is a huge achievement for our professional team. With a small staff all working from home during lockdown, we faced many challenges ranging from school closures and no childcare for half the team to one member of staff being hospitalised from Covid-19, and suffering a bereavement due to the virus. Despite the significant challenges every staff member faced during this period, the charity raised its highest total in over a decade. At various times in the pandemic we made use of the Government Coronavirus Job Retention Scheme ('furlough'). One member of staff was furloughed from the beginning of the scheme and others made use of the scheme when it became a flexible arrangement.

Objective 3: Improving our operations and strategic planning

The organisational strategy continues to be implemented with a focus on key areas for organisational growth and fundraising opportunities based on our organisational strengths, key areas for improvement and new opportunities. All areas of activity are subject to regular evaluation and analysis. The global pandemic had an unforeseen impact on our operations in 2020. As such we are in the process of regularly reviewing strategic planning and income forecasts in light of the ever changing landscape.

We continue to develop contacts with other potential Members and a new committee of lay leaders is in the process of being recruited as part of succession planning by our trustees. Nigel Sloam joined our board as a new trustee in August 2020.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Supplier costs are regularly reviewed resulting in savings from renegotiating supplier contracts. As our communications materials continue to increase donor engagement, it is our intention to create sponsorship opportunities to meet these costs in order to keep administrative expenses as low as possible.

The CRM system used to manage donor records is regularly updated to comply with the GDPR legislative guidance to ensure we are fully compliant with the legislation. We continually update our donor records in advance of our appeals to ensure donors are contacted only when they wish to be, keeping good faith with our supporters and saving the charity unnecessary expenditure on producing and mailing appeals. We are registered with the Fundraising Regulator and the Fundraising Preference Service and to date have never received any complaints through either body.

Financial review

The current economic climate continues to impact on our ability to raise new funds. Given the tough climate we were delighted to have increased our income this year, having raised £4,492,953 (2019: £1,664,005). We have maintained a healthy financial position with closing fund balances totalling £849,484 (2019: £889,024), of which £42,728 (2019: £37,788) relates to restricted funds. Furthermore, £93,018 (2019: £16,224) within the closing unrestricted fund balance is designated for specific purposes. Hence, the general unrestricted funds the charity holds amounts to £671,273 (2019: £792,171) at the end of the reporting period after making allowance for restricted and designated funds. We are delighted to have raised significant funds enabling us to send £4,244,962 (2019: £1,265,056) directly to Shaare Zedek in Jerusalem. This year we were in a position to send 94% of our total income directly to the hospital, the balance being held in reserves in the UK.

Legacy gifts continue to be a vital source of income, with 23% of all donations this year being from legacy gifts in donors' wills and one large gift of £800,000. Legacies are unpredictable, at times materialising without our prior knowledge and we continue to maintain and develop this income whilst recognising the need for a diversification of income from other sources to maintain the level of support we currently provide to the hospital.

General donations including major gifts increased significantly to £3,477,771 (2019: £1,088,813). Although we continue to enjoy the support of our loyal donors, the economic situation continues to be challenging. In common with other charities, we continue to find ways to engage new donors in a challenging climate. Existing donors too are lowering their donations due to reduced income to their Trusts or change in personal circumstances due to the pandemic.

Reserves policy and going concern

It is the policy of the Charity to maintain unrestricted funds, which are the free reserve of the Charity, at a level that takes account of the needs of the likely administration costs of the Charity over the next 24 month period. The Board has the power to invest in such assets in secure money market instruments.

Risk management

The Board has assessed the major risks to which the charity is exposed, in particular those related to the operations and finances of the Charity and is satisfied that systems are in place to mitigate its exposure to those risks.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2020

Plans for the future

With a new Director General now in post at Shaare Zedek, our Executive Director and trustees are in discussions with the hospital regarding their plans and priorities for the future. We are supporting the Emergency Room and Radiotherapy Institute capital building projects in addition to the annual requests received from the hospital to upgrade existing equipment and facilities and purchase the latest new technology.

2020 has been an unprecedented year for the charity in the UK and hospital in Jerusalem. We hope to return to our regular programme of events and activities and use our ability to connect donors to our medical professionals through online events further. There is an acute need to obtain mid-level and major gifts on an annual basis or preferably a multi-year pledge basis. Efforts to increase major gift fundraising were planned to focus on applications to trusts and foundations, alongside our renewed efforts to engage new and existing mid-level donors. As a result of the Covid-19 pandemic, fundraising has largely been focused on supporting the efforts of the hospital to fight the pandemic. We launched an Emergency Appeal in April 2020 and the hospital is continuing its efforts to fight Coronavirus in its clinical work and research whilst forging ahead with plans for development and growth.

Our professional team have worked exceptionally hard in difficult circumstances to ensure our levels of activity and donor engagement could support the emergency campaign. Our financial forecast for the year has been impacted by the pandemic but we managed to finish 2020 with a higher level of restricted funds than anticipated. We do expect that unrestricted income from the non-emergency appeals will be lower as a result of the success of the Emergency Campaign for the Coronavirus Unit.

From internal research, the Shaare Zedek UK message is very strong with existing donors. We need to expand awareness of the hospital amongst the Jewish community and wider society to ensure that we can engage with future generations of supporters. The core brand message has informed new approaches to marketing, events and other activities that work towards this aim. Engaging new major donors will be a greater challenge in the current climate but we are working on creative ways to use the international resonance of a front-line hospital fighting a global pandemic to engage new supporters at all levels.

Structure, governance and management

The charity is a company limited by guarantee, incorporated on 14 December 2010 and registered as a charity on 8 August 2011. The charity's reference and administrative details are as set out within these accounts. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.

The Board of Trustees

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr Michael Sorkin
Mr Anthony Rosenfelder
Mr Alain Stechler
Mr Martin Paisner
Mr Michael Sandler
Mr Nigel Sloam

(Appointed 6 August 2020)

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute such sum (not exceeding £10) in the event of a winding up.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Key personnel

The following individuals whilst not statutory members of the charity were involved in an advisory capacity:

Dan Adler
David Bernstein
David Cohen
Geoffrey Goldkorn
Eva Greenspan
John Jay
Margot Lew
Angela Margolis-Raz
Marcus Margulies
Hilary Natoff
Jonathan Paull
Marcus Pearl
Margaret G Rothem
Simon Sackman
Nolan Wengrowe
Michael Ziff
Emma Pearl

Recruitment, appointment and terms of office of Trustees

Trustees are appointed in accordance with the Charity's Memorandum & Article of Association.

Trustee induction and training

New trustees are made aware of the organisation structure of the charity and are shown financial statements of the charity for the three preceding years.

All trustees are now already familiar with the practical work of the charity. Induction procedures are in place for new trustees.

Operations and staffing

The trustees delegate day to day management of the charity to the Executive Director, Simona Bennett to deliver the aims and objectives of the charity.

Safeguarding

Shaare Zedek UK has a safeguarding policy and this year the Executive Director completed safeguarding training. The charity makes regular enquiries of the hospital with regard to its own robust safeguarding policies and notification of any relevant safeguarding issues we should be aware of.

Related parties

Included within other creditors is an amount of £83 (2019: £1,657 due from) due to Sharzed Advertising Limited, a 100% owned subsidiary.

Aggregate donations received from related parties without conditions amounted to £265,925 (2019: £190,471) for the year.

Aggregate remuneration of key management personnel amounted to £72,600 (2019: £78,000) for the year.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT AND STRATEGIC REPORT)
(CONTINUED)**

FOR THE YEAR ENDED 31 DECEMBER 2020

Auditor

A resolution proposing that RDP Newmans LLP be reappointed as auditors will be put to the members.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report, including the strategic report, was approved by the Board of Trustees.

Mr Michael Sorkin

Trustee

Dated: 24 September 2021

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees, who are also the directors of Shaare Zedek UK for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT
TO THE TRUSTEES OF SHAARE ZEDEK UK**

Opinion

We have audited the financial statements of Shaare Zedek UK (the 'charity') for the year ended 31 December 2020 which comprise the statement of financial activities, the summary income and expenditure account, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF SHAARE ZEDEK UK**

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report [or the strategic report] included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept; or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF SHAARE ZEDEK UK**

The extent to which the audit was considered capable of detecting irregularities including fraud

We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006 and The Charities Act 2011 together with the Charities SORP (FRS102). We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company's ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and the group for fraud. The laws and regulations we considered in this context for the UK operations were, General Data Protection Regulation (GDPR), and employment legislation.

We assessed the susceptibility of the charity's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed and tested journal entries to identify unusual transactions and other adjustments for appropriateness, and evaluating the business rationale of significant transactions outside the normal course of business;
- assessed whether judgements and assumptions made in determining the accounting estimates set out in note 2 were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- reviewing and agreeing financial statement disclosures and testing to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE TRUSTEES OF SHAARE ZEDEK UK**

RDP Newmans LLP

24 September 2021

**Chartered Accountants
Statutory Auditor**

Lynwood House
373-375 Station Road
Harrow
Middlesex
HA1 2AW

RDP Newmans LLP is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under of section 1212 of the Companies Act 2006.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	Unrestricted funds 2020 £	Restricted funds 2020 £	Endowment funds 2020 £	Total 2020 £	Total 2019 £
<u>Income and endowments from:</u>						
Donations and legacies	3	1,222,151	3,270,090	-	4,492,241	1,663,325
Other trading activities	4	712	-	-	712	680
Investments	5	7,322	-	-	7,322	12,373
Other	6	9,682	-	-	9,682	-
Total income		1,239,867	3,270,090	-	4,509,957	1,676,378
<u>Expenditure on:</u>						
Costs of raising funds	7	219,394	-	-	219,394	245,063
<u>Charitable activities</u>						
Payments to hospital	8	1,046,755	3,265,150	376	4,312,281	1,356,653
Total charitable expenditure		1,046,755	3,265,150	376	4,312,281	1,356,653
Other	13	17,698	-	-	17,698	11,811
Total resources expended		1,283,847	3,265,150	376	4,549,373	1,613,527
Net gains/(losses) on investments	14	(124)	-	-	(124)	73
Net movement in funds		(44,104)	4,940	(376)	(39,540)	62,924
Fund balances at 1 January 2020		808,395	37,788	42,841	889,024	826,100
Fund balances at 31 December 2020		764,291	42,728	42,465	849,484	889,024

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
SUMMARY INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2020

	All income funds	
	2020	2019
	£	£
Gross income	4,509,957	1,676,378
(Losses)/gains on investments	(124)	73
	<hr/>	<hr/>
Total income in the reporting period	4,509,833	1,676,451
	<hr/>	<hr/>
Total expenditure from income funds	4,549,373	1,613,527
	<hr/>	<hr/>
Net (expenditure)/income for the year	(39,540)	62,924
	<hr/> <hr/>	<hr/> <hr/>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET

AS AT 31 DECEMBER 2020

	Notes	2020		2019	
		£	£	£	£
Fixed assets					
Tangible assets	15		15,977		18,086
Investments	16		399		523
			<u>16,376</u>		<u>18,609</u>
Current assets					
Debtors	18	86,181		62,043	
Cash at bank and in hand		772,103		832,362	
		<u>858,284</u>		<u>894,405</u>	
Creditors: amounts falling due within one year	19	(25,176)		(23,990)	
Net current assets			833,108		870,415
Total assets less current liabilities			<u>849,484</u>		<u>889,024</u>
Capital funds					
Endowment funds - general	21		42,465		42,841
Income funds					
Restricted funds	20		42,728		37,788
<u>Unrestricted funds</u>					
Designated funds	22	93,018		16,224	
General unrestricted funds	22	671,273		792,171	
			<u>764,291</u>		<u>808,395</u>
			<u>849,484</u>		<u>889,024</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2020

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2020, although an audit has been carried out under section 144 of the Charities Act 2011. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these accounts under the requirements of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 24 September 2021

Mr Michael Sorkin
Trustee

Mr Alain Stechler
Trustee

Company Registration No. 07469168

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	2020 £	£	2019 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	26		(64,528)		5,395
Investing activities					
Purchase of tangible fixed assets		(3,053)		-	
Investment income received		7,322		12,371	
Net cash generated from investing activities			4,269		12,371
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(60,259)		17,766
Cash and cash equivalents at beginning of year			832,362		814,596
Cash and cash equivalents at end of year			<u>772,103</u>		<u>832,362</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies

Charity information

Shaare Zedek UK is a private company limited by guarantee incorporated in England and Wales. The registered office is 5 Technology Park, Colindeep Lane, London, NW9 6BX.

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's memorandum and articles of association, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income or gift aid donations is recognised at the time the relevant income is receivable.

Legacy income is included in the Statement of Financial Activities when the Charity's entitlement has been established with a sufficient level of certainty, normally on receipt of the legacy or a letter confirming that it will be sent.

Grants received are accounted for as receivable as and when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. Income from charitable activities includes income received under contract.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies **(Continued)**

Trading income is recognised as and when monies are received and stated after trade discounts .

Trading income related to events is recognised in the year the events took place.

The charity is not registered for VAT so all income shown in the SOFA and notes to the accounts are shown gross (i.e. inclusive of VAT).

1.5 Expenditure

Expenditure is recognised when a liability is incurred. Contractual arrangements and performance related grants are recognised as goods or services are supplied. Other grant payments are recognised when a constructive obligation arises that result in the payment being unavoidable.

Costs of generating funds are those costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities include both the direct and support costs relating to these activities.

Governance costs include the cost of any legal advice to trustees on governance or constitutional matters, external accountancy and audit costs.

Support costs include central functions and have been allocated to the different categories of activities based on the time spent on each activity.

The charity is not registered for VAT so all expenses shown in the SOFA and notes to the accounts are shown gross (i.e. inclusive of VAT).

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Plant and machinery	25% straight line
Fixtures, fittings & equipment	10% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

A subsidiary is an entity controlled by the charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies **(Continued)**

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13 Foreign exchange

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the statement of financial activities.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies **(Continued)**

1.14 Group accounts

The financial statements present information about the charity as an individual undertaking and not about its group. The company and its subsidiary undertaking comprise a small-sized group. The company has therefore taken advantage of the exemptions provided by section 399 of the Companies Act 2006 not to prepare group accounts.

1.15 Volunteers

A substantial contribution to the activities of Shaare Zedek UK is supplied in the form of voluntary services for raising funds. The financial benefit of these non-cash donations have not been recognised in these accounts as by their nature it would be impractical to quantify in monetary terms.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

In the view of the Trustees, there are no significant accounting estimates and judgements applied.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2020	2020	2020	2019	2019	2019
	£	£	£	£	£	£
Donations and gifts	253,181	3,224,590	3,477,771	253,706	835,107	1,088,813
Legacies receivable	968,970	45,500	1,014,470	182,190	392,322	574,512
	<u>1,222,151</u>	<u>3,270,090</u>	<u>4,492,241</u>	<u>435,896</u>	<u>1,227,429</u>	<u>1,663,325</u>

4 Other trading activities

	Unrestricted funds	Unrestricted funds
	2020	2019
	£	£
Non-charitable trading income	712	680
	<u>712</u>	<u>680</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

5 Investments

Unrestricted funds	Unrestricted funds
2020	2019
£	£

Interest receivable	7,322	12,373
	<u>7,322</u>	<u>12,373</u>

6 Other

Unrestricted funds	Total
2020	2019
£	£

Coronavirus Job Retention Scheme grant	9,682	-
	<u>9,682</u>	<u>-</u>

7 Costs of raising funds

Unrestricted funds	Unrestricted funds
2020	2019
£	£

Costs of generating donations and legacies

Advertising	38,922	35,498
Other fundraising costs	4,551	17,186
Staff costs	146,194	147,893
Depreciation and impairment	1,404	1,237
Support costs	27,990	42,891
	<u>219,061</u>	<u>244,705</u>

Fundraising trading: costs of goods sold

Other trading activities	304	279
Staff costs	24	60
Depreciation and impairment	-	1
Support costs	5	18
	<u>333</u>	<u>358</u>
Fundraising trading: costs of goods sold	333	358
	<u>219,394</u>	<u>245,063</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

8 Charitable activities

	Payments to hospital 2020 £	Payments to hospital 2019 £
Staff costs	18,961	27,398
Depreciation and impairment	1,404	1,237
Payments to hospital	4,244,962	1,265,056
	<u>4,265,327</u>	<u>1,293,691</u>
Share of support costs (see note 9)	33,518	48,460
Share of governance costs (see note 9)	13,436	14,502
	<u>4,312,281</u>	<u>1,356,653</u>
Analysis by fund		
Unrestricted funds	1,046,755	137,411
Restricted funds	3,265,150	1,211,896
Endowment funds - general	376	7,346
	<u>4,312,281</u>	<u>1,356,653</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

9 Support costs

	Support costs	Governance costs	2020	Support costs	Governance costs	2019
	£	£	£	£	£	£
Staff costs	32,397	13,436	45,833	34,556	14,502	49,058
Premises costs	26,837	-	26,837	22,423	-	22,423
Other costs	2,279	-	2,279	34,390	-	34,390
	<u>61,513</u>	<u>13,436</u>	<u>74,949</u>	<u>91,369</u>	<u>14,502</u>	<u>105,871</u>
Analysed between						
Fundraising	27,990	-	27,990	42,891	-	42,891
Trading	5	-	5	18	-	18
Charitable activities	33,518	13,436	46,954	48,460	14,502	62,962
	<u>61,513</u>	<u>13,436</u>	<u>74,949</u>	<u>91,369</u>	<u>14,502</u>	<u>105,871</u>

Support costs excluding staff costs which cannot be directly attributed have been apportioned equally between costs of raising funds and the charitable activity of payments to the hospital. Within support costs, other costs include telephone costs, postage costs, travel costs, computer running costs and staff training costs.

Staff costs have been apportioned on an estimated basis of the allocation of time spent on each specific activity.

10 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

	2020	2019
	£	£
Audit of the annual accounts	15,230	10,000
Non-audit services		
All other non-audit services	1,189	1,309

11 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year, nor were reimbursed travelling expenses.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

12 Employees

The average monthly number of employees during the year was:

	2020	2019
	Number	Number
Administration	1	1
Fundraising	3	3
Finance	1	1
	<u> </u>	<u> </u>
Total	<u> </u> <u> </u>	<u> </u> <u> </u>

Employment costs	2020	2019
	£	£
Wages and salaries	191,462	195,926
Social security costs	14,940	16,765
Other pension costs	4,610	4,372
	<u> </u>	<u> </u>
	<u> </u> <u> </u>	<u> </u> <u> </u>

Included in the wages and salaries costs is an amount of £Nil (2019: £Nil) related to redundancy costs for the year.

The number of employees whose annual remuneration was £60,000 or more were:

	2020	2019
	Number	Number
Between £70,000 - £79,999	1	1
	<u> </u>	<u> </u>

13 Other

	Unrestricted	Unrestricted
	funds	funds
	2020	2019
Net loss on disposal of tangible fixed assets	2,354	202
Audit fees	15,230	10,420
Legal and professional fees	114	1,189
	<u> </u>	<u> </u>
	<u> </u> <u> </u>	<u> </u> <u> </u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

14 Net gains/(losses) on investments

	Unrestricted funds	Unrestricted funds
	2020	2019
	£	£
Revaluation of investments	(124)	73
	<u> </u>	<u> </u>

15 Tangible fixed assets

	Plant and machinery	Fixtures, fittings & equipment	Total
	£	£	£
Cost			
At 1 January 2020	16,448	36,807	53,255
Additions	3,053	-	3,053
Disposals	(13,030)	(12,157)	(25,187)
	<u> </u>	<u> </u>	<u> </u>
At 31 December 2020	6,471	24,650	31,121
	<u> </u>	<u> </u>	<u> </u>
Depreciation and impairment			
At 1 January 2020	15,928	19,241	35,169
Depreciation charged in the year	1,286	1,522	2,808
Eliminated in respect of disposals	(13,030)	(9,803)	(22,833)
	<u> </u>	<u> </u>	<u> </u>
At 31 December 2020	4,184	10,960	15,144
	<u> </u>	<u> </u>	<u> </u>
Carrying amount			
At 31 December 2020	2,287	13,690	15,977
	<u> </u>	<u> </u>	<u> </u>
At 31 December 2019	520	17,566	18,086
	<u> </u>	<u> </u>	<u> </u>

16 Fixed asset investments

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

16 Fixed asset investments	(Continued)		
	Listed investments £	Other investments	Total £
Cost or valuation			
At 1 January 2020	423	100	523
Valuation changes	(124)	-	(124)
	<u>299</u>	<u>100</u>	<u>399</u>
At 31 December 2020	299	100	399
	<u>299</u>	<u>100</u>	<u>399</u>
Carrying amount			
At 31 December 2020	299	100	399
	<u>299</u>	<u>100</u>	<u>399</u>
At 31 December 2019	423	100	523
	<u>423</u>	<u>100</u>	<u>523</u>
		2020	2019
Other investments comprise:	Notes	£	£
Investments in subsidiaries	25	100	100
		<u>100</u>	<u>100</u>
17 Financial instruments		2020	2019
		£	£
Carrying amount of financial assets			
Instruments measured at fair value through profit or loss		299	423
		<u>299</u>	<u>423</u>
18 Debtors		2020	2019
Amounts falling due within one year:		£	£
Amounts owed by subsidiary undertakings		-	1,657
Other debtors		8,361	6,292
Prepayments and accrued income		77,820	54,094
		<u>86,181</u>	<u>62,043</u>
		<u>86,181</u>	<u>62,043</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

19 Creditors: amounts falling due within one year

	2020	2019
	£	£
Other taxation and social security	5,313	4,990
Trade creditors	5,310	8,247
Amounts owed to subsidiary undertakings	83	-
Other creditors	751	753
Accruals and deferred income	13,719	10,000
	<u>25,176</u>	<u>23,990</u>
	<u><u>25,176</u></u>	<u><u>23,990</u></u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

20 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds			Balance at 31 December 2020 £
	Balance at 1 January 2019 £	Incoming resources £	Resources expended £	Balance at 1 January 2020 £	Incoming resources £	Resources expended £	
Bikur Cholim Campus	10	17,364	(9,889)	7,485	680	(7,500)	665
Children's Hospital	2,100	21,125	(19,881)	3,344	11,581	(7,334)	7,591
Emergency Department	452	221,227	(219,937)	1,742	374,199	(374,199)	1,742
Neurosurgery and Neurology Department	530	52,014	(51,906)	638	50,000	(50,000)	638
Others	14,052	67,968	(62,915)	19,105	13,307	(6,708)	25,704
Neonatal Intensive Care Unit	5,111	81,847	(81,635)	5,323	66,893	(66,552)	5,664
Nursing Scholarships	-	84,738	(84,738)	-	77,439	(77,439)	-
Obstetric Department	-	156,765	(156,765)	-	153,974	(153,974)	-
Radiotherapy Institute	-	220,000	(220,000)	-	181,233	(181,233)	-
Intensive Care Department	-	304,381	(304,230)	151	35,250	(35,200)	201
Robotic Surgery	-	-	-	-	1,223,581	(1,223,581)	-
Cardiology Department	-	-	-	-	3,420	(3,420)	-
Coronavirus Department	-	-	-	-	1,078,533	(1,078,010)	523
	<u>22,255</u>	<u>1,227,429</u>	<u>(1,211,896)</u>	<u>37,788</u>	<u>3,270,090</u>	<u>(3,265,150)</u>	<u>42,728</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

20 Restricted funds

(Continued)

Bikur Cholim Campus is a separate campus hospital that merged with Shaare Zedek Medical Centre in Jerusalem. The fund is dedicated to fund the general running of the hospital.

Children's Hospital was set up as a separate fund to support a new building designed specifically for Children. The work on this site began in 2008 and the Children's Hospital officially opened in August 2015. The fund is dedicated to provide equipment and general running costs for the department.

The Emergency Department was set up to develop and extend the existing size of the old department. The fund is dedicated to provide general running costs for the department.

The Neurosurgery and Neurology Department at the Shaare Zedek Medical Center treats a wide range of diseases involving the nervous system, with the aim of preserving and restoring brain and spine function and has a designated operating theater which includes a new navigating system, intra-operation ultrasound and an innovative robot enabling procedures such as tumor tissue biopsy with great precision. The fund is dedicated to provide equipment and general running costs for the department.

Included within Others are various smaller funds which relate to various activities including CT Scanner, various pieces of equipment, Haematology Department, pending allocation, Geriatrics Department, Cardiology Department and LDA Educational Institute.

The Neonatal Intensive Care Unit (NICU) at the Shaare Zedek Medical Center treats infants born from week 24 of pregnancy. The complex includes 70 beds (with another 20 at the Bikur Cholim Campus), and state-of-the-art respiratory and monitoring equipment which provides precise data 24/7 on each of the babies in the unit. The fund is dedicated to provide equipment and general running costs for the department.

The Nursing Scholarships Fund is dedicated to provide support and training for student nurses.

The Obstetric Department includes the delivery rooms, the maternity wards, the High-Risk Pregnancy Unit and the Obstetric Ultrasound Unit. The fund is dedicated to provide equipment and general running costs for the department.

The Radiotherapy Institute is currently being built and is due for completion in 2022. The fund is dedicated to provide a Linear Accelerator for the Radiotherapy Institute.

Our Intensive Care Unit treats the most severe urgent care cases in the hospital. 70% of cases are post-surgery while others are complex cases referred from the Internal Medicine Departments.

Our state of the art new ICU was upgraded in 2017 the first major upgrade and renovation of this Unit since the hospital moved to its current location in 1979. The Unit is now equipped with the latest technology and care methods in the most advanced setting possible. The risk of infection is a top priority for intensive care patients. The redesigned ICU gives each patient their own largely self-sufficient room to minimise the spread of infection. Almost all of the equipment is wall or ceiling mounted, meaning the room can be kept to a higher standard of cleanliness. There are 14 patient rooms in total, almost all of which are in constant use.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

20 Restricted funds

(Continued)

Robotic surgery is a field which has developed in recent years, increasingly becoming a standard and indispensable approach to care in a variety of surgical disciplines. It allows extremely fine and complex movements in a tight space, without the need to open large cavities that can involve more complications and a longer, more painful recovery period. Appreciating that this represents the future of modern surgery, we are proud that Shaare Zedek Medical Centre, which currently sees around 35,000 surgical procedures performed each year, has been a local pioneer in introducing advanced robotic approaches to the Israeli medical community.

The Cardiology Department provides a comprehensive response to the gamut of cardiac and cellular diseases. Our team performs catheterization, installs stents in the coronary arteries and implants pacemakers, defibrillators and valves without open heart surgery. There is also a state-of-the-art Cardiac Imaging Institute which uses 3-D Echo, CT and MRI. We can also administer advanced treatment for congenital and structural disorders. The department stresses preventative care and accompanies patients throughout the post-heart attack rehabilitation process.

The Coronavirus Department was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation.

The trustees are satisfied that sufficient resources are held in an appropriate form to enable each fund to be applied in accordance with any restrictions.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

21 Endowment funds

Endowment funds represent assets which must be held permanently by the charity. Income arising on the endowment funds can be used in accordance with the objects of the charity and is included as unrestricted income. Any capital gains or losses arising on the assets form part of the fund.

	Movement in funds					Movement in funds					
	Balance at 1 January 2019	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at 1 January 2020	Incoming resources	Resources expended	Transfers	Investments gains/losses	Balance at 31 December 2020
	£	£	£	£	£	£	£	£	£	£	£
Permanent endowments											
Rayne Endowment Fund	50,187	-	(7,346)	-	-	42,841	-	(376)	-	-	42,465
	<u>50,187</u>	<u>-</u>	<u>(7,346)</u>	<u>-</u>	<u>-</u>	<u>42,841</u>	<u>-</u>	<u>(376)</u>	<u>-</u>	<u>-</u>	<u>42,465</u>
	<u><u>50,187</u></u>	<u><u>-</u></u>	<u><u>(7,346)</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>42,841</u></u>	<u><u>-</u></u>	<u><u>(376)</u></u>	<u><u>-</u></u>	<u><u>-</u></u>	<u><u>42,465</u></u>

The Rayne Endowment Fund was donated by Lord Rayne to fund an international urology conference held at Shaare Zedek Medical Centre.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

22 Unrestricted funds

The income funds of the charity include unrestricted funds, within which designated funds have been set aside by the trustees for specific purposes:

	Movement in funds			Movement in funds			Balance at 31 December 2020
	Balance at 1 January 2019	Incoming resources	Resources expended	Balance at 1 January 2020	Incoming resources	Resources expended	
Designated - Neo-Natal Department	16,224	-	-	16,224	-	-	16,224
Designated - Pending Allocation	-	-	-	-	76,794	-	76,794
Designated - Coronavirus Department	-	-	-	-	802,000	(802,000)	-
General Unrestricted Fund	737,434	448,951	(394,214)	792,171	361,073	(481,971)	671,273
	<u>753,658</u>	<u>448,951</u>	<u>(394,214)</u>	<u>808,395</u>	<u>1,239,867</u>	<u>(1,283,971)</u>	<u>764,291</u>

The Neo-Natal Department Fund has been set up to allow the legacy of one of our donors to contribute to the work they had supported throughout their life.

The Pending Allocation Fund relates to a single donation which is yet to be remitted to the Shaare Zedek Medical Centre, as the trustees have not yet confirmed what the donation should be used for.

The Coronavirus Fund was set up in the wake of the global Covid-19 pandemic to treat Covid-19 positive patients safely in isolation.

The General Unrestricted Fund relates to "free reserves" after allowing for all designated funds.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

23 Analysis of net assets between funds

	Unrestricted funds 2020 £	Designated funds 2020 £	Restricted funds 2020 £	Endowment funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Designated funds 2019 £	Restricted funds 2019 £	Endowment funds 2019 £	Total 2019 £
Fund balances at 31 December 2020 are represented by:										
Tangible assets	15,977	-	-	-	15,977	18,086	-	-	-	18,086
Investments	399	-	-	-	399	523	-	-	-	523
Current assets/(liabilities)	654,897	93,018	42,728	42,465	833,108	773,562	16,224	37,788	42,841	870,415
	<u>671,273</u>	<u>93,018</u>	<u>42,728</u>	<u>42,465</u>	<u>849,484</u>	<u>792,171</u>	<u>16,224</u>	<u>37,788</u>	<u>42,841</u>	<u>889,024</u>

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

24 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2020	2019
	£	£
Aggregate compensation	72,600	78,000
	<u>72,600</u>	<u>78,000</u>

Transactions with related parties

Included within other creditors is an amount of £83 (2019: £1,657 due from) due to Sharzed Advertising Limited, a 100% owned subsidiary.

Aggregate donations received from related parties without conditions amounted to £265,925 (2019: £190,471) for the year.

25 Subsidiaries

The financial statements below are separate from the charity's financial statements.

Details of the charity's subsidiaries at 31 December 2020 are as follows:

Name of undertaking	Registered office	Nature of business	Class of shares held	% Held	
				Direct	Indirect
Sharzed Advertising Limited	England and Wales	Advertising	Ordinary	100.00	

The aggregate capital and reserves and the result for the year of subsidiaries excluded from consolidation was as follows:

Name of undertaking	Profit/(Loss)	Capital and Reserves
	£	£
Sharzed Advertising Limited	(321)	7

The principal activity of the subsidiary undertaking during the year was that of advertising and promoting fund raising for Shaare Zedek UK.

SHAARE ZEDEK UK
(A COMPANY LIMITED BY GUARANTEE)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2020

26 Cash generated from operations	2020	2019
	£	£
(Deficit)/surplus for the year	(39,540)	62,924
Adjustments for:		
Investment income recognised in statement of financial activities	(7,322)	(12,373)
Loss on disposal of tangible fixed assets	2,354	202
Fair value gains and losses on investments	124	(73)
Depreciation and impairment of tangible fixed assets	2,808	2,475
Movements in working capital:		
(Increase) in debtors	(24,138)	(33,674)
Increase/(decrease) in creditors	1,186	(14,086)
Cash (absorbed by)/generated from operations	(64,528)	5,395
27 Analysis of changes in net funds		
The charity had no debt during the year.		